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ABSTRACT 
 
 Tuberculosis and malaria are among the most deadly infectious diseases in the world. 
The prevalence in regions without well-established public health causes economical and 
financial burdens for both society and patients. There is an urgent need to find effective 
treatments due to the emergence of drug-resistant strains. The aim of the studies reported here 
was to gain knowledge from the protein structures that can lead to the elimination of these 
pathogens. In these studies, protein crystallography is the main method used to solve protein 
structure. Based on the protein structure, we used different methods to characterize the 
protein function of three lipid-binding proteins (LprG, LprA, and gp232), and to identify 
potent inhibitors against Plasmodium falciparum enoyl-ACP reductase (PfENR), a drug target 
protein involved in central lipid metabolism. To characterize the function of two lipid-binding 
proteins (LprG and LprA), liquid chromatography-mass spectrometry (LC-MS) was used to 
analyze the ligand extract. In the study of tail fiber protein from mycobacteriophage, we used 
protein sequence alignment to identify gp232 as a major tail fiber protein, which potentially 
binds to lipids on the cellular surface of mycobacteria. A pull-down assay and imaging 
methods (fluorescence microscopy and electron microscopy) were conducted to confirm the 
function of gp232. In the structural study of PfENR, the structure-activity relationships 
method was used to find potent inhibitors against PfENR, which would show stronger 
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inhibition than the known inhibitor triclosan. The triclosan-like analogs with modification at 
the 5-position revealed a new binding site in PfENR that has great potential for improving the 
potency of inhibition. We found that two inhibitors containing the core structure of piperidine 
and tetrahydroquinoline reached this new binding site and were 10-fold more potent than 
triclosan. The structural study of PfENR provides structural insights into the inhibitor-binding 
site that can lead to the discovery of new drugs. The comprehensive knowledge that we 
gained from the structural studies of these lipid-binding proteins provide new information that 
could lead to a greater understanding of pathogen physiology or guide the discovery of 
effective treatments to eliminate the pathogens. 
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1. INTRODUCTION  
 
 Lipids are essential components for living organisms from bacteria to mammals. 
This essentiality is supported by the functions of lipids in cells that intrigue us to 
understand lipid metabolism that is related to drug target and pathogen physiology. 
Because they are associated with lipids, lipid-binding proteins play an important role in 
carrying out the function of these lipids. In addition, some lipids are signals used for 
recognition by the host immune system to identify the intrusion of pathogens. This 
recognition of lipids on the cell wall of pathogen also is used by phages and is performed 
by a type of proteins from the phages. The proteins that are associated with bacterial 
recognition are involved in the phage infection specificity, and they show great potential 
in therapeutic applications such as targeted drug delivery systems. To find effective 
treatments for deadly infectious diseases such as tuberculosis (TB) and malaria, 
structural studies of lipid-binding proteins can guide us from a structural perspective to 
design potent drugs, understand the pathogen physiology, and improve the efficacy of 
known treatments. Therefore, in this study, I am interested in the protein structures of 
four potential lipid-binding proteins that conform to the requirements and functions 
mentioned above.  
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1.1 The functions of lipids in living organisms 
Lipids comprise a large number of naturally occurring cellular components and 
are important for the survival of all living organisms [1, 2]. They are defined by their 
hydrophobicity, which distinguishes them into a group of biomolecules that is different 
from other biomolecules. The atomic composition of lipids is carbon, hydrogen, and 
oxygen, and some forms of lipids contain phosphorus, nitrogen, and other elements. 
They are essential components in all organisms and constitute a broad group of naturally 
present molecules with chemical modifications that assist in the survival of organisms. 
For example, fats and oils, including diverse fatty acids and cholesterol, are lipid forms 
that have metabolic and nutritional functions that support life [3]. The structural 
functions of lipids are essential for all organisms, from single-cell to higher organisms, 
because the formation of cell membranes requires phospholipids [4]. Some lipids such as 
eicosanoid serve a role in the intercellular signaling for inflammation in humans [5]. 
Therefore, lipids are instrumental in the evolution of species, playing important 
structural roles in building cellular membranes, acting as primary source of energy (9 
kcal/g), and functioning as signaling elements or the precursors of hormones. 
Lipid functions are indispensable for pathogens to survive inside the host. Lipids 
provide protection or a means that modulates the host immune response [6]. To survive 
and cause infection, pathogens have to propagate through replication, which requires the 
production of large amounts of lipids to make the cellular membrane. Due to the lipid 
dependency of the pathogens residing in the host, studies related to lipid metabolic, 
structural, or signaling functions would help to elucidate pathogen survival mechanisms. 
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Then, therapeutic treatments could be designed based on the survival mechanisms. For 
example, the essentiality of lipid production in building cell membrane has led to the 
design of inhibitors that could block lipid biosynthesis. A front line anti-tuberculosis 
drug, isoniazid, inhibits the enzyme, InhA, which is involved in fatty acid biosynthesis 
[7, 8]. Moreover, the knowledge of structural and signaling functions could guide us to 
develop applications in diagnosis and disease prevention. 
 
1.2 The important functions of lipids to mycobacteria 
Energy storage 
Lipids such as fatty acids and triacylglycerol (TAG) (Fig 1.1), which are more 
accessible for catabolic reactions compared to smaller units of carbon building blocks 
(acetyl CoA), makes them the ideal storage of energy[9]. These lipids supply energy 
through respiration and provide a carbon source[10]. When a harsh environment lacks 
sufficient nutrients, such as inside the macrophage, mycobacteria will enter a dormant 
(non-replicative) state that causes a re-routing of carbon flow in the tricarboxylic acid 
(TCA) cycle [8]. For aerobic organisms, the TCA cycle is the key component in the 
metabolic pathway that generates energy from carbohydrates or sugars. The metabolic 
flexibility in mycobacteria allows it to be persistent in the macrophage by switching its 
carbon source from sugars to fatty acids. Therefore, fatty acids, which are broken down 
by beta-oxidation and used to generate acetyl CoA for the TCA cycle, become the main 
energy source for mycobacteria to survive in energy-limited conditions[11]. Due to this 
capacity of the fatty acids stored in TAGs, mycobacteria accumulate TAG-based lipids 
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from the macrophage in which mycobacteria are engulfed by the first-line of host 
defense [12, 13]. This is also supported by the fact that large amounts of TAGs are 
observed in the sputum of tuberculosis patients [13]. 
 
Figure 1.1 Chemical structure of triacylglycerol (TAG) [14] 
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Structural function and protection 
A few classes of lipids such as phospholipids have a unique physical property in 
that they possess amphiphilic characteristics. These lipids contain a polar head group and 
a non-polar tail group, and they are the main components that make the double layers of 
cellular membranes. Not all the lipids used for building structural compartments are 
amphipathic, but they all act as the structural components for maintaining the integrity of 
the cell membrane[15]. This membrane builds a compartment to isolate its own cellular 
contents from the surrounding environment, and provides a selectively permeable barrier 
for protection[16]. Therefore, making the structural compartment is essential for 
mycobacteria to multiply in the host and lead to further infection. The main components, 
phospholipids, are required for pathogen replication once they emerge from the dormant 
state[16, 17]. To confer protection, cell membranes must be strong and stable enough to 
maintain cellular integrity, and flexible enough to bear conformational or environmental 
changes. The composition of lipids in the membrane is dynamic in response to a wide 
range of environment conditions (e.g., temperature, pH, and the hostile environment 
inside the host phagosomes)[16]. Changes in the membrane lipid composition of single-
celled organisms have a more direct impact than those in multicellular organisms. For 
example, the acyl chains of phospholipids determine the viscosity of the membrane and 
influence cell permeability. Disruption of the acyl chain modification on phospholipids 
leads to a loss of stability of the membrane, which in turn causes single-celled organisms 
such as bacteria to become weak and susceptible to stress such as antibiotics[16]. 
However, mycobacteria have unique cell wall structures that make them waxy and hard 
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to penetrate. The constituents of the cell wall are mainly mycolic acids that have long 
carbon chains with hydroxyl or branched modifications, which are normally metabolic 
burdens in nutrient-restricted environments. By contrast, the same mycolic acids in the 
outer shell of the cell wall are the reason that several strains of mycobacteria are 
successful pathogens that co-evolve with humans and develop resistance to 
treatments[18, 19]. 
 
Signaling function 
Some pathogens such as E. coli, Mycobacterium tuberculosis (Mtb), and 
Plasmodium take advantage of certain lipids that have an ability to modulate the host 
immune system for survival in the host[19, 20]. For mycobacteria to cause infection and 
proceed into a disease state after invasion, modulation of immune signaling in the host is 
one of the key factors to survive and propagate under the harsh environment that is 
created by the host immune system[21]. 
 
1.3 The current epidemic and background of tuberculosis 
Tuberculosis (TB) is an infectious disease among higher animals including 
humans and is caused by the pathogen, Mycobacterium tuberculosis. TB typically affects 
the lung (pulmonary TB), but can also infect other organs in the human body such as 
skeletal TB and central nervous system TB. Pulmonary TB has a long history since the 
seventeenth century, and the infectious nature of the disease was reported at that time. 
Later, Benjamin Marten, an English physician, published that the disease is caused by 
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microorganisms and is transmitted by close contact[22]. In 1882, Robert Koch 
discovered that the symptoms and the disease are caused by a single pathogen, which 
was later named Mycobacterium tuberculosis.[22] The effort to find treatments for TB 
has been explored with three approaches: strengthening immunity, the BCG vaccination, 
and the use of chemotherapy. In the early 1990s, the incidence of TB cases increased 
rapidly due to co-infection in HIV-positive patients[22]. In 1997, the World Health 
Organization (WHO) started to monitor TB epidemiology globally, and kept optimizing 
the strategy for the administration of treatment. Despite all the efforts in combating TB, 
there were 8.7 million new cases in 2011 and 1.4 million TB deaths (990,000 deaths of 
patients without HIV-infection and 430,000 deaths of HIV-positive patients)[23]. The 
global burden of TB is enormous; geographically, the biggest burden is in Asia and 
Africa, which had the largest number of incident cases in 2011. Among The rate of the 
overall global incident cases is 59% in Asia and 26% in Africa[23]. The estimated TB 
incidence rate of all six regions, including Africa, Europe, South-East Asia, Western 
Pacific, The Americas, and Eastern Mediterranean, are declining. In addition to 
monitoring the incidence numbers, the WHO surveillance of TB care and control 
evaluates the global prevalence and the mortality rate. The prevalence was estimated as 
12 million people in 2011, which translates to 170 cases per 100,000 people, and this is 
36% lower than the prevalence rate in 1990. The global TB mortality rate shows a 
decline of 41% since 1990[23]. 
Without chemotherapy, TB mortality rates are high. When the TB infection 
progresses, and patients without co-infection of HIV are positive in the sputum-smear 
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test, 70% of all patients die within 10 years. However, 90% of TB cases can be cured 
using the short-course regimen consisting of front-line drugs that have been available 
since the 1980s[23]. After patients are diagnosed by the sputum-smear microscopy test 
or the culture-method test, applying a proper treatment regimen is crucial to fight off the 
infection. Therefore, DOTS (directly observed treatment, short-course) is implemented 
to reinforce the patient’s compliance. Due to the unique nature of Mtb, such as the thick 
layer of the cell wall and the complex metabolism (with the ability to switch to the non-
replication state), the effective treatment regimen requires patients with newly diagnosed 
drug-susceptible TB to take a 6-month course of anti-tuberculosis drugs. This treatment 
regimen includes four front-line drugs including isoniazid, rifampicin, ethambutol, and 
pyrazinamide. The implementation of DOTS requires physical monitoring of patients 
taking isoniazid-rifampicin-ethambutol-pyrazinamide for 2 months, and subsequently 
isoniazid-rifampicin for 4 months. This program shows a success rate higher than 
95%[23]. The administered DOTS strategy is aimed to prevent the emergence of drug-
resistant strains of Mtb. 
 
Two variables that influence disease control  
The co-infection of TB with HIV and the occurrence of drug-resistant TB are two 
variables that exacerbate the TB epidemic. The emergence of the AIDS pandemic was 
widely recognized in the 1980s[24]. The major increase in the number of cases and the 
mortality rate of TB persisted in southern and east Africa from 1990 to 2004. HIV-
positive patients with an impaired immune system who are also infected with TB have a 
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higher risk of developing TB. The WHO report in 2011 states that 13% of people who 
developed TB are HIV-positive[23]. Due to the compromised immunity, HIV infection 
also affects the TB cure rate and mortality rate. The other factor that influences disease 
control is the identification of drug-resistant strains of Mtb. Drug-resistant TB refers to 
an infection that cannot be controlled by the first-line drugs. For example, the multidrug-
resistant (MDR) Mtb is resistant to at least two front-line drugs such as isoniazid and 
rifampicin. Among all the new cases of TB, 3.7% are estimated to be MDR-TB 
cases[23]. The incidence rate of MDR-TB is high in Eastern Europe and Central Asia. 
The standard treatment for patients infected with MDR-TB lasts 20 months or longer, 
and the chemotherapy drugs are more toxic to humans. Due to the lack of potent drugs 
for MDR-TB, the WHO launched drug-resistance surveillance in 1994 to monitor the 
epidemic of MDR-TB. This also revealed the need for new treatments for TB to prevent 
an upsurge in the incidence number. 
 
Characteristics and cell structure of Mtb 
Mycobacterium tuberculosis is a pathogenic bacterial species. The unique cell 
structure has characteristics of both Gram-positive and Gram-negative bacteria. The 
shape of mycobacteria is thin-rod-like, with a length of 2−5 µm and width of 0.2−0.3 µm 
(Fig 1.2a)[25, 26]. Mtb has a slow growth rate and divides every 15−20 hours. As an 
aerobic bacterium, the growth rate strictly depends on the available oxygen[22, 27]. 
When Mtb is engulfed by macrophages, it stops replicating and stays in a dormant state 
due to the limited nutrient conditions. Under the protection of the thick cell wall, Mtb is 
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able to avoid eradication by the host immune system.[28, 29] The mycobacterial cell 
wall reveals a unique structure of Gram-positive bacteria, with an extra outer membrane 
consisting of high lipid content; with a thickness of 7−8 nm, the cell wall is similar to the 
outer membrane of Gram-negative bacteria (Fig 1.2b)[25, 30]. The inner lipid bilayer 
mainly contains phospholipids, which separate the cytoplasmic region from the 
periplasm. The periplasmic region is the compartment formed between the outer cell 
wall and the inner membrane, which is a unique feature of the mycobacteria. This 
compartment is built by polysaccharides, such as peptidoglycan (PG) and 
arabinogalactan (AG)[25]. The waxy outer cell wall is composed of mycolic acids 
attached to the AG moieties, and provides a barrier and a habitat favorable for all the 
outer glycolipids to form a cell envelope. These glycolipids are shown to act as a signal 
that modulates the host immune response[28]. 
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Figure 1.2a Electron micrograph of Mycobacterium tuberculosis[31] 
 
 
Figure 1.2b Model of mycobacterial membrane and cell wall [29] 
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Defense mechanism 
 Once mycobacteria invade a host, the host front-line protection is the innate 
immune response, which involves antigen-presenting cells (APC) like macrophages and 
dendritic cells. Macrophages engulf the mycobacteria and become phagosomes, where 
the cellular environment becomes acidic and nutrient-limited. While mycobacteria are 
lysing in the phagosome, the antigen-presenting cells present the pathogen receptor to T-
cells. This is the adaptive immune response that recruits CD4 and CD8 T-cells to 
eliminate mycobacteria[32]. 
 
1.4 Three major types of lipids in mycobacteria 
Lipids for the storage of energy and carbon  
Fatty acids are the reserves of energy and carbon storage and serve as metabolic 
precursors for other lipid biosynthesis pathways such as mycolic acid and 
phospholipids[25] . The chemical structure is formed by more than four carbons in a 
long chain, which is attached to a carboxylic acid group, and the acyl chain length can be 
in the range of 4−20 carbons (C4−C20)[11]. The covalent bonds between carbons in 
fatty acids are either a single (saturated) or double (unsaturated) bond. There are other 
modifications on the acyl chain of fatty acids. The common modifications are 
methylation and cyclopropantion, which are used to alter the cellular membrane 
viscosity[16, 33]. For example, palmitic acid (C16:0) is linear and can pack very tightly, 
which leads to poor fluidity and lower permeability into the membrane. The significance 
of these components with long or short carbon-chain lengths to the Mtb pathogenicity or 
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adaptation to the environment has not been fully established. However, from monitoring 
the changing lipid composition in the bacterial membrane, the composition of the fatty 
acid carbon chain length seems to be optimized by evolution of bacterial strains that 
change to adapt to the temperature, culture age, and nutrients[16, 34]. In general, the 
most abundant fatty acids in Mtb are palmitic acid (C16:0) and tuberculostearic acid 
(C19:0)[35]. During culture aging, the tuberculostearic acid (C19:0) composition of the 
lipids increases in all species, whereas the composition of oleic acid (C18:0) and 
palmitoleic acid (C16:0) decreases[36, 37]. Mycobacterial species with different growth 
rates show different chain lengths in the fatty acid composition. The normal population 
of fatty acids is C16−C19[38]. Despite a lack of understanding of the correlation 
between fatty acid composition and bacterial viability, these fatty acids are the essential 
building blocks of phospholipids, glycolipids, triacylglycerides, and other cell wall 
components (such as mycolic acids) through further metabolic and modification 
reactions. 
 
Lipids and the structure of the plasma membrane  
Phospholipids are the major elements of cell membranes[11]. A phospholipid 
molecule is constructed with four components (Fig 1.3), including fatty acid, a platform 
for fatty acid attachment, a phosphate, and a head group attached to the phosphate. All 
phospholipids contain a diglyceride that has two fatty acyl chains connected to the 
glycerol moiety at the sn-1 and the sn-2 positions. A phosphate moiety is esterified to the 
glycerol at the sn-3 position. This is the basic unit of phospholipid, also known as 
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phosphatidic acid. Only small amounts of phosphatidic acid are present in 
membranes[39]. However, the molecule is a key intermediate in the biosynthesis of 
other phospholipids. The forth component, the head group, is hydrophilic, and 
differences in the head groups are important criteria that modify the property of the 
phospholipids. The hydrophobic tail and the hydrophilic head group result in 
phospholipids having an amphipathic character. The fatty acyl chains in the tail are 
repelled by water and are forced to aggregate, and this leads to the formation of the cell 
membrane lipid bilayers. The fatty acid components provide a hydrophobic barrier, 
whereas the remainder of the molecule has a hydrophilic character that enables 
interaction with the environment.  
Based on the head group, phospholipids are classified into eight types: 
phosphatidic acid (PA), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylinositol (PI), cardiolipin 
(CL), and sphingomyelin (Fig 1.3). Bacterial cell membranes, in general, have five 
phospholipids, which are PA, PG, PE, CL and PS. However, mycobacterial cell 
membrane contains one extra type of phospholipid, phosphatidylinositol (PI), which is 
not observed in most bacteria, except for the species in the suborder of 
Corynebacterineae[39]. Among all the phospholipids in the mycobacterial cell 
membrane, PG, PE, and CL are the most abundant components, followed by PI[11]. 
However, the percentage composition of these phospholipids changes in response to 
environmental or cellular changes[39]. The distribution of these phospholipids is 
heterogeneous. The hypothesis proposed for lipid polymorphism was that the membrane 
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formed by phospholipid was required to be dynamic to produce a specific environment 
for recruiting membrane proteins to function. The environment is defined by the 
potential, which is determined by the polarity of the modification on phosphatidic 
acid[16]. For example, the ethanolamine moiety of PE confers a positive charge on the 
cell membrane, whereas the phosphate moiety of phospholipids produces a negative 
charge on the surface of the membrane. The other head groups likely lead to different 
polarity. In addition, the fatty acyl chains of the phospholipids can be modified to adjust 
the fluidity and the rigidity of the membrane by adding cyclopropanyl groups or methyl 
groups and unsaturations in the acyl chains[16, 33]. 
The function of phospholipids is more than building barriers that protect cells 
from the environment. Some phospholipids in pathogenic mycobacteria serve as a signal 
to mediate bacterial stress responses or host immune responses.  Phosphatidylinositol 3-
phosphate (PI3P) is identified in both Mycobacterium smegmatis and Corynebacterium 
glutamicum and only shows a transient accumulation when the salt concentration 
increases rapidly[40]. The PI3P could serve in the signaling cascade to react to stress 
from the environment. Another example is observed in Plasmodium, the cause of 
malaria. This pathogen can survive under constant monitoring from the host immune 
system. Humans get Plasmodium infection through a mosquito bite. At one stage of its 
life cycle, the pathogen dwells dormant in hepatocytes (liver cells) after drifting in the 
blood stream. Before entering the next infection stage by invading erythrocytes (blood 
cells), the parasites propagate in hepatocytes. The dormant Plasmodium in liver survives 
under the surveillance of the host immune system by inhibiting the exposure of 
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phosphatidylserine on the outer leaflet of host plasma membrane[41]. Plasmodium 
utilizes this change of phospholipid composition in the membrane to suppress the signal 
to the immune response and thereby prevent elimination. 
 
Figure 1.3 Chemical structures of phospholipids 
 
Lipids and the structure of the cell wall 
The mycobacterial cell wall is waxy and provides a second layer of protection 
built in a layer outside the plasma membrane. It is essential for the growth and survival 
of the pathogen inside the infected host because of its low permeability. The cell wall 
consists of two segments, the core and outer segments (Fig 1.4). The core layer of the 
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cell wall is comprised of three covalently linked macromolecules beyond the membrane. 
These three major chemical constituents are PG, AG, and mycolic acids[18, 42]. The PG 
is covalently attached to the AG component, which is linked sequentially to the mycolic 
acid with their long meromycolate chains and short alpha chains. This layer is a 
covalently fused structure of the three macromolecules, also known as the mycolyl-
arabinogalactan-peptidoglycan (mAGP) complex, and is the core of the cell wall. The 
outer segment consists of free lipids, including some fatty acids with modifications 
(alpha chains), and the cell-wall associated proteins[18]. The free lipids, which are non-
covalently associated with the mAGP complex, are mainly fatty acyl chains with 
modifications in the sugar moiety. These glycolipids are commonly found in 
mycobacteria and include phosphatidylinositol mannosides (PIMs), the phthiocerol-
containing lipids (PDIM, DIM), lipomannan (LM), sulfolipids, cord factor, and 
lipoarabinomannan (LAM)[43]. The sugar modification makes these glycolipids become 
soluble in various solvents, but the mAGP complex remains insoluble. This unique cell 
wall structure of mycobacteria with various lipid contents is crucial for pathogenicity 
when mycobacteria proceed in the infection process. The proteins on the surface of the 
cell wall and the polar molecules of free lipids have the capability of cellular signaling, 
and therefore become effecter molecules in the pathogenicity and survival in the defense 
system of the host[6]. The waxy mAGP complex provides low permeability 
characteristics that contribute to the resistance of the pathogen to any common 
chemotherapeutic agents[18]. 
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Figure 1.4 Major components in the cell wall[42] 
 
One of the major lipids in the mycobacterial cell envelope is the 
phosphatidylinositol-derived lipoglycan family of LAM/LM/PIM (Fig 1.4)[39]. These 
glycolipids share a common core structure of mannoyl-phosphatidyl-myo-inositol (MPI), 
with phosphatidylinositol as the base. The PIM group has two to six mannosyl units 
attached to the base with two acyl chains, which are either palmitic, stearic, or 
tuberculostearic acids. The most abundant PIM-type glycolipids are PIM2 and 
PIM6[43]. LM and LAM are extensions of PIM with either a mannose or arabinose 
branch. LM has α-(1→6)-linked mannosyl units branched out from the O-2 position of 
the mannose residue from PIM. LAM has LM with α-(1→5)-linked arabinosyl units[44, 
45]. Therefore, there are three building blocks on LAM, including MPI core, 
polysaccharide backbone, and capping motif[46]. The core structure of LAM is 
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conserved in mycobacteria, whereas the capping motif moieties are different in different 
species. The three different capping moieties are identified to be mannose-capped LAM 
(ManLAM), phosphatidylinositol-capped LAM (PILAM), and non-capped LAM 
(AraLAM)[47-49].  
The physiological functions of the glycolipids are not clear. Depending on their 
structure, they display different immune-modulating properties. ManLAM reduces the 
bactericidal activity of macrophages by inhibiting phagosomal maturation[50]. It is also 
able to load onto CD1 molecules for presenting to T-cells. The macrophage immune 
response to PILAM is different from ManLAM. ManLAM induces an anti-inflammatory 
response by negatively modulating the production of inflammatory cytokines, but 
PILAM elicits a pro-inflammatory response[51]. These LAMs are the markers for 
mycobacterial species. ManLAM is found in slow-growing mycobacteria such as M. 
tuberculosis, M. leprae, M. avium, and M. bovis, whereas PILAM and AraLAM are only 
found in fast-growing M. smegmatis (M. smeg) and M. chelonae, respectively[44]. 
 
1.5 Mycobacterial lipid-associated proteins  
Based on the general functions of lipids described above, the physiological 
functions of lipids for pathogens such as mycobacteria can be classified into three types, 
which could lead to the research interest into these lipid-associated proteins. The main 
function of this group of proteins is to carry lipids for catalyzing metabolic reactions, for 
intracellular/intercellular signaling, or for lipid translocation due to lipid insolubility. 
Due to their insolubility in water, lipids are biomolecules that commonly require a 
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protein for transport in the cytoplasm of bacteria or through the cellular membrane. The 
type of lipid that binds to the protein is an indication of the function of the lipid-binding 
protein. The functions of the lipid-binding proteins that are associated with 
mycobacterial lipids can be categorized into three types: proteins involved in the lipid 
biosynthesis pathway, proteins that act as lipid transporters, and proteins that play a role 
in lipid recognition. The bacterial lipid-binding proteins involved in lipid biosynthesis 
and lipid transport are expressed and function intracellularly, whereas the proteins 
involved in lipid recognition are found in the extracellular environment. Due to the 
abundance of lipids in mycobacteria, lipid-binding proteins play important roles in 
maintaining cellular function. Approximately 30% of the genes are predicted to function 
in the pathway related to lipid transport or biosynthesis[42, 52]. 
The lipid-binding proteins involved in lipid biosynthesis pathways such as FASII 
biosynthesis and mycolic acid biosynthesis bind to substrates that have a long acyl chain. 
Acyltransferases bind to long fatty acids and transfer fatty acids to make phospholipids 
and triglycerides. These types of lipid-binding proteins have a catalytic function. Often, 
they are candidates for drug targeting because the functions of these proteins link them 
to an essential pathway that produces fatty acids as building blocks of lipids, or directly 
makes a final product as a component in the cell wall that stabilizes membrane integrity. 
The lipid-transport proteins serve as vehicles that carry lipids in the water-soluble 
environment, which is similar to the function of albumin in the blood plasma, and 
maintain a proper lipid distribution. The binding of lipid-transport proteins, unlike that 
of albumin, could be specific and assist to transport lipids that are synthesized in the 
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cytoplasm to their designated locations in the periplasm or though the membrane into the 
cell wall. Bacterial lipids are not only the main source of energy and components of the 
cellular structure, but also are used for sending signals inside and outside the bacteria. 
This expands the purpose of lipid binding from cellular metabolism to extracellular 
signaling, which is related to lipid recognition. There are proteins in host immune 
systems that recognize mycobacterial lipids and modulate the immune response, such as 
antigen-presenting proteins like major histocompatibility complex (MHC)-class and toll-
like receptors such as Toll-like receptor 2 (TLR2). Phages also have lipid-binding 
proteins that construct the phage tail, which defines its host range by recognizing the 
mycobacterial glycolipids on the cell wall. 
 
 Lipid-associated proteins that are involved in fatty acid biosynthesis  
Proteins involved in lipid biosynthesis often are essential for bacteria surviving in 
the environment because metabolic lipids are the fundamental elements for essential and 
physiological functions. One of the essential pathways in lipid biosynthesis is type II 
fatty acid biosynthesis (FAS-II), which is present in all bacteria sequenced so far, and 
makes precursors for phospholipids and mycolic acids. Typically, the enzymes 
catalyzing FAS-II have potential as therapeutic targets because the FAS-II system is 
only found in plants, bacteria, and some microorganisms[53]. The fact that FAS-II is 
absent in humans indicates that the enzymatic reactions related to FAS-II are attractive 
targets for designing inhibitors. In the bacterial FAS-II system, one discrete enzyme is in 
charge of the individual enzymatic reactions, unlike the multifunctional macro-enzyme 
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FAS-I found in humans[53]. Although the reactions of FAS-I and FAS-II are identical, 
the differences in the active sites provide an opportunity for designing potent inhibitors 
that are specific for the bacterial FAS-II system. 
The genes and the chemical reactions related to FAS-II biosynthesis are well 
conserved in microbial genomes. Both Mtb and Plasmodium have FAS-II, and both have 
identical chemical reactions, but the enzymes of FAS-II are named differently in Mtb 
and Plasmodium. The names of the enzymes used hereafter are based on those for 
Plasmodium, which is related to the study in Chapter 4. FAS-II has a repeating cycle of 
four reactions, including condensation, reduction, dehydration, and reduction of carbon-
carbon bonds (Fig 1.5). Each reaction is carried out by a different enzyme, called FabH 
(β-ketoacyl-ACP synthase III), FabG (β-ketoacyl-ACP reductase), FabZ (β-hydroxyacyl-
ACP dehydrogenase), and FabI (enoyl-ACP reductase). The initiation of FAS-II starts by 
converting acetyl-CoA to malonyl-CoA, which is catalyzed by an enzyme complex of 
acetyl-CoA carboxylase (AccABCD). When FabD (malonyl-CoA:ACP transacylase) 
transfers malonyl to ACP (acyl-carrier protein), the ACP protein carries the 
intermediates to enter the four-step reaction cycle that is catalyzed by FabH, FabZ, 
FabG, and FabI[54, 55]. To date, the FAS-II enzymes related to the condensation (FabB, 
FabF, and FabH) and the carbon-bond reduction (FabI) have been identified as targets 
for antibiotic design in different organisms[55]. 
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Figure 1.5 Diagram of fatty acid biosynthesis pathway[56] 
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 Lipid-associated proteins that are involved in lipid transport 
Lipid transport should facilitate the process of lipid biosynthesis due to the 
solubility issue. The reactions of lipid biosynthesis in bacteria occur initially in the 
cytosol, and the location of the final product is either in the plasma membrane or the cell 
wall. The translocation of metabolic intermediate lipids would require a lipid-transport 
system through the membrane. For example, LAM, one of the free glycolipids found in 
the cell wall, is the final product of the LAM biosynthesis pathway. The model for this 
pathway overlaps with the biosynthesis pathways for PI, PIM, and LM. The biosynthetic 
relationship is PI → PIM → LM → LAM[44]. The biosynthesis starts from the first step 
in PI synthesis and requires an inositol phosphate synthase (Rv0046) that catalyzes the 
conversion of glycose-6-phosphate to myo-inositol-1-phosphate [57](Fig 1.6). The 
dephosphorylation step is carried out by inositol-mono-phosphatase (IMP) to produce 
myo-inositol. The proteins Rv1604, Rv2701c, Rv2131c, and Rv3137 are homologs of 
IMP[58]. Subsequently, PgsA (Rv2612c) transfers diacylglycerol (DAG) from CDP-
DAG to myo-inositol by esterifying a phosphate, and generates the phosphatidylinositol 
(PI) core[59]. Then, a mannopyranosyltransferase, PimA (Rv2610c), is the first enzyme 
to make PIM by adding mannose on PI at the O-2 position[60]. The next step involves 
Rv2611c, an acyltransferase, that acylates the 6-position of the newly added mannose 
and generates Ac1PIM1[61]. Further mannosylation is done by PimB (Rv0557c), α-D-
mannose-α-(1→6)-phosphatidyl-myo-inositol mannopyranosyl transferase, adding 
mannose to the 6-OH of inositol and generating AcPIM2[61, 62]. PIMs contain 2−6 
mannose attached to the PI core, and the α-(1→6)-mannopyranosyltransferases PimC 
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and PimD catalyze the formation of Ac1PIM3 and Ac1PIM4, respectively[63]. This is 
the branch point of the PIM and LM/LAM biosynthesis pathways[44]. Ac1PIM4 is the 
precursor for mannosylation at α-(1→2) by PimE (Rv1159c) to produce Ac1PIM6, or 
mannosylation at α-(1→6) by the MptA (Rv2174) / MptB (Rv1459c) / MptC (Rv2181) 
complex that feeds LM/LAM biosynthesis[45, 64]. MptB and MptA synthesize the α-
(1→6)-mannan core. MptB catalyzes the proximal end of mannosylation by adding 
12−15 mannose residues to the core, whereas MptA makes the α-(1→6)-mannan 
attachment at the distal end[65]. LM-containing branches of the α-(1→2)-mannan 
connected to the core are catalyzed by MptC[66].The transition from LM to LAM is the 
extension of 12−16 α-(1→5)-arabinosyl residues transferred by EmbC[67]. A few other 
proteins such as AftC, AftD, and AraT might have bi-functional roles in the 
arabinosylation of both LAM and AG biosynthesis in the cell wall[68-70]. This is a 
typical example, in that the proteins associated with the initial reactions are expressed in 
the cytosol and the final products are located in the cell wall. During glycolipid 
biosynthesis, there is a point where PIM is flipped from the cytosol to the plasma 
membrane. This could involve membrane proteins such as flippase to open a channel in 
the membrane and lipoproteins to facilitate the process. Mycobacterial lipoproteins are 
characterized into families based on the N-terminal signal peptide, which directs 
lipoproteins to the plasma membrane. The function of the lipoprotein LppX is involved 
in lipid transport on the PDIM biosynthesis pathway, in which the PDIM virulence 
factor is initially synthesized in the cytosol then translocated into the cell wall[71]. Only 
a few lipoproteins have an identified function that is similar to LppX. Therefore, the 
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glycolipids (PIM, LM, and LAM) also could require lipoproteins to assist lipid transport 
at a point between AcPIM4 and AcPIM6. 
 
 
Figure 1.6 Lipoarabinomannans (LAM) biosynthesis pathway[72] 
 
Host and phage lipid-binding proteins involved in recognition of 
mycobacteria  
Glycolipids on the mycobacterial cell surface are located at important places, 
where proteins from other organisms can access them and use them for typing 
mycobacteria. Host and phage proteins that recognize mycobacterial glycolipids are this 
kind of lipid-associated proteins. In mycobacteriophages, they are tail fiber proteins 
(TFPs), which phages use to make initial contact with mycobacteria and to carry out 
infection specificity. In the host, they are pathogen recognition receptors that are used in 
the host immune system. 
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In phages, TFPs constitute the tip of a tail fiber, whose function is to make 
contact on the cell surface of bacteria. It has been demonstrated that the tip of TFP 
contributes to infection specificity[73]. Because mycobacteriophages only can cause 
infection in mycobacteria, their TFPs are likely responsible for binding onto the 
mycobacterial cell wall. Although the binding mechanism is still unknown, TFPs in 
mycobacteriophages have potential in selecting the specific glycolipids on the cellular 
surface that contribute to the recognition between phage and bacteria.  
In the host immune system, mycobacterial glycolipids serve as biomarkers that 
pathogen-pattern receptors (such as TLR) and antigen-presenting molecules (such as 
CD1) can sense and detect the structural pattern to initiate the host defense system[74]. 
TLR proteins are evolutionarily conserved from worm to mammals. TLRs are associated 
primarily with innate immunity and are expressed on various immune cells, including 
macrophages, dendritic cells, B cells, and monocytes. A total of 12 TLRs are identified 
in mammals. They are type-I integral membrane glycoproteins, which are characterized 
by an extracellular domain and an intracellular domain. The extracellular domain of TLR 
that consists of 16−28 leucine-rich repeats is an immunoglobulin domain, and this 
domain also is the ligand-binding domain. The intracellular domain is a TIR domain, 
which is required for interaction with various adaptor molecules for activating the 
downstream signaling pathway[75]. To date, LAM from mycobacteria is recognized by 
TLR2[76]. The formation of TLR complexes such as TLR2/TLR1 and TLR6 responds to 
mycobacterial lipoproteins and tri- or di-acyl lipoproteins[77]. The antigen-presenting 
protein CD1 inspects through the endocytic compartment of the antigen-presenting cell 
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for either endogenous or exogenous lipid antigens. Subsequently, CD1 presents those 
lipid antigens to activate T-cells or NKT cells. Both PIM and ManLAM from 
mycobacteria are CD1-restricted lipid antigens[78]. 
 
1.6 Application of structural biology 
 Solving the protein structure of these lipid-associated proteins could provide 
information about protein function and insights into the mechanism related to protein 
function. When the essentiality of a gene is identified from genomic data, the structural 
study can fill in the gap between the genomic data and protein function. One of the 
major techniques in the determination of three-dimensional macromolecular structure is 
X-ray crystallography. Given the current technology, it can yield protein structures in a 
high-resolution range of 1−3 Å. Since Perutz and Kendrew solved the first protein 
structures of myoglobin and hemoglobin in 1953, there have been 89,212 protein 
structures deposited in the Protein Databank. Because of advances in the process of 
protein structure determination, such as high-throughput crystallization, liquid-handling 
robots, MAD-phasing method, and synchrontron source with automation, the rate of 
protein structure determination has increased rapidly in the past decade. Along with 
improvements in X-ray crystallography techniques, genome sequencing also is making 
progress and the genomic data of multiple species is available. Combined with the 
knowledge of the genome, cloning a gene is now precise and fast. Once the genomic 
DNA is obtained, it takes only a few days for protein production. However, protein 
crystallization and obtaining the phase are still the rate-limiting steps in this process of 
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protein structural determination. Furthermore, mapping the nucleotide sequences in the 
TB genome reveals that more than 50% of genes have no annotation and no identified 
functions[79]. When the genomic data become available, functions of the proteins get 
highlighted. Therefore, the focus of understanding biological mechanisms in living 
organisms has been switched to elucidate how proteins function. Consequently, the 
interest in protein function identification can be transitioned into a genome-wide project. 
For example, the Mtb structural and genomic consortium is putting effort into getting as 
many protein structures as possible and identifying their functions. The goal is to map all 
the protein functions through protein structural studies, which could be a useful database 
for therapeutic design of inhibitors. 
The protein structural study can be useful in the function determination of target 
proteins and also in inhibitor optimization. Solving a protein structure provides insights 
into the different aspects of protein folding and conformation, which guide in the 
determination of function. When a protein function is unknown, the general protocol for 
annotating a function is to align the protein sequence to the database. If the alignment 
shows sequence identity higher than 30−40%, proteins with unknown function can be 
related to a protein family. A protein crystal structure shows the overall protein fold that 
may lead to the identification of a class of proteins, or could reveal a new fold for a new 
protein family. If this class of proteins has been identified, the function can be tested 
based on the structurally related protein family. For those proteins without known 
functions, a structural study is usually a guideline. When a protein structure shows a 
putative reaction site or cavity, an enzyme assay or a binding assay can be used to study 
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the protein function. In Section 2, the structural study of two lipoproteins of Mtb, LprG 
and LprA, is undertaken to perform the functional study. The key to understanding the 
function of both proteins is that the structures of both show a cavity, which indicates the 
presence of a binding / active site. Later, a binding assay is used to define the binding 
specificity. Mass spectrometry is a powerful tool for assisting functional studies. 
Therefore, the knowledge gained from functional and structural studies of proteins can 
expand the database of linkages from protein sequence to protein function. In addition, 
protein structure determination is a strategy used in drug design. Obtaining a protein 
structure forming a complex with an inhibitor is a probe to explore the potential 
interaction site that would help for inhibitor optimization. In Section 3, using the crystal 
structure of PfENR in complex with inhibitors in a structure-activity relationship study, 
the inhibition by a new series of inhibitors shows tight binding. Structural studies could 
be used as pilot studies of technology innovation. In Section 4, by identifying a tail fiber 
protein from a phage that has selective binding to mycobacteria, the protein structure 
becomes a guide for designing target therapeuticals at the initial stage. 
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2. STRUCTURAL STUDY OF LPRA AND LPRG* 
 
 2.1 Introduction 
 Proteins of various organisms undergo different post-translational modifications, 
such as lipid modification, for regulated functions. Lipid modification is a common 
process in bacterial organisms to make lipoproteins, which are the proteins secreted out 
of the membrane that function after post-translational modification[80]. The lipidation of 
lipoproteins facilitates protein anchoring to the cell membrane through the hydrophobic 
interaction of the lipidated acyl group and the cell membrane phospholipids[81]. In 
general, the bacterial genome contains 1−3% of genes encoded as lipoproteins[82]. This 
family of proteins has heterogeneous functions including nutrient uptake, signal 
transduction, adhesion, and conjugation, which are related to antibiotic resistance, 
transport, and extracytoplasmic folding of proteins. In addition to their functions, 
lipoproteins are associated with pathogen virulence such as colonization, invasion, 
evasion of host defense, and immunomodulation[80]. Therefore, mycobacterial 
lipoproteins are classified into a group of secreted proteins, and have been implicated in 
a broad spectrum of functions that participate in different pathways[83]. Either the  
_______________________________________________________________________ 
*Part of this section is reprinted with permission from “Mycobacterium tuberculosis 
lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2 
” by Drage, M. G., Tsai, H. C., Pecora, N. D., Moody, D. B., Boom, W. H., Sacchettini, 
J. C. and Harding, C. V. et al. 2010. Nature Structural and Molecular Biology, 17(9): p. 
1088-95., Copyright 2010 by Nature America, Inc. 
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lipoproteins themselves or the pathways in which lipoproteins are involved are directly 
related to the survival of mycobacteria in vivo and their virulence[84, 85]. The interest in 
the study of lipoproteins has expanded from finding the physiological function to 
exploring the mechanism of virulence. There are extensive studies about lipoproteins 
that are unique to Mtb, including immunodiagnostics and the use of vaccine 
immunogens. 
 The lipoprotein biosynthesis pathway is a major virulence factor in Mtb[86-88]. 
The open reading frames of mycobacterial lipoproteins, which are known as pre-
lipoproteins, are first translated to a full-length peptide chain. The N-terminal of these 
proteins contains a transmembrane domain, which is a signal peptide that directs protein 
localization and post-translational modification. This signal peptide is then cleaved after 
translocation of the lipoproteins across the membrane. In the lipoprotein biosynthesis 
pathway, these nascent pre-lipoproteins are processed by three integral-membrane 
proteins located in the plasma membrane: diacylglyceryl transferase (Lgt), signal 
peptidase (LspA), and N-acyl transferase (Lnt)[89]. These lipoproteins are often 
characterized by the presence of a conserved sequence, the lipobox, located in the C-
terminal part of the signal peptide, and they consist of four amino acids 
(LVI/ASTVI/GAS/C)[83]. This lipobox motif functions as a recognition signal for lipid 
modification, which is made on the conserved and essential cysteine residue. The first 
step of lipoprotein biosynthesis is the formation of a thioether linkage catalyzed by Lgt, 
which attaches a diacylglycerol to the sulfur from the conserved cysteine in the lipobox. 
Then, LspA cleaves the N-terminal signal peptide by hydrolyzing the amide bond. N-
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acyltransferase catalyzes the last step, which is the amino-acylation of the N-terminal 
cysteine residue[89]. After lipid modification, the mature lipoproteins are located in the 
outer leaflet of the cell membrane[89]. The mature lipoproteins are essential for Mtb to 
adapt to the environment, because disruption of the lipoprotein biosynthetic pathway in 
the lspA-deficient strain of Mtb resulted in decreased virulence and susceptibility to 
malachite-green[86]. 
 When the mycobacteria invade the host, the receptors on the surface of the 
antigen-presenting cells (APCs) recognize the secreted proteins and the glycolipids from 
the mycobacterial surface[90]. These mycobacterial lipid and protein antigens induce the 
signaling pathways of the innate and adaptive immune responses[90]. In the innate 
immune response, the APCs (e.g., macrophages and dendritic cells) become phagocytes 
and engulf the Mtb to remove the bacteria from the host[91]. In the adaptive immune 
response, T-cells are activated by APCs to eliminate Mtb from causing further disease 
progression[92]. The Mtb lipoprotein pathway is crucial for T-cell activation, because 
the lspA-deficient Mtb shows loss of the T-cell response[84]. Therefore, mycobacterial 
lipoproteins have immunodominant properties of cell-wall-associated antigens. Despite 
having immunity as a protection from bacterial infection, bacterial-related infectious 
diseases like tuberculosis are still a major concern in public health. In humans, 10% of 
the population infected with Mtb proceeds with development of the disease[93]. One 
way Mtb survives the host defense system is by utilizing glycolipids (ManLAM) and 
lipoproteins to mediate the host immune system through receptors on the APCs, 
including Toll-like receptors and MHC-class proteins[32, 94]. Mtb with a deletion of 
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lprG fails to survive in mice and has decreased virulence in macrophages[95]. The LprG 
protein has the ability to induce TLR2 signaling through tri-acylation of the ligand 
Ac1PIM2[96]. This indicates that a small set of mycobacterial lipoproteins could 
contribute to mycobacterial virulence by suppressing the human immune response 
through the TLR2 signaling pathway. LprA is in a subset of the lipoprotein family that 
contains three other lipoproteins known as LprG, LppX, and LprF; it is able to induce 
the TLR2 signaling pathway[83, 97]. 
 The mycobacterial lipoprotein LprA is a potent TLR2 agonist that induces the 
cytokine response and regulates APC function[97]. The TLR2 signaling induced by 
LprA is through a heterogeneous toll-like receptor complex of TLR2/TLR1 and 
TLR2/TLR6[90]. The acylation of the protein at the N-terminus is crucial for activation 
of TLR2 activity. It has previously been shown that triacylated lipopeptide 
(Pam3CSK4), a lipoprotein mimic containing six residues and a triacyl moiety at the N-
terminus, is able to induce TLR2 activity. The structure of TLR2/TLR1 with Pam3CSK4 
reveals how the acyl chains interact with the heterogeneous TLR complexes[98]. The 
truncated protein of recombinant LprA lacking the signal peptide results in a reduced 
signal through TLR2 when compared with that of the acylated LprA. To date, 
mycobacterial lipoproteins that have been characterized as TLR2 agonists (LprG, LpqH, 
and LprA) activate TLR2 activity by interacting with the TLR2/TLR1 complex[90]. 
However, LprA is able to induce the immune response through TLR2/TLR1 and 
TLR6/TLR2[90, 97]. LprG induces TLR2 signaling through one of the tri-acylated 
glycolipids (Ac1PIM2) that is carried by this lipoprotein, and more studies have shown 
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that mycobacterial lipids send a signal to mediate the host immune response. This 
suggests that the ligand of LprA, which will be defined by its structure, could assist in 
the elucidation of the role of this lipoprotein. 
 In this study, the crystal structure of LprA is solved and provides insight into a 
cavity, which is located at the center of the whole protein and has an entrance from the 
side. The crystallographic data shows that the cavity of LprA has a ligand bound when 
the protein is purified from E. coli. We identified that the ligand in the crystal structure 
is phosphatidylglycerol. The ligand identification is carried out in three bacterial species, 
including E. coli, M. tuberculosis, and M. smeg. Because LprA is a putative lipid-
binding lipoprotein that is not involved in any catalytic reaction, ligand identification 
becomes one of the major indicators in finding the function of this lipoprotein. Utilizing 
the cavity of LprA to pull out the ligands from mycobacteria, the resulting ligand is 
analyzed by liquid chromatography-mass spectrometry (LC-MS). The differential LC-
MS profiles in E. coli and Mtb indicate that a mixture of lipids bind to LprA, and most 
of the lipids share a backbone structure of phosphatidylinositol (PI). This finding is 
supported by the binding assay, in which PI shows a relatively strong affinity for LprA. 
LprA is on the same operon with two membrane proteins (Rv1272c and Rv1273c), 
which are homologs to a liposaccharide transporter protein MsbA from E. coli. Given 
our analysis on the ligand pool and the operon that contains LprA and MsbA in Mtb, the 
function of LprA can be predicted to be involved in the binding of phospholipids. 
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2.2 Results and discussion 
Crystal structure of LprG 
 The data have been published and the paper is attached in Appendix A. 
 
Crystal structure of LprA without signal peptide 
 LprA, which was cloned and expressed without a signal peptide, was purified 
with a His-tag on the N-terminus. Crystals of Mtb LprA grew from 25% PEG3350 and 
0.1 M citric acid, pH 3.5, in the C2 space group with unit cell dimensions of a = 119.1 
Å, b = 41.5 Å, c = 88.2 Å, β = 102.0°, and α = γ = 90.0°. The diffraction data was 
collected to 2.2-Å resolution. The structure was solved by using molecular replacement 
with an LprA homology model that was generated by the CPH program based on the 
LprG structure (PDB code: 3MH8). The initial model had four regions (Val69−Thr79, 
Thr98−Asp107, Asp120−Leu142, and Ans178−Pro201) that required model building to 
fit residues in the electron density map. After repetitive cycles of model building and 
refinement, the final model had a crystallographic R-factor of 0.21 and R-free of 0.25. 
There were two molecules of LprA present in one asymmetric unit, containing a 6-
histidine tag, residues 45−235, two ethyleneglycols, one glycerol in one of the protein 
molecules in the asymmetrical unit (molecule B), and 309 water molecules. The C-
terminal residues 236−244 could not be modeled due to the missing electron density. 
The buried surface between these two molecules was 2%. This indicates that the protein 
stays in solution as a monomer, as confirmed by analyzing on the gel filtration column. 
The two protein molecules in the asymmetrical unit have almost identical conformation, 
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with a root mean square deviation (RMSD) of 1.1 Å calculated with all observed α-
carbons. 
 The overall structure of LprA has an alpha/beta fold, which is the same as the 
protein folding reported for the other two lipoproteins (LprG and LppX) from the family. 
This folding in LprA consists of four alpha helices and an anti-parallel beta sheet formed 
by 10 beta-strands (Fig 2.1a). A helix (α3) and a loop-helix (α2)-loop motif are at the 
center of the curved β-sheet. Two helices of α1 and α4 are parallel to α3, located on the 
same side of the β-sheet. There is a cavity formed between the helices and the beta-sheet. 
The cavity in this lipoprotein family shares two common features, a large volume and 
hydrophobicity, which also have been observed in the LprA structure from other 
organisms. This cavity, located at the curvature of the beta sheet, is solvent-accessible 
and the volume of the cavity is ~1300 Å3. The depth of this cavity is 18 Å, and it is lined 
with the side chains of hydrophobic residues. In the X-ray data, there is an unknown 
electron density in the cavity, which is not from protein. The shape of this unknown 
electron density suggests that the bound molecules have two long chains. 
 The LprA cavity has an entrance that is surrounded by loops, including three 
short loops (Pro74−Arg77, Gly189−Ser190, and Val101−Glu103), residues 
Lys104−Glu106 on β4, and a long loop of the loop-helix-loop motif (Asp120−Asn138, 
connecting β5 to α2). Except for Arg77, Glu106, Ser135, and Ser139, the residues at the 
entrance are hydrophobic. There is a small opening constituted by Ser135, Tyr137, and 
Gly189, which connects the cavity entrance to a groove on the surface of the protein (Fig 
2.1b). This groove, constituted by residues Thr186−Ala188 from α2 and residues 
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Tyr137−Gly148 from the centered loop-helix-loop motif, is at the conjoint region on the 
protein surface between α2 and α4. 
 
Figure 2.1a Superimposition of two crystal structures of LprA (molecules A and B) from 
an asymmetrical unit cell. The loops of molecule A are in yellow and the flexible loop of 
molecule B is highlighted in brown. 
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Figure 2.1b  Overview of the LprA surface. The left figure shows the surface of one 
conformation found in molecule A of LprA. The right figure is the surface view made by 
the other conformation from molecule B of LprA. The hydrophobic groove on the 
surface and the cavity are highlighted with cyan and pink, respectively. The small portal 
connecting the cavity and the groove is in blue. 
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The overall structure of the two molecules (A and B) in the asymmetrical unit is 
highly similar, except for residue Arg77 and a long loop region (residues 
Asp120−Asn138) in the structure at the cavity entrance. The different conformations 
strongly suggest that this long loop on the centered loop-helix-loop motif, which covers 
half of the cavity entrance, is flexible. The carbonyl groups on the peptide backbone of 
Ile136 and Ser135 flip 147° and 108°, respectively, and cause a conformational change 
in residues Phe130−Asn138, which is a part of the long loop. The cavity was narrowed 
down by the γ-carbon of Ile136 shifting 5.8 Å and the ε-nitrogen of Arg77 flipping 101° 
(Fig 2.1a). Therefore, the cavity entrance of molecule B showed an opening size with 
dimensions of 7 Å × 15 Å, which is smaller than the cavity of molecule A (11 Å × 15 
Å). The protein surface at Ile136 moves 4.8 Å to narrow the entrance, which is measured 
from carbon on the peptide backbone in molecule A to the carbonyl oxygen in molecule 
B. The position of Ile136 in molecule B blocks the small portal from the cavity to the 
groove. Apparently, the residues Phe130−Tyr137 of this flexible long loop region cause 
a major conformational change at the cavity entrance. Therefore, this flexible loop is 
likely to facilitate ligand binding and confer selectivity of the type of ligand. 
 
The structure of Mtb LprA shows similarity to LprG and Lppx 
 The overall crystal structures of Mtb lipoproteins in this family (LprA, LprG, and 
LppX) are similar, and all of them have a large hydrophobic cavity. However, LprA and 
LprG are even more structurally alike because the cavities of LprA and LprG have the 
cavity entrances located in relatively the same position in each protein structure (Fig 
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2.1b). The superimposed structures of LprA and LprG show a high similarity with each 
other, with RMSD value of 1.7 Å calculated based on the α-carbon. Despite the overall 
resemblance of the protein folding, there are two regions that show different 
conformations, both of which are in the vicinity of the cavity entrance. The first 
difference is at the long loop region of the centered loop-helix-loop motif in LprA 
between α2 and β5 (Asp120−Asn138). This long loop region encompasses half of the 
cavity entrance and shows different conformations in the two molecules in the 
asymmetrical unit in the LprA crystal structure. The other region in LprA, which acts 
like the lid to the cavity, contains α4 (Ala181−Ala188) and a loop (Gly189−Lys198), 
connecting between α4 and β8. Here, the difference between the two proteins results in a 
smaller volume in the cavity of LprA. When superimposing the structures of LprA and 
LprG, the lid region shifts 4.3 Å as measured between the carbonyl oxygen of Ala188 
from LprA and the carbonyl carbon of Ala153 from LprG. The position of α4 reduces 
the cavity size and narrows the cavity entrance in LprA. The smaller size of the cavity 
entrance and the cavity itself will constrain the ligand binding. Indeed, the structural data 
shows that the shape of the unknown electron density in the LprA cavity contains two 
acyl chains, whereas the LprG cavity can accommodate three acyl chains. This 
description implies that there is a possibility that LprA binds sphingomyelin and 
phospholipids (e.g., phosphatidylglycerol (PG), phophatidylcholine (PC), 
phosphatidylserine (PS), and phosphatidylethanolamine (PE)). 
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Ligand identification from the crystal structure by liquid chromatography 
and mass spectrometry 
 Considering the hydrophobicity of the cavity and the similarities in the 
architecture of the binding site to the cavity in Mtb LprG, the ligand of LprA can be 
predicted to be a lipid. To identify the bound ligand in the LprA crystal structure, it was 
extracted from the purified recombinant protein by treating with organic solvent (ethyl 
acetate) followed by strong acid denaturation of the protein. The extract was directly 
infused into the mass spectrometer (Bruker® MicrO TOF-Q-II). The results were 
analyzed by the software Compass DataAnalysis® (Bruker), which showed that the 
extract was a mixture of ligands that were presumably bound to the LprA protein 
expressed in E. coli (Fig 2.2a). The results also indicate that the ligands are tightly 
bound, because they are co-purified with LprA. The binding specificity was confirmed 
by comparing the mass spectra to the extract of Mtb LpqH, another Mtb lipoprotein that 
was expressed and purified in E. coli as a control. The ion peaks were found only in the 
Mtb LprA extract. 
  
 
 
43 
 
 
Figure 2.2a  Mass spectral analysis of the ligand extraction from E. coli purified LprA. 
The extraction sample was injected into the mass spectrometer by the direct-infusion 
method and monitored in the ESI-positive and ESI-negative modes. 
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 The high-resolution mass spectrometric data of the LprA extract showed one 
cluster of ion peaks in the ESI-negative and ESI-positive mode. The mass-to-charge ratio 
(m/z) of both ion clusters from the negative and positive modes are both in the range of 
693 to 850. The molecular weight matched diacyl phospholipids, which also fit into the 
unknown electron density in the structural data. The ion peaks were preliminarily 
assigned by comparing them to the mass spectrometric database of lipids (Lipidomic 
Gateway). In the ESI-positive mode, two types of phospholipids were identified. The 
strongest ion peak (m/z 726.53) was phosphatidylethanolamine, PE(35:4), which has 
four unsaturated carbon-carbon bonds on the acyl chains. There were two more ion 
peaks (m/z 712.52 and 752.55), which also corresponded to the PE group, but they had 
different lengths of the acyl chains. The rest of the peaks in the ESI-positive mode were 
low intensity and corresponded to phosphatidylglycerol containing 32 to 37 carbons on 
the chain length (Fig 2.2a). In the negative mode, all of the major ion peaks were found 
to be in agreement with the molecular weight of PGs. The strongest peak (m/z 733.42) 
was PG(33:1). The rest of the ion peaks in this cluster was PG with 32 to 37 carbons on 
the diacyl chains. The data from both ionization modes indicate that LprA expressed in 
E. coli is mainly bound to PG and PE. 
 To quantify and further analyze individual components in the mixture, LC-MS 
analysis was performed. The ethyl acetate extract of LprA was injected into a liquid 
chromatography system (Agilent) and was monitored by high-resolution mass 
spectrometer (Bruker® MicrOTOF-Q II). The purpose of the liquid chromatography was 
to separate the ligand mixture based on polarity in a gradient of acetonitrile and water on 
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a reversed-phase column (C8, Waters®) at a flow rate of 0.5 mL/min. The extract was 
fractionated into three groups of eluents that were eluted with different percentages of 
acetonitrile (Fig 2.2b). The first group eluted in the range of 55−70% acetonitrile. It 
contained four components that were observed in both the positive and negative modes 
of ionization. Each of these four components in the first group represented one major ion 
peak, individually shown with a m/z of 501.4, 515.4, 529.4, and 543.4 in the positive 
mode that matched the molecular weight of LPE(18:1)+Na, LPE(19:1)+Na, 
LPE(20:1)+Na, and LPE(21:1)+Na, respectively. The negative mode also showed four 
components for the first group. The most intense ion peaks were m/z 297.1, 311.2, 325.2, 
and 339.2, representing LPA(15:1), LPA(16:1), LPA(17:1), and LPA(18:1), 
respectively. The ion peaks with m/z of 481.3, 495.3, 509.3, and 523.3 corresponding to 
LPG(16:1), LPG(17:1), LPG(C8:1), and LPG(19:1) also were observed, but with much 
lower peak intensity. The second group of eluents in the LC-MS profile eluted at 90% 
acetonitrile concentration in the solvent gradient, and was detected in both ionization 
modes. These ion peaks from the second group, showing m/z of 693.5, 719.5, 733.5, 
747.5, 759.5, 761.5, and 773.5 in the negative mode, were attributed to PG(30:0), 
PG(32:1), PG(33:1), PG(34:1), PG(35:2), PG(35:1), and PG(36:2), respectively. The last 
group contained five eluents in the LC-MS profile that eluted at 100 % acetonitrile 
concentration. The ion peaks were assigned as fatty acids of FA(16:1), FA(17:1), 
FA(16:0), FA(18:1), and FA(19:1) with m/z values of 253.2, 267.2, 255.2, 281.2, and 
295.3 in the negative mode, respectively. The LC-MS data showed that the ligands of 
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LprA were phospholipids (PG and PE), lysophospholipids, and fatty acids, which were 
known to be the most abundant lipids in the cellular membrane of E. coli. 
 
Figure 2.2b LC-MS profile of the E. coli purified LprA. This is monitored by the 
micrOTOF Q II  in the positive and negative mode. The eluted peaks are integrated into 
three groups, based on the polarity. Except for the first group, the peak ions in both 
modes are the same. In the positive mode, lyso-PE was found and in the negative mode, 
lyso-PA and lyso-PG were identified. The second group of peaks is contributed by the 
diacylated PGs with various acyl chain lengths. Most of the ion peaks in the third group 
are fatty acids from FA(16:0) to FA(19:0). 
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Identifying the structure of the Mtb LprA bound ligands by the collision-
induced dissociation method 
 The LC-MS profile indicated that the major molecules in the ligand pool 
matched the mass of PGs with various fatty acyl chain lengths, where the m/z was 719, 
733, 747, 759, and 761. To confirm the fatty acyl chain lengths of the PGs, the collision-
induced dissociation (CID) method was used to fragment the PGs. This was done by 
applying varying voltage to the collision cell inside the mass spectrometer that 
fragmented the PGs and generated free fatty acyl chains to be detected in the ESI-
negative mode. The results of CID indicated that the molecule showing the peak at m/z 
733.4 [M-H]- was indeed PG. This molecule was shown to contain two fatty acyl chains, 
FA(17:1) and FA(16:0), each with a mass of 267 and 255 in the collision mode (Fig 
2.2c). Another molecule (m/z 747.5) that was identified as a PG had two fatty acyl 
chains of FA(16:0) and FA(18:1), showing a mass of 265.2 and 281.2. Using the same 
method to identify the rest of the molecules observed in the LC-MS profiling, the ion 
peak of the m/z 719 was attributed to PG(32:1), which was found to contain FA(16:0) 
and FA(16:1). Similarly, the other two ion peaks, which showed m/z of 759 and 761, 
were assigned to PG(35:2) and PG(35:1), with two acyl chains FA(17:1) and FA(18:1) 
for PG(35:2), and two acyl chains FA(16:0) and FA(19:1) for PG(35:1). The CID results 
supported our preliminary ion peak assignment by comparing with the lipidomic 
database, and confirmed that the majority of the ligands had two acyl chains, which 
matched what was observed in the structural data. 
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Figure 2.2c MS-MS of the bound ligands from the extraction. The potential ligands from 
the LC-MS result are analyzed by the collision-induced dissociation (CID) method. 
Varying voltages are applied to the collision cell, which results in fragmentation of the 
selected ions. These fragments are detected by mass spectrometry to help in identifying 
the molecular structure of the ligand. Two peak species of m/z=733.4 and 747.5 are 
selected to demonstrate the CID mass spectra. 
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The crystal structures of LprA with ligand bound in the cavity reveal two 
different conformations  
 Among all of the identified PGs in our study, PG(16:0,17:1) and PG(16:1,16:0) 
are the best fit in the electron density that is seen in the cavity of protein molecule A and 
B in an asymmetrical unit of LprA, respectively. Two acyl chains of both ligands are 
bound inside the cavity at identical positions in molecule A (Fig 2.3a) and molecule B 
(Fig 2.3b). Except for the length of one acyl chain, these two PGs have identical 
molecular structures. Despite the structural similarity of these two PGs, they reveal two 
different binding conformations, which are accommodated by the two different 
conformations of the protein shown in the two protein molecules in the asymmetrical 
unit.  
 
 
Figure 2.3a Crystal structure of LprA with PG(16:0, 17:1) in the cavity. (mol A)  
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Figure 2.3b Crystal structure of LprA with PG(16:0, 16:1) in the cavity. (mol B). 
 
 The ligand PG(16:0, 17:1) in molecule A reveals a binding conformation that 
forms two hydrogen bonds to the residues on the long loop (Asp120−Asn138) 
connecting α2 and β5. The hydroxyl (-OH) on the sn-1 position of the glycerol head 
moiety forms a hydrogen bond to the carbonyl group of Phe130. The distance measured 
from the carbonyl of Phe130 to the sn-1-OH of the glycerol head is 3.2 Å. The other 
hydrogen bond is formed between the carbonyl moiety of FA(17:1) at the sn-2 position 
of the phosphoglycerate and the amine group of Ile136 at a distance 3 Å. A π-π stacking 
interaction between the side chain of Phe130 and the carbonyl group of FA(16:0) is 
observed in this conformation. However, these hydrogen bonds are not found in the 
structure of PG(16:0, 16:1) bound in molecule B. Instead, the sn-1-OH of the glycerol 
head turns away by 60° from Phe130, where phosphorus is set as center and the angle is 
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measured between the carbonyl oxygen of Phe130 and the oxygen of the sn-1-OH on the 
glycerol of the head group. Here, the phosphate moiety of PG(16:0, 16:1) forms 
relatively weak interactions with the side chain of Arg77 and the backbone of Gly102, 
where the distance between the oxygen on the phosphate moiety to the amine on the side 
chain of Arg77 and the amine on the Gly102 backbone are both 4.5 Å. The side chain of 
Arg77 flips 101° toward the phosphate moiety of PG(16:0, 16:1), which is measured 
between two ε-nitrogen of Arg77 from two conformations with a center fixed on γ-
carbon. In this conformation, the phosphate moiety located outside the cavity makes 
contact with the residues Gln165 and Gln166 from the adjacent molecule formed by the 
crystal packing. The distance from the oxygen of the phosphate moiety to the amine 
group of Gln166 is 3.2 Å. Hence, the distance between the sn-1-OH of the 
phosphoglycerol and the carbonyl-oxygen of Phe130 is 9.6 Å, and the distance between 
the carbonyl group of sn-2-FA(16:1) and the amine of Ile136 is 8.1 Å. 
 The phosphate moiety of PG(16:0, 16:1) is bound at a different site from where 
the phosphate moiety of PG(16:0, 17:1) is bound. The superimposition of molecules A 
and B shows that the different ligand-binding conformations correlate to the long loop 
movement (Asp120−Asn138) and the rotation of the Arg77 side chain. The peptide 
backbones of Ile136 and Ser135 flip 147° and 108°, respectively, toward PG(16:0, 16:1), 
when the angle is measured by the carbonyl groups in the two conformations. Hence, the 
side chain of Ile136 also flips 142°. The angle is from the position of the β-carbon in 
molecule B to the α-carbon and β-carbon in molecule A. The β-carbon on the side chain 
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of Ile136 shifts 4.5 Å toward the ligand to form a hydrophobic interaction, and narrows 
the cavity entrance where the ligand PG(16:0, 16:1) binds. 
 
Identifying the ligands of LprA protein from an Mtb extract 
 The Mtb LprA protein, similarly as other Mtb lipoproteins such as LprG and 
LppX, is expected to have a similar ligand-binding pattern. Mtb LprA overexpressed and 
purified from E. coli binds ligands specifically from the membrane of E. coli. Therefore, 
if LprA is mixed with the lysate from Mtb, the protein would be able to bind ligands that 
are found in Mtb. However, because the Mtb LprA was originally expressed in E. coli, 
the active site of the protein is already occupied by phospholipids from E. coli. Before 
the protein was mixed with an Mtb lysate, an apo-LprA was prepared by removing the 
bound ligands. This required two steps. The first step of removing ligand involved 
unfolding LprA protein in a buffer (20mM Tris pH 7.0 and 0.5 M NaCl) with 8 M urea 
to release the bound ligands, and the ligands were removed from the solution by adding 
1 mM of β-cyclodextrin. Then, the protein was loaded onto a Ni-column and washed 
with 5 column volumes of buffer containing 8 M urea and 1 mM β-cyclodextrin. The 
protein was re-folded on the Ni-chelating affinity column by decreasing the 
concentration of urea from 8 M down to zero, followed by eluting in buffer with 300 
mM imidazole. After dialysis with buffer (20mM Tris pH 7.0 and 0.2 M NaCl), LprA 
protein was homogenized with a cell pellet of Mtb and was lysed together with the cells. 
Then, the protein was purified again through a Ni-chelating affinity column. 
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 The formation of the apo-LprA protein and re-loading of ligands from different 
extracts were confirmed by LC-MS. Three proteins samples, including the LprA purified 
from E. coli, the apo-LprA protein, and the protein mixed with an Mtb lysate, were 
extracted with the same protocol described above. Comparing the LC-MS profiles of 
these three extracts showed that ligands were removed before incubating LprA protein 
with the Mtb lysate, and that the LprA was loaded with ligand from the Mtb lysate. For 
example, the components that were identified in the LC-MS profiles of the E. coli 
purified LprA at 90−100% acetonitrile concentration had completely disappeared from 
the LC-MS profile of the apo-LprA protein. However, the extract of the LprA protein 
mixed with the Mtb lysate had two components in the LC-MS profiles that reappeared at 
the same percent of acetonitrile concentration. The mass (m/z) of these two eluents were 
733 and 719, which matched the mass of PG(33:1) and PG(32:1), and these two ion 
peaks also were observed in the extract of the E. coli purified LprA. This indicated that 
LprA protein bound the ligands from the Mtb lysate (Fig 2.4a). 
 There is no LprA homolog in E. coli; therefore, LprA might have the capacity to 
load ligands that are found only in Mtb lysate. To identify the ligands bound to the LprA 
protein that were unique to the Mtb lysate, the LC-MS profiles of the extracts from LprA 
protein mixed with the Mtb lysate were compared to those of the extract from the E. coli 
purified LprA protein. To capture the ligand without knowing the polarity, two protein 
samples (10 nmol) were extracted with two organic solvents, methanol and ethyl acetate, 
and analyzed by LC-MS. The LC-MS profiles were analyzed by subtracting the 
reference run (the extract of E. coli purified LprA) from the sample run (the extract of 
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Figure 2.4a Identification of potential ligands from the Mtb lysate by LC-MS. 
The overlapped LC-MS profiles of the three extraction samples show the reloaded ligand 
from Mtb lysate. The LC-MS profiles of LprA containing ligands from E. coli (blue), 
ligands removed by cyclodextrin (orange), and ligands from Mtb (red) are shown in an 
overlapped format. Two peaks appear after incubation with Mtb lysate. These reloaded 
peaks represent m/z of 733.5 and 719.5, which match the exact mass of the best fit 
ligands in the crystallographic data. 
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LprA protein mixed with the Mtb lysate). Major differences were found between these 
two extracts in the ESI-positive mode. From the different profiles of the methanol 
extracts, the eluents were in the range of 45−60% acetonitrile concentration in the 
gradient, which indicated that the ligands extracted in methanol were more hydrophilic. 
There were two major eluents at the elution time of 3.5−5 minutes, and three more 
eluents that came later in the elution at about 7.5 minutes (Fig 2.4b). The first eluent in 
the LC-MS that was eluted at 46% acetonitrile contained lyso-PIM3(C17), which was 
observed in the MS at m/z 1094.58, 547.80, and 365.54, corresponding to the same 
molecule in three different charge states. The second major eluent was eluted at 59% 
acetonitrile, and the major ion peak could be attributed to phosphatidylinositol 
phosphate, PIP(38:5), which was observed at m/z 965.50 (z = +1) and 483.3 (z = +2). 
More than one species of PIP was found in the eluents, containing different acyl chain 
lengths that were 913.53 corresponding to PIP(34:3), 937.45  corresponding to 
PIP(36:5), 959.43 corresponding to PIP(36:5), and 987.48 corresponding to PIP(38:5). 
These PIP ion peaks also were observed in the ESI-negative mode. There were two ion 
peaks that were attributed to lysophosphatidylinositol with only one acyl chain, 
LPI(17:1) and LPI(20:4). Peaks representing PIM1 and PIM2 were observed at a lower 
intensity with m/z 1009.46 (PIM1[35:3]), 1038.50 (PIM1[37:1]), and 1170.64 
(PIM2[35:3]). At later elution with organic solvent content close to 100% acetonitrile, 
there were three minor peaks, and each of them contained a single ion peak 
corresponding to LPG(16:1) of 483.26, LPE(17:1) of 488.25, and LPA[10:0] of 349.14, 
respectively. 
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Figure 2.4b Differential LC-MS profiles of E. coli purified LprA and the Mtb lysate 
incubated LprA from methanol extraction. Two protein samples of LprA, one of which 
is purified from E. coli and the other that is incubated with the Mtb lysate, are prepared 
in the same amount (10 nmol) and extracted in methanol. Each sample is analyzed by the 
LC-MS method on a C8-reverse column. The profile shown above is the differential LC-
MS profile, made by subtracting the profiles of these two samples.  
3 4 5 6 7 8 Time [min]
0
25
50
75
100
Acetonitrile
[%]
POS_Me50_ETEE_385A2ID001.d: BPC 230.0-3000.0 +All MS
A2ETMeOH50_pos_jan182011_1-A,4_01_385.d: Solvent B
365.5
465.2
547.8
654.8 1094.6
+MS, 3.7-3.9min #(222-233)
0
2
4
6
4x10
Intens.
300 400 500 600 700 800 900 1000 1100m/z
483.3
585.8
621.4
702.4 866.4
965.5
+MS, 4.6-4.8min #(276-285)
0
1
2
3
4
5
4x10
Intens.
500 600 700 800 900 1000 m/z
913.5
937.5
965.5
987.5
1009.5 1054.6 1100.5 1122.5 1170.6
+MS, 4.6-4.8min #(276-285)
0.00
0.25
0.50
0.75
1.00
1.25
4x10
Intens.
900 950 1000 1050 1100 1150 m/z
eluent2 
Lyso-P
IM
3 (17:0) 
+ N
a 
Lyso-P
IM
3 + N
a 
Z=+2 
P
IP(38:5) 
Z=+2 
P
IP(38:5) 
Z=+1 
P
IP(38:5) 
P
IP(34:3) 
P
IP (36:5) 
P
IP (38:5) + N
a 
P
IM
1 (35:3) 
P
IM
2 (35:3) 
P
IM
2 (31:0) 
P
IM
1 (37:1) 
eluent1 
eluent2 
Lyso-P
IM
3 
+N
a Z=+3 eluent1 
  
 
 
57 
 Following the same experimental procedure in the previously described methanol 
extraction, the protein samples of the E. coli purified LprA and the Mtb lysate mixed 
LprA protein were extracted with ethyl acetate to extract any bound hydrophobic 
molecules. The difference in the elution profiles of the two samples showed four well-
separated eluents, which eluted at the acetonitrile concentration of 87−100% (Fig 2.4c). 
The first two eluents contained small lipids such as monoglycerides (MG), 
lysophospholipids, mycerosic acids, and mycolipenic acids (MP). The mass spectra of 
the first eluent revealed that the m/z of the abundant molecules in that fraction were 
359.30 [MG(C18)] and 431.32 [MP(C27)+Na] in the ESI-positive mode. The second 
eluent contained the same type of lipid molecules, but they had a slightly higher m/z 
387.33 of MG(C20) and 459.36 of MP(C29)+Na. The third and fourth eluents had 
higher intensity shown in this difference profile, and each corresponded to the mass 
spectra signals 337.12 (m/z) and 365.15 (m/z), corresponding to lyso-PIP(16:1) and lyso-
PIP(20:1), respectively. Both mass spectral ions of LPIP were detected in the +2 charge 
state. This was confirmed by observing the ion peaks corresponding to the singly 
charged state at 651.24 (m/z, z = 1) and 707.30 (m/z, z = 1) with a lower-intensity signal 
in the same mass spectrum. 
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Figure 2.4c Differential LC-MS profile of the E. coli purified LprA and the Mtb lysate 
incubated LprA from ethyl acetate extraction. Two protein samples of LprA, one of 
which is purified from E. coli and the other that is incubated with the Mtb lysate, are 
prepared in the same amount (10 nmol) and extracted in ethyl acetate. Each sample is 
analyzed by the LC-MS method on a C8-reverse column. The profile shown above is the 
differential LC-MS profile, made by subtracting the profiles of these two samples. 
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phosphatidylinositol phosphate (PIP). The abundance of PGs in Mtb was favored in 
binding to the LprA. PG was observed as the dominant molecule in the LC-MS profile, 
suggesting that the lipid content in the environment affects ligand binding to the LprA. 
This observation emphasized that the localization of LprA inside the bacteria is crucial 
for ligand identification. Therefore, it was hypothesized that extracting the ligand from 
the full-length LprA, where the N-terminal signal peptide would direct the LprA to the 
designated region, might yield the most physically relevant ligand. 
 The LprA contains a lipo-box at the end of the signal peptide. The signal peptide 
directs the protein to localize in the periplasm and anchor itself to the membrane. The 
lipo-box leads the LprA through the lipoprotein maturation process, in which the N-
terminal signal peptide is cleaved and the signal peptide is swapped by a triacylated 
moiety attached to the N-terminal cysteine. Then, the LprA associates with the 
membrane through the triacylated moiety at the periplasmic side. Because the yield of 
the full-length LprA expressed in Mtb is extremely low, and M. smeg is shown to have a 
lipid composition closer to the Mtb, the full-length Mtb LprA protein obtained from the 
Clifford lab was expressed and purified from M. smeg (SmLprA). The software 
MetaboliteDetect (Bruker Daltonics) was used to process two sets of LC-MS profiles at 
the same time by comparing the signals of the sample to the blank. The software was 
used to subtract the background (blank control) from the MS profile of the sample, 
which resulted in magnification of the signal intensities from the ligand. The extraction 
of protein SmLprA followed the previously described procedure of acid denaturation and 
extraction in ethyl acetate. The extract of SmLprA was run on the LC-MS system with a 
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gradient of water to acetonitrile for 25 minutes, and was analyzed by the mass 
spectrometer (MicrOTOF-Q II, Bruker) in both the ESI-negative and ESI-positive 
modes. The LC-MS data showed a single major eluent in the ESI-negative mode. 
However, there were three major eluents in the ESI-positive mode (Fig 2.5). The first 
compound eluted at 30% acetonitrile, and mostly contained lysophosphates (LPAs). The 
last compound eluted at 88% acetonitrile and contained ion peaks with m/z ranging from 
507.3 to 991.6 that could not be identified (each peak had an m/z interval of 44). The 
retention time of the second eluent in the ESI-positive mode matched the single eluent in 
the ESI-negative mode. Integrating the mass spectrometric peak from the negative mode 
showed that m/z 421.2 was the dominant ion. In the positive mode, the three ion peaks 
were at m/z 445.2, 440.3, and 423.2. Because an ion peak at m/z 844 was observed in the 
negative mode, the ion peak of m/z 421.2 in the negative mode was proposed to be the 
same ion species at a +2 charge state. The same observation in the positive mode 
confirmed that 432.2 and 445.2 both came from the same ion species showing m/z 421.2 
in the negative mode. These ion peaks were all generated from a molecule with neutral 
molecular weight of 844, which matched the molecular weight of PI(35:4) from the 
lipidomic database. The other ion peak in the positive mode (m/z 440.3) followed a 
similar pattern, where it had a positive charge of +2 and a neutral molecular weight of 
878, which also matched the molecular weight of a PI(37:1) in the database. Despite 
LprA bound to diverse forms of phospholipids, the LC-MS analysis of the extract of full-
length SmLprA showed that PI was the major phospholipid bound to LprA when 
expressed in the designated periplasmic region. 
  
 
 
61 
 
Figure 2.5 LC-MS profiles for analyzing the extraction of the full-length LprA purified 
from M. smeg. The top shows the LC-MS profiles of the LprA expressed and purified 
from M. smeg, shown in two ESI modes (the positive mode in orange and the negative 
mode in blue). The lower two figures illustrate the mass spectral data of the eluent (at the 
retention time of 12.5 min) in the ESI-positive and the ESI-negative modes. 
LPA
s PE
s PI
s 
6 8 10 12 14 16 Time [min]
0
20
40
60
80
Acetonitrile
[%]
Sample1_neg_Me_01172012_1-B,4_01_2909A2ID003.d: TIC -All MS
Sample1_pos_Me_01172012_1-B,4_01_2915A2ID004.d: TIC +All MS
Sample1_neg_Me_01172012_1-B,4_01_2909.d: Solvent B
423.2
440.3
445.2
457.3 467.2
+MS, 11.2-11.8min #(667-704)
0.0
0.5
1.0
1.5
2.0
2.5
4x10
Intens.
400 420 440 460 480 m/z
PI(17:1,18:3) 
MW:844(Neutral) 
m/z:423 = (844+2)/2 
m/z:445 = (844+23+23)/2 
PI(18:0,19:1) 
MW:878(Neutral) 
m/z:440 = (878+2)/2 
positive mode 
421.2
489.2
-MS, 11.3-11.9min #(674-707)
0
2
4
6
8
4x10
Intens.
300 350 400 450 500 550 600 650 700 750 m/z
PI(17:1,18:3) 
MW:844(Neutral) 
m/z:421  
(844-2(charge -2))/2=421 
negative mode 
  
 
 
62 
The measurement of the dissociation constant of LprA and phospholipids in 
the intrinsic fluorescent-quenching assay  
 LC-MS analysis of three kinds of LprA protein samples (E. coli purified, Mtb 
ligand loaded, and M. smeg purified) showed that LprA is able to accommodate different 
types of phospholipids from the cellular membrane with various chain lengths such as 
PG, PE, and PI. However, the relative affinity of the lipids for LprA was not known. To 
determine the ligand affinity preference of LprA, a wide range of commercially available 
phospholipids and sphingolipids were selected to measure the dissociation constant (Kd) 
of LprA (Table 2.1). The affinity was measured by monitoring the change in the 
fluorescent emission at 340nm (the excitation is at 278nm) when LprA was titrated by 
phospholipid in buffer (20 mM Tris pH 7.0 and 300 mM NaCl). The fluorescent signal 
from residue Tyr137 located at the center of the cavity is quenched as phospholipids 
bind. The binding results in a decrease of the fluorescent signal, which was monitored by 
a fluorometer. The result showed that the tighter binding types of phospholipids are PE 
(Kd =0.35 mM) and PI (Kd =0.25 mM), which were detected in the previous LC-MS 
profiles. Cardiolipin (18:1) (Kd =0.36 mM) was shown to have a similar affinity for 
LprA. PS, which is another type of phospholipid that localizes in the bacterial 
membrane, had a fairly strong affinity for LprA, where both the Kd to PS(16:0, 18:1) and 
PS(18:1, 18:1) were in the range of 0.6−0.7 mM. By contrast, lipid molecules with a 
similar overall structure and similar chain length as the bacterial phospholipids but only 
found in mammalian cells, such as phosphatidylcholines (PC) and sphingolipids, showed 
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poor affinity for LprA. This indicates that LprA is selective for bacterial phospholipids, 
despite accommodating a broad range of ligands from phospholipids.  
Surprisingly, among all the commercially available lipids tested, one of the major 
components of the bacterial membrane, PG, showed the lowest affinity to LprA. PG was 
shown in the LC-MS profile to be the dominant ligand of the E. coli purified LprA, and 
was observed to be taken up from a Mtb lysate. Therefore, it may be speculated that 
weak PG binding was very likely compensated for by its abundance in the bacterial 
membrane. After comparing the binding affinities of LprA to the different 
phospholipids, it was clear that the phospholipid head group played a critical role in 
defining the binding affinity to the protein. The fatty acyl chain length of the 
phospholipids does not significantly affect the binding affinity, even though the fatty 
acyl chains contribute to binding by forming van der Waals interactions in the binding 
cavity, as seen in the Mtb LprA crystal structures. 
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Table 2.1 Measurement of the dissociation constant. 
 
 
 
 
Phospholipids 
Kd (mM) 
Cardiolipin (18:1, 18:1) 0.36±0.26 
PG160181 2.6±1.1 
PS160181 0.59±0.14 
PS181181 0.71±0.62 
PE160181 0.35±0.36 
PC160160 1.3±0.7 
PC170170 1.9±1.1 
SPH_brain(18:0) 2.1±0.44 
SPH_milk(23:0) 0.93±0.19 
PI181181 0.25±0.04 
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Discussion 
 Based on the crystal structures showing the conformations of the bound PGs, two 
conformations reveal a similar binding pattern. The acyl chains of phospholipids interact 
with the side chains of the hydrophobic residues lined in the cavity, and the head group 
binds at the cavity entrance. Due to the identical core structure of phospholipids, one can 
infer that all of the phospholipids that are found in the extract bind to LprA in a similar 
binding pattern. Furthermore, based on the data presented in Table 2.1, the head groups 
of phospholipids affect the ligand affinity for LprA more than the acyl chains. Taking a 
closer look at the residues at the entrance to the cavity, it may be noted that the residues 
are mainly hydrophobic, except for a few residues of Arg77, Glu106, Ser135, and 
Ser190. These residues are the regions of the protein that are likely to interact with the 
phospholipid head group and act as the key factors for ligand recognition. The two sets 
of ligand-binding geometries show that the head moiety that connects to the phosphate 
group could form interactions with a hydrophilic residue (either Glu106 or Asp129). One 
of the geometries in molecule B shows that the phosphate moiety is positioned where the 
distance of the oxygen of phosphate to the ω-nitrogen of Arg77 is 4.4 Å. The interaction 
between residue Arg77 and the phosphate moiety of any phospholipid might be essential 
for tight ligand binding. In molecule A, the distance between the hydroxyl group of 
Ser135 and the oxygen of the phosphate group is 5.2 Å. This leads to a hydrogen bond 
formed from the carbonyl group of the sn-2-acyl chain to the backbone amide of Ile136. 
Among the ligands found in the extract, the PEs and PIs, which have a higher affinity for 
LprA, could be favored in both binding geometries because both binding geometries 
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result in the head group of the ligand potentially reaching to the hydrophilic residues of 
Glu106 or Asp129.  
 To get the LprA structure with the ligands identified from the extracts, the LprA 
protein mixed with the Mtb lysate and the M. smeg purified LprA was set up in the 
crystallization trial, but no crystals were produced. It was difficult to obtain the crystals 
of the E. coli purified LprA protein. Adding grinded seaweed powder as a nucleation 
agent was the only way to grow the crystals of the E. coli purified LprA protein, and 
obtaining crystals required high concentrations of the protein (70 mg/mL). The difficulty 
to produce protein crystals could be explained by the fact that the phosphate of PG in 
molecule B formed hydrogen bonds with the amide of Gln166 from an adjacent protein 
molecule in the crystal packing. Also, the sn-2-hydroxyl of the head glycerol moiety 
formed interactions to the residues Thr172 from the adjacent protein molecule through a 
water molecule. The distance of this water molecule to the sn-2-hydroxyl and the amide 
of Thr172 were 2.7 Å and 3.0 Å, respectively. Hence, PG binding might be crucial for 
growing the LprA crystals. Because ligands were found to be a mixture in the LC-MS 
analysis, it explained why LprA crystallized only at such high concentrations. There was 
identical core structure of phospholipids and a similar binding pattern in the cavity. 
Hence, the PG-bound structure can reveal how the head group of phospholipid interacts 
with the residues at the entrance. The amine group of the PEs could form hydrogen 
bonds to the side chain of Glu106 or Asp129, which may result in tighter binding when 
compared to the affinity and binding of PGs. The other major ligand group, PI, possibly 
also follows the same patterns of ligand-binding geometries. The head group of PIs, the 
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inositol moiety, interacting with either Glu106 or Asp129 could assist in increasing the 
affinity toward glycolipids (PIMs and PIs). 
 
Structural comparison of the ligand binding to other Mtb lipoproteins, 
LprG and LppX 
 In our study, the crystal structure of LprA is shown to bind a phospholipid in the 
cavity. Similarly to LprA, the other two lipoproteins (LprG and LppX) in this lipoprotein 
family also have been reported to co-purify or co-crystallize with ligands bound in the 
hydrophobic cavity. These three proteins in this lipoprotein family all have a similar fold 
and a conserved lipid binding character. The crystal structure of LppX showed three 
long fatty acids (two C18:0 and one C22:0) in the cavity, which were co-purified from E. 
coli (Fig 2.1c). The crystal structure of LprG bound with a triacylated glycolipid 
(Ac2PIM1) was obtained in our previous study. Unlike LppX, in which the cavity 
entrance is located at the center of the helix-loop side of the protein molecule, LprA has 
more similarity to the LprG fold when comparing the relative location of the cavity to 
the overall structure (Fig 2.1a and 2.1c). The cavity shape in LprG and LprA is similar, 
and the ligands (Ac2PIM1 and PG, respectively), which contain an identical core 
structure of phosphatic acid, have a similar binding pattern in the cavity. The difference 
in the two lipoprotein-folds is in the volume of the cavity, so that LprA can only 
accommodate diacyl phospholipids. The residue of Ala188 and Gly189 on helix-4 
(Ala181−Leu192) in LprA makes the cavity narrower by 4.3 Å, which prohibits a third 
acyl chain to bind (Fig 2.6). 
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Figure 2.6 Structural comparison of the cavity in LprA and LprG shows a major 
difference on helix4. The structure of LprG (PDB code) with the ligand Ac1PIM2 (in 
white) is superimposed with LprA with PG (in pink). Ac1PIM2 has three acyl chains 
bound in the cavity of the LprG. The superimposed structures show that the cavity of 
LprA, unlike that in LprG, can only accommodate two acyl chains. The position of 
helix4 (in cyan) shifts close to the cavity to 3.6 Å, compared to that of the helix in LprG 
(in orange) The protein surface of that helix4 (shown in purple) completely blocks the 
space for the third acyl chain. 
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 The result of the ligand extraction analysis highlighted a few major ligands that 
LprA bound from the mycobacterial lysate, and most of the ligand molecules identified 
in the extracts had a core structure of PI. From the Mtb lysate, LPIP, PIP, and PIM3 
were the major ligands. The core structure shared by PIM3 and PIP has either three 
mannosides or a phosphate attached to the inositol moiety of the PI. PIM is a group of 
glycolipids that is found in the mycobacterial cell wall, and it has various numbers of 
branched mannose on the inositol moiety. PIP is produced when mycobacteria are in a 
stressed environment. The PIs are the dominant ligands in the extract of the full-length 
LprA expressed in M. smeg, which revealed that the LprA bound to specific ligands 
from mycobacteria. 
 We also observed PG and PE in the mycobacterial extract. This implies that the 
promiscuous ligand binding of LprA would have an influence in the protein function. 
The function of LprA could relate to the membrane proteins on the same operon. It has 
been known that LprG is in an operon with a MFS pump, and LprG is required for 
substrate transport mediated by the pump. Similarly, the gene lppX is located within a 
region in the genome that is involved in DIM biosynthesis (phthiocerol dimycocerosates, 
one of the mycobacterial virulence factors), and the function of LppX is related to DIM 
translocation through the cellular membrane. Because lprA is in an operon with two 
genes (Rv1272c and Rv1273c) that make a putative ABC transporter, the function of 
LprA (similarly to that of LprG) could be to mediate substrate transport. It is known that 
the cell membrane composition is dynamic and the PI turnover rate is fast. There is a 
possibility that LprA presents the cell wall environment to the cell for sensing and 
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adapting to stress. The neighboring genes, Rv1272c and Rc1273c, are the homologs to a 
lipid A/phospholipid flippase (MsbA) in E. coli, which transports phospholipids and 
lipopolysaccharides through membrane. This suggests that the promiscuous ligand 
binding is related to the function of LprA. 
 
Lipid antigen comparison  
 Similar ligand-binding patterns are reported in all of the pattern recognition 
receptors (e.g., TLRs) and lipid antigen-presenting proteins (e.g., CD1b and CD1d). The 
lipid antigens bind to the antigen-presenting protein, with the acyl chains in the 
hydrophobic cavity and the head group at the cavity entrance. Mostly hydrophobic 
residues comprise the cavity entrance of the lipid antigen-presenting proteins, similarly 
as that in LprA, and there are two regions containing hydrophilic residues such as Arg, 
Asp, Glu, and Ser, which are conserved in the CD1 protein family. In the structure of the 
CD1 protein with ligand bound (PI-CD1b: 1GZQ, PIM-CD1d: 2GAZ, PC/PE-CD1b3: 
3L9R, cardiolipin-CD1d: 3MA7), all the head groups of those phospholipids show 
interactions with these hydrophilic residues at the entrance. For example, the CD1d of 
PIM2 bound shows that the 3ʹ-hydroxyl of the mannose interacts with the residue Arg79, 
and a distance of 3.3 Å is measured for the 3ʹ-hydroxyl and the ω-nitrogen of Arg79. 
The oxygen of the phosphate moiety forms a hydrogen bond to the side chain of Ser76, 
which could relate to the interaction observed in LprA between the phosphate moiety of 
PG and Ser135. Therefore, the interactions between ligands and these hydrophilic 
residues at the entrance are definitely crucial for ligand binding and recognition. 
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Cardiolipin, which shows tight binding to LprA, is one of the lipid antigens that have 
been shown to bind to the cavity of the CD1b. The structural similarity between CD1b 
and LprA suggests that cardiolipin binds in the cavity of LprA, whereas the two acyl 
chains would bind inside the cavity of the LprA, similarly to that in PG. The other two 
acyl chains could to be exposed to the solvent and might reach the groove at the surface 
of the LprA. The hydrophobic residues at this groove could provide additional 
interactions for ligands such as cardiolipin [CD1b with ligand bound (PDB code: 
3MA7)]. 
 Most of the ligands bound to LprA are identified as the ligands for the antigen-
presenting proteins, and the N-terminal lipopeptide of LprA also is the agonist of TLR2, 
which induces the cytokine response. There are two signaling pathways in which the 
mycobacterial lipids could modulate the host immune response, and LprA shows a 
potential ability to modulate the immune response. TLR2 forms a heterodimer with 
TLR1 or TLR6 and becomes a receptor. It can be induced to send a signal to the 
downstream pathway by binding a subset of the glycolipids on the di-acylated or the tri-
acylated lipoproteins. LprA is the TLR2 agonist because it undergoes N-terminal 
triacylation, which would likely bind to the receptor complex of TLR2/1. The other 
complex (TLR2/6) is induced by the binding of the di-acylated lipopeptides, and it also 
is able to respond to the LprA. Therefore, one cannot eliminate the possibility that the 
diacylated lipids bound to LprA could activate the signal through the complex of 
TLR2/6. PIM1 and PIM2, which were found in the LprA ligand extraction, inhibit the 
LPS-induced inflammatory response through TLR4. The other antigen-presenting 
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pathway is related to the type I and type II CD proteins, in that both adapt to different 
sizes of lipid ligands to present to the T-cell. For example, mammalian PI(18:1/16:0) and 
mycobacterial PIM, which also were found in the LprA ligand extraction, are the 
antigens of CD1d, and are recognized by the T-cells or the NKT cells for antimicrobial 
host defense. 
 
2.3 Methods 
Cloning, expression, and purification of the truncated LprA 
 The gene LprA is encoded with an N-terminal signal peptide, which is for the 
lipoprotein translocation to the periplasmic region of the bacteria through the bacterial 
membrane. Overexpressing proteins that associate with the membrane might not have 
enough yield for the crystallization process. To increase the protein yield, the gene lprA 
was cloned in a truncated form without the signal peptide. The forward primer with an 
NdeI restriction site and the reverse primer with a HindIII restriction site were designed 
to amplify the target nucleotides from the genomic DNA of the Mtb H37Rv (BEI 
resource). This construct contained a His-tag and 190 residues (numbering 45−235) of 
the full length LprA (244 residues). The PCR product was digested with restriction 
enzyme and ligated into the pET30 vector (Novagen). The plasmid of pET30b-lprA with 
antibiotics selection (kanamycin) was isolated and transformed into the cell line E. coli 
BL21 (Novagen). The transformants were plated on Luria-Bertani (LB) agar medium 
containing 50 µg/mL kanamycin. A single colony was picked to inoculate the starter 
culture (20 mL). The cultures were grown to an OD600 of 0.6 at 37°C, and then the 
  
 
 
73 
starter culture was added to 2 L LB media. IPTG (1 mM) was added to the 2-L culture 
when the OD600 reached 0.6−0.8. After inducing protein production with IPTG, the cell 
cultures were placed in a shaker at 18°C for 16 hours. The cells were harvested by 
centrifugation at 3000×g for 40 minutes. The cell pellets were lysed by passing through a 
high-sheer fluid processor in buffer containing 50 mM Tris pH 7.5, 500 mM NaCl, 2 
mM β-mercaptoethanol, and 10 µg/mL DNase. The lysate was centrifuged at 10,000×g 
for 60 minutes at 4°C to remove the cell debris from the soluble protein. The supernatant 
was passed through a 0.22 µm syringe filter before purification on the chromatographic 
system. The clarified supernatant was loaded onto a nickel column (GE Healthcare) in 
buffer 20 mM Tris pH 7.5, 500 mM NaCl, and 2 mM β-mercaptoethanol. After washing 
the Ni-column bound with immobilized LprA with 5 column-volumes of buffer, the 
protein was eluted in an elution gradient of the buffer (20 mM Tris pH 7.5, 500 mM 
NaCl, 2 mM β-mercaptoethanol, and 500 mM imidazole). The LprA protein was 
obtained at ~90% purity, concentrated to 100 mg/mL, and stored at −80°C. 
 
Crystallization and structural determination 
 The truncated LprA (100 mg/mL) was screened under 576 conditions from five 
different crystallization screening blocks, which were set up in the sitting-drop vapor-
diffusion method with the format of 96-well plates (Intelli-Plate, Art Robbins 
Instruments). The protein was pre-incubated with ground seaweed. Under each 
condition, the protein and the well solution were mixed in the protein well with the 
volume ratio of 1:1. After the crystallization plates were sealed for the equilibration, they 
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were placed on a shelf with limited vibration in a room with the constant temperature of 
19°C. Crystals were obtained in the condition of 25% PEG3350 and 0.1 M citric acid pH 
3.5.  
 The crystals were stable under the cryo-protectant (33% ethylene glycol and 67% 
well solution), and the flash-frozen crystals in liquid nitrogen were mounted on the 
home-source copper rotating X-ray generator (MMHF7000-RaxisIV++, Rigaku). The 
best crystal was diffracted to a resolution 2.0 Å, and the data were collected for 180° 
using a 1°-oscillation range per image. LprA was crystallized in the space group C2, 
indexed by HKL2000, with the unit cell dimension of a = 119.059 Å, b = 41.492 Å, c = 
88.204, α = γ =90°, and β = 102°. The complete dataset was integrated and scaled using 
HKL2000.  
 The homology model of LprA was generated from the protein structure of LprG 
in the SwissModel server [99], because the protein sequence identity is 35%. This model 
was the input model for searching the initial phase information. The crystal structure of 
LprA was solved by the molecular replacement method. The initial solution was 
obtained by searching the input model at two steps (rotational and translational model 
searching) to determine the correct orientation of the input model in the unit cell. The 
initial LprA structure was generated in the MOLREP program from the CCP4 suite. The 
initial electron density was generated after a few cycles of the rigid-body coordinate 
refinement (Refmac, CCP4). The model building was done in COOT to fit the protein 
structure in the electron density map. The coordination of each residue from the model 
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building was refined against the X-ray data in PHENIX and Refmac. After rounds of 
iterative model building and refinement, the final model was obtained. 
 
Ligand-reload  
 The truncated LprA was purified in E. coli and the crystal structure showed that 
the cavity was occupied with ligands from E. coli. To load the ligands from Mtb, the 
ligands from E. coli had to be removed first before introducing the metabolite pool from 
Mtb to LprA. Purified LprA was unfolded in the presence of urea at 8M. Then, beta-
cyclodextrin was added at final concentration of 1mM. Unfolded LprA was loaded on 
the Ni-column and washed with 2 column-volumes of buffer containing 3 mM 
cyclodextrin (20 mM Tris pH 7.0 and 500 mM NaCl). When LprA was unfolded, the 
ligands from E. coli were released. An excess amount of cyclodextrin in the buffer could 
carry away those hydrophobic ligands during the washing step while LprA was 
immobilized on the Ni-column. The protein sample was extensively washed on the 
column without beta-cyclodextrin in buffer, and the concentration of urea was decreased 
in the buffer from 8 M to zero. During this washing step, LprA was folded back into an 
apo form without ligand occupying the cavity. Then, protein was eluted by the elution 
gradient of buffer, containing 20 mM Tris pH 7.0, 500 mM NaCl, and 300 mM 
imidazole. After dialysis in buffer without imidazole, apo-LprA was added to the cell 
suspension of Mtb mc2 7000. The cells and the protein were lysed together in the bead 
beater (BioSpec), and the cell lysate was centrifuged at 10,000×g for 60 minutes at 4°C 
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to remove the cell debris. The supernatant was purified on the Ni-column, following the 
same elution gradient protocol mentioned previously. 
 
Ligand extraction 
 The truncated LprA was purified into three forms. Each of them presumably 
presented three different binding groups of ligands in the cavity. To identify the 
difference in ligand binding between these three samples, LprA was required to be 
removed first. Based on the crystal structure of the cavity with the hydrophobic residues 
lining up, the target ligands bound to LprA were predicted to be hydrophobic. Therefore, 
all proteins of these three forms were denatured in an acidic solution (1 M acetic acid) 
and were extracted with organic solvent (methanol or acetyl acetate) for further analysis. 
The purified full-length LprA was extracted with acetyl acetate or methanol, followed by 
protein denaturation in an acidic solution (1 M acetic acid). 
 
LC-MS 
 Each sample obtained from the organic solvent extraction was transferred into 
methanol or a mixture of methanol/acetonitrile, which depends on the solubility in 
methanol. The analysis of the ligands from the extraction was based on the polarity by 
running a separation profile on the C8 column (Waters), which was connected to a liquid 
chromatography system (Agilent). The ligands were eluted in a gradient of solvent 
exchange from water to acetonitrile. The whole process of liquid chromatography was 
monitored by a mass spectrometer (Bruker Micro-QTOF). Data acquired from the 
  
 
 
77 
Micro-QTOF were integrated and analyzed by programs Compass DataAnalysis and 
MetaboliteDetect. 
 
Binding assay 
 To determine the affinity of the potential ligands for LprA, intrinsic fluorescent 
spectroscopy was used to detect the signal decreasing as the ligand bound to protein. The 
LprA was unfolded to remove the ligand with beta-cyclodextrin, which yielded an apo 
form of LprA without ligand bound in the cavity. The wavelengths of excitation and 
emission were 280 nm and 340 nm, respectively, which were determined and optimized 
by scanning the protein at different wavelengths on a fluorometer (Cary Eclipse). 
Adding the stock solution of the phospholipids to the protein (3 µM) would quench the 
emission signal when the phospholipids bound to LprA. The quenched signal indicated 
the fraction of protein that was bound with ligand. Based on the plot of the concentration 
versus quenched signal, each data point was fitted in a linear equation to obtain the slope 
that represented the affinity to the LprA. 
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3. STRUCTURAL ANALYSIS OF PFENR FOR INHIBITOR OPTIMIZATION 
 
 3.1 Introduction 
Malaria is transmitted by mosquitos and occurs mostly in tropical countries. The 
annual incident cases were estimated to be 219 million and caused 660,000 deaths in 
2010 [100]. Regions with a prevalence of malaria are strongly and directly associated 
with poverty in those countries, and the high cost associated with preventative 
administration for controlling the spread of malaria makes the implementation difficult 
to sustain in poor and developing countries[101]. The total cost estimation for 
controlling and monitoring malaria globally according to the WHO malaria report is 
predicted to exceed USD 5.1 billion per year between 2011and 2020. However, the total 
funding was estimated to be USD 2.3 billion in 2011, which was considerably less than 
the amount needed to administer the disease control plan[101]. Given the favorable 
climate, weak infrastructure for implementation, and high cost, many countries are 
struggling to improve the incident and mortality rates. In areas with high incidence and 
transmission rates, malaria is the leading cause of illness and death. Malaria also is an 
opportunistic disease that affects populations with vulnerabilities in natural immunity 
such as young children who have not yet fully developed immunity and pregnant women 
who have weakened immunity[101]. 
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 Following the bite from an infected female Anopheles mosquito, the malaria 
parasites are transmitted into the human body and the incubation period takes from 7−30 
days before the patient has the first-onset malarial symptom[102]. Usually, the most 
dangerous and fatal species, Plasmodium falciparum, has a shorter incubation period. 
Patients might have the three stages of symptoms from a cold stage (chills and shivering), 
hot stage (fever, headaches, and vomiting), and a final sweat stage (sweat, tiredness, and 
body aches), and are required to take the proper treatment according to the 
diagnosis[102]. The proper treatment might require more tests on the parasite species 
that caused infection, the clinical status of the patients, and the drug susceptibility. The 
WHO recommended a general treatment for patients who are suspected to have 
uncomplicated malaria caused by Plasmodium falciparum is most effective with 
artemisinin-based combination therapy[100]. Yet, in regions with lower incidence rates 
of complicated cases, the guideline is to take chloroquine treatment for 2 days when 
symptoms show up, as suggested by the CDC in the United States[102]. A high cure rate 
and low relapse rate are possible once patients comply with proper treatment plan. 
Despite the extensive efforts toward elimination of the disease, the resurgence of parasite 
strains with drug-resistance to effective drugs such as quinoline and antifolate 
(pyrimethanmine and sulphadoxine) catches our attention for a novel treatment 
design[103]. Ideally, the newly developed drug would work to expand the current 
repertoire of drugs and for use in combination therapies that could minimize the 
possibility of spreading drug-resistant strains. 
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 The characteristic of having a plant-like plastid in Plasmodium provides new 
perspectives to search drug targets. Plasmodium belongs to a group of unicellular 
eukaryotes in the phylum of Apicomplexa, which is characterized by a non-
photosynthetic plastid called the apicoplast. This organelle has four layers of membrane 
and is clearly a product of secondary endosymbiosis, in which the eukaryote has 
engulfed and retained another eukaryote with a plastid obtained by primary 
endosymbiosis from a prokaryote[104]. As an evolutionary homolog of plant and algal 
plastids, the apicoplast could be derived from an endosymbiotic Cyanobacterium.[105] 
Therefore, the prokayotic nature of the metabolic pathways is still contained in the 
apicoplast. In addition, a loss of apicoplast results in a block of replication and parasite 
death, indicating that apicoplast-related pathways are essential for parasite survival[106]. 
The finding of the apicoplast and its essentiality to the parasite are intriguing for the 
opportunities they present for therapeutic development. However, the genome of the 
apicoplast (encoding less than 50 proteins) provides limited information about its 
function except for basic metabolic processes such as DNA replication[107]. It was 
found that the majority of apicoplast proteins are nuclear-encoded. These peptides have 
an N-terminal bipartite leader for trafficking proteins into this organelle, which is 
associated with four pathways including fatty acids, isoprenoids, iron-sulphur cluster, 
and heme biosynthesis[105, 108]. These pathways are distinct from the pathways in 
mammals, and this highlights the potential for antimalarial drug targets. 
 Inhibition of the fatty acids biosynthesis pathway is a validated strategy as an 
appropriate target for developing antimalarial drug. Plasmodium has a FAS-II system, 
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commonly found in plants and bacteria. The four enzymes involved in this pathway are 
distinct from the type I FAS (FAS-I) pathway in mammals. In higher eukaryotes, the 
enzymes coordinating the FAS-I biosynthetic pathway are integrated into a 
multifunctional single polypeptide, and the substrate is carried by CoA[109]. By contrast, 
the FAS-II pathway utilizes acyl carrier protein (ACP) to carry the substrate for the 
iterative 2-carbon elongation, and employs four discrete enzymes to catalyze each 
reaction step, including β-ketoacyl-ACP synthase, β-ketoacyl-ACP reductase, β-
hydorxyacyl-ACP dehydrogenase, and enoyl-ACP reductase[55, 110]. The last step is 
the rate-limiting step in the cycle of 2-carbon elongation, and it is catalyzed by enoyl-
ACP reductase (PfENR). The mechanism of this reaction involves a hydride transfer 
from the cofactor NADH to the C3 position of 2-trans-enoyl of the substrate. The target 
study of PfENR has been done with triclosan, which is an effective antimicrobial agent. 
Triclosan is a broad-spectrum antibacterial and antifungal agent, which was first 
characterized as targeting lipid synthesis in E. coli[111]. This finding was confirmed by 
comparing to drugs with known target pathways and the rescued enzyme activity at three 
individual mutated residues in E. coli FabI[111]. Researchers compared the percentage 
of acetate incorporated into lipids in the presence of triclosan and three other known 
antibiotics, including diazaborine (specific inhibitor of FabI), chloramphenicol (protein 
synthesis inhibitor), and ciprofloxacin (DNA synthesis inhibitor). They found that 
triclosan (0.24 µg/mL) inhibited 92% of acetate incorporation, which was similar to 
diazaborine that reduced acetate incorporation by 93%. By contrast, chloramphenicol 
and ciprofloxacin only reduced the incorporation by 19% and 2%, respectively.[111, 112] 
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Triclosan lost its potency of blocking lipid synthesis against the mutant FabIs. Triclosan 
and diazaborine have a similar minimal inhibitory concentration (MIC) value with three 
mutant strains[113]. The results again showed that triclosan targets lipid biosynthesis, 
especially on FabI, which is a protein homolog of PfENR. The Surolia group found that 
triclosan exhibited anti-malarial activity against the growth of Plasmodium with an 
MIC50 of 0.7 µ M, whereas cerulenin, a non-competitive inhibitor of fatty acid synthase, 
had an MIC50 of 20 µ M. When applying 2 µ M of triclosan in the media for measuring 
FAS-II activity, the amount of 1,2 [14C]-acetate incorporated into fatty acids was shown 
to be reduced by 50%[114]. 
The essentiality of FAS-II to Plasmodium and the distinct active site of PfENR 
compared to the enoyl reductase from the mammalian FAS-I system make PfENR a 
qualified drug target for chemotherapeutic treatment. Combined with the potent 
inhibition of triclosan, the triclosan-bound PfENR structure serves as an initial survey of 
the chemical space in the active site. By substituting functional groups at the different 
positions of triclosan, the enzyme inhibition and the structural study of PfENR with 
triclosan analogs are correlated to generate a spatial analysis of the active site. This 
assists to explore the chemical space and the crucial residues for inhibitor binding. 
Therefore, the goal of structure-based inhibitor design of PfENR is to obtain inhibitors 
with higher affinity in vitro. 
 
  
 
 
83 
3.2 Results and discussion 
Overall crystal structure of PfENR-inhibitor complex 
 The protein PfENR was purified based on the protocol published previously. The 
truncated PfENR was made with removal of the bipartite N-terminal signal sequence 
targeted to the apicoplast, and was constructed with an N-terminal His-tag for 
purification with the metal-affinity column. The pure protein was used with inhibitor 
during crystallization, and the crystals were produced from the condition containing 2.4 
M ammonium sulfate and 0.1 M sodium acetate pH 5.6. The crystals with inhibitors or 
substrate were obtained by either soaking or co-crystallization. Inhibitor solubilized in 
acetonitrile was soaked in the  PfENR crystals. This process took more than four weeks 
to get enough inhibitor occupancy in the active site. To efficiently obtain crystals of the 
PfENR protein in complex with inhibitors (days rather than weeks), co-crystallization 
was combined with a screening approach in a grid of 48 conditions, which was an 
optimized work platform to obtain crystals within two days. This grid was made with 
small variations in the ingredient concentration of the "hit" condition. Pure protein was 
incubated with inhibitors individually for one hour prior to setting up the crystallization 
plates. Then, crystals were mounted with the cryo-protectant paratone, and data were 
collected at the home-source X-ray generator with detectors (Raxis and Bruker CCD). 
The crystals from soaking and co-crystallization were isomorphous to the crystals of the 
PfENR-NAD+ complex, and were in the space group of P43212 with unit cells of (131.8 
Å, 131.8 Å, 83.1 Å, 90.0°, 90.0°, 90.0°). Therefore, the crystal structures were all 
obtained by using the model of PfENR-NAD+ complex (PDB:1VRW) in rigid-body 
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refinement in REFMAC (CCP4), and refined with REFMAC (CCP4) or PHENIX to get 
the final structures with each inhibitor individually. 
 The structure of PfENR is reminiscent of the Rossmann fold and each subunit of 
PfENR is composed of 7 β-strands, which form a parallel β-sheet surrounded by 9 α-
helices. The six beta-strands (β1−β6) from the parallel β-sheet compose two repeats of β-
α-β-α-β in the topological order (β1-α1-β2-α2-β3 and β4-α5-β5-α6-β6). Between α7 and 
α8, there is a low-complexity insertion region, where the electron density is missing. The 
overall protein structure is similar to other ENRs when compared in the superimposition 
of PfENR with ENRs from T. gondii, B. napus, M. tuberculosis, and E. coli. The RMSD 
(root-mean-square deviation) of the Cα positions for PfENR with ENR are: 0.6 Ǻ for T. 
gondii, 0.3 Ǻ for B. napus, 0.75 Ǻ for M. tuberculosis, and 0.78 Ǻ for E. coli. The active 
site of PfENR is surrounded by α2, α3, α7, and the long loop between β4 and α5. Within 
the active site, the cofactor NADH binding site is located in the enzyme between α7 and 
the C-terminal end of the β-sheet. Although ENRs share similar folds, there is a major 
difference in a region corresponding to the conformation of α7 (residues 318−321) in the 
PfENR structure. In the E. coli and B. napus ENR structures, this region is a flexible 
loop, showing open and closed conformations of each individual active site. The protein 
structure of B. napus reveals that this loop region has an open conformation, showing 
that the region where triclosan binds is solvent accessible. This loop of E. coli ENR is in 
a closed conformation and is similar to the structure of PfENR. Based on the proximity 
to the active site, the residues on α7 contribute affinity for inhibitor binding and 
substrate recognition. 
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The NADH binding site  
The substrate NADH is located primarily between α7 and α6, but it also is close to 
the C-terminal portion of the β-sheet and α7, and it is wrapped by several connecting 
loops (Fig 3.1). NADH binds to Trp131, Phe167, Ala169, Ser170, and Asn218 with the 
adenine ring moiety. The pyrophosphate moiety of NADH interacts with the loop region, 
connecting between α1 and β1, and the loop region immediately following α4. The 
nicotinamide ring binds deep within the active site and forms interactions with Tyr111, 
Leu265, Tyr267, Tyr277, Ala312, Gly313, Pro314, Leu315, and Ile369. The 
carboxamide moiety of NADH forms hydrogen bonds with Leu315. Tyr277, conserved 
among ENR, is the site where the reaction with the acyl thioester carbonyl group of the 
substrate occurs. 
 
 
Figure 3.1 Overall PfENR structure. 
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 Triclosan binding site 
 Triclosan, a potent inhibitor of PfENR, binds the substrate binding site by 
forming a non-covalent complex with NAD+ and protein primarily through hydrogen 
bonds (Fig 3.2). The crystal structure was reported previously, which was produced by 
incubating protein with triclosan and NAD+, and showed that the binding orientation of 
triclosan is similar to the structures of the ENRs of E. coli, M. tuberculosis, T. gondii, 
and B. napus. In PfENR, triclosan binds between NAD+ and α-helices α6 and α7 to form 
a stacking interaction with the nicotinamide ring of NAD+.  It also forms a hydrogen-
bonding interaction with the 2ʹ-hydrozyl moiety of nicotinamide ribose and Tyr277. In 
the PfENR:NAD+:triclosan crystal structure, the π-π stacking interaction is formed 
between the nicotinamide ring and the phenol ring (Ring A) of triclosan (Fig 3.2). The 5-
chloro moiety of this phenol ring, pointing toward the deepest portion of the active site 
in the closed conformation, formed van der Waals interactions with the side chains of 
Tyr267, Phe368, Ile369, Ala372, and Pro314. On the same ring, the phenolic hydroxyl is 
hydrogen-bonded to the 2ʹ-hydroxyl moiety of the nicotinamide ribose and the oxygen of 
Tyr277. This residue is completely conserved in all known ENRs, and these interactions 
are crucial for the catalytic mechanism and inhibitor design. On the other ring, the 
dichloro-phenoxy ring (ring B) interacts with the pyrophosphate of NAD+, and the 
distance of 2ʹ-chloro from ring B and the oxygen from pyrophosphate is 3.5 Å. This ring 
B is located at the entrance of the pocket that is surrounded by the side chains of 
Asn218, Val222, Tyr277, Met281, and the backbone of residues of 217−231. The two 
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chloro-moieties, individually, interact with Asn218, Ala219, Val222, Met281(4-chloro), 
Ala217, and the oxygen of the pyrophosphate group from NAD+. 
 
 
 
Figure 3.2 Active site of PfENR including triclosan-binding and NAD+-binding sites. 
 
Overall substrate binding in the PfERN-crotonoylCoA complex structure 
 Co-crystallizing PfENR with crotonoyl-CoA (C4:1), which is used in the enzyme 
assay, can explore where the real substrate, acyl carrier protein (ACP), would bind on 
the surface. This protein-NAD-crotonoyl-CoA complex was crystallized in the space 
group P43212 and the crystal diffracted to 2.0 Å, showing the same unit cells (131.5 Å, 
131.5 Å, 82.6 Å, 90.0°, 90.0°, 90.0°) obtained before. Therefore, the structure was 
solved by the same method using the Rigid Body program in REFMAC (CCP4 program 
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suite) due to the identical packing of protein molecules. Crotonoyl-CoA has four carbons 
linked to coenzyme A (CoA) through a thioester bond. In the structure, the butyl group 
on the crotonoyl-CoA binds at the triclosan binding site between Tyr267, Tyr277, and 
the nicotinamide moiety of NAD+, forming hydrophobic interactions with Tyr267 (5.0 
Å) and Tyr277(3.8 Å) (Fig 3.3a). The carbonyl at the C4-position of the butyl group 
forms a hydrogen bond with the 2ʹ-hydroxyl on the ribose of NAD+ at a distance of 3.2 
Å. The butyl chain of the CoA pointing into the deepest part of the active site leaves the 
adenine-ribose-phosphate moiety outside and the pantothenate moiety at the entrance 
portal. This portal is constituted by α7 (residues 317−322) and a loop (residues 
216−219). The thiol group on the beta-mercapto-ethylamine moiety of the CoA formed a 
sulfur-sulfur interaction with Met281 at a distance of 4.4 Å. The electron density for the 
pantothenate at the middle section of the CoA is not as clear as those of the butyl group 
and the adenine-ribosyl-phosphate group. This indicates the binding between PfENR and 
the pantothenate moiety is not tight, which allows crotonoyl-CoA to be flexible at the 
portal region. During crotonoyl-CoA binding, the side chain of Arg318 flips 108°, 
measured from the end nitrogen of Arg in the PfENR-triclosan structure to the same 
nitrogen atom in this structure with a center on γ-carbon of Arg. The conformational 
change allows the portal to become available to accommodate the pantothenate moiety 
binding at the portal between Val134 and Arg318. The adenine-ribosyl-phosphate group 
of CoA binds on the protein surface between α2 (residues 132−143) and the residues 
185−189 on the loop connecting α3 and α4. At this region, which is far from the active 
site with a distance of 23 Å, an adenine group forms a hydrogen bond to Lys140 and the 
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bond length is 3.4 Å between the 3-nitrogen of the adenine and the ε-nitrogen of Lys140. 
The oxygen of the phosphate moiety on this phosphate ribosyl adenine group interacts 
with the nitrogen of Lys185 and the nitrogen of Arg186 and forms hydrogen bonds at a 
distance of 2.8 Å to Lys185 and 2.7 Å to Arg186. 
 
 
 
Figure 3.3a Overall view of crotonoyl-CoA binding in the active site (upper) and the 
structure of crotonoyl CoA (lower). The chemical moieties of crotonoyl CoA are labeled 
as following: 1, 3’-Adenine ribose, 2, diphosphate, 3+4, pantothenic acid (pantothenate), 
4, beta-alanine, 5, beta-mercapto-ethylamine, 3+4+5, panthetheine 
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The PfENR structure with crotonoyl-CoA reveals two crucial regions on the 
surface for substrate binding (Fig 3.3b). One is solely contributed by Arg318 and the 
other is between Lys185, Arg186, and Lys140, where the adenine-ribosyl-phosphate 
group binds. The real substrate is carried by an acyl carrier protein (ACP), where one 
serine residue of ACP attaches to a phosphate-panthetheine moiety and the sulfhydryl 
group at the end of this moiety forms a thiol bond to the acyl chain. It is likely that ACP 
would bind through similar interactions as those observed in the crystal structure of 
PfENR-crotonoyl CoA. Indeed, the protein complex structure of BioH and ACP shows 
that ACP utilizes two sites to bind Arg residues on the surface of BioH(PDB: 4ETW). In 
the structure of ACP, one site is located at residues Asp38 and Asp41; the other is at 
Asp59 and Glu50 (PDB:3GZL). Therefore, these two major sites in ACP (PDB:3GZL) 
have potential for forming the interaction with PfENR when the enzymatic reaction 
occurs. As we proposed, when docking the ACP manually on the surface of PfENR, 
these two major interaction sites from ACP are able to bind to the two regions of Arg318 
and Lys185/Arg186/Lys140 from PfENR (Fig 3.3C). Therefore, the pantetheine moiety 
from ACP likely binds between Val134 and Arg318, and ACP makes contacts to the 
surface of PfENR composed by α7 (residues 318−325) and α2 (residues 132−143). The 
residues Asp38 and Asp41 from ACP will be able to form interactions with Arg138 from 
PfENR, and residues Glu50 and Asp59 from ACP will be able to reach the residues of 
Lys185, Arg186 and Lys140 from PfENR (Fig 3.3d). Based on this model, ACP binding 
will not block the potential entrance for NADH. This reveals a tunnel for NADH to 
access the active site, which is constructed by Asp168, Lys240, Lys220, and Asn218. 
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Figure 3.3b Surface view of PfENR with crotonoyl-CoA. The highlighted regions are the 
possible binding site for ACP-docking to form a complex. 
 
 
Figure 3.3c Model of ACP (PDB:4ETW) docking on PfENR 
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Figure 3.3d Possible residues making contact in PfENR and ACP. 
 
Triclosan derivatives with modification at the 2-position 
Inserted in Appendix B. 
 
Triclosan derivatives with modification at the 5-position 
Inserted in Appendix C. 
 
Triclosan derivatives with modification at the 6-position 
This is a continued structural study of exploring the PfENR active site to 
optimize the structure of triclosan, which has an enzyme inhibition (IC50) of 70 nM. A 
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series of chemical modifications was designed to synthesize 4 clusters of triclosan 
analogs with functional groups attached at the 6-position (Table 3.1). The first cluster 
contains six compounds (11−16), and has small functional groups attached such as 
methyl and formyl group. The compounds in the second cluster (21−25) are slightly 
larger than those in cluster one, and have an amide backbone with different numbers of 
methyl moiety attached to the nitrogen. To expand the knowledge of the space in this 
direction of the 6-position, the compounds in the third cluster (aminosulfonyl group, 
31−33) and the forth cluster (ring group, 41−48) have much bulkier functional groups 
attached. Compounds 45 and 46 in the fourth cluster are chlorinated at the different 
positions of the benzyl ring.
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Table 3.1 IC50 of the 6-substitution triclosan analogs. 
Compound R IC50 (µM) 
11 COOH 25±18 
1*2 CH3 0.19± NA 
13 CF3 2.3±2.2 
1*4 formyl 0.20±0.14 
15 cyano 1.5±0.50 
16 CH2OH 4.4±1.8 
21 CH(OH)CH3 3.0±1.0 
22 C(O)CH3 4.7±1.6 
2*3 C(O)NH2 1.6±0.98 
24 C(O)NHCH3 5.6±3.5 
25 C(O)N(CH3)2 5.8±4.8 
31 SO2NH2 4.2±2.1 
3*2 SO2NHCH3 7.0±0.59 
33 SO2N(CH3)2 6.0±3.2 
41 2-propenyl 11±1.0 
42 Tetrazol-5-yl >10 
4*3 Benzyl 0.19±NA 
44 Phenyl 0.55±NA 
45 m-chloro-benzyl 3.7±2.2 
46 p-chloro-benzyl 3.9±3.0 
47 CH(OH)-ph 3.4±1.4 
48 C(O)-ph 1.6±0.50 
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 All compounds were tested in the enzyme assay to measure the IC50 value. 
Compounds were diluted into a series of concentrations ranging from 100 µM to 0.01 
µM and incubated with a mixture of 50 nM PfENR, 400 µM NADH, and 40 µM NAD+ 
for 30 minutes. The enzyme reaction was initiated by injecting crotonoyl-CoA (300 µM) 
and followed by monitoring the depletion of NADH by the omega plate reader. The 
result of the enzyme assay for the 6-position triclosan analogs showed that compounds 
with smaller substituted moieties and hydrophobic moieties have stronger affinity and 
inhibition against PfENR. Comparing the inhibition and the size of the modification at 
the 6-position among the clusters, the compounds in the first cluster with smaller 
modifications all have better inhibition with IC50 in the range of 0.2−5.0 µM, except for 
compound 11 with a carboxy moiety. Compound 12 (methyl) and 14 (formyl) show the 
lowest IC50. However, substitutions of benzyl group, 43, and phenyl group, 44, also have 
low IC50 in the range of 0.2−0.5 µM. The correlation of inhibition versus chemical 
structure from the 6-postion modifications indicates that the additional hydrophobic 
interaction is more favorable to get potent inhibition.  
 Within these 6-position substituted derivatives, five crystal structures of 
PfENR:NAD+ have been obtained with compounds 12, 14, 23, 32, and 43. The binding 
conformations of these triclosan analogs elucidate an interesting result. Except for 
compound 32, the other four compounds in this group bind to the active site with a 
completely opposite orientation that has not been reported previously (Fig 3.4a-d). In 
this new orientation, the positions of ring A and ring B are flipped compared to the 
triclosan-bound structure. Hence, unlike all triclosan analogs, the critical hydrogen bond 
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for tight inhibitor binding between Tyr277 and the phenolic hydroxyl on ring A is not 
seen in the structure of these four 6-position modified analogs. Instead, this hydrogen 
bond is replaced by an interaction between the 2'-chloro moiety from ring B and the 
hydroxyl of Tyr277, given a distance of 2.4 Å from the 2'-chloro to the oxygen of the 
Tyr277 hydroxyl. The two rings flipping results in the 6-position modifications reaching 
where originally the 3'-position modifications would point in the structure of triclosan. 
Now, the modified groups point outward from the active site to a new site, which is the 
NADH access tunnel. At this site, the protein surface for making interactions with the 
modified functional groups are through the side chains of residues Ala319, Ala322, 
Asn218, and Trp131, and the backbone of Ala217 (Fig 3.4e). This supports the result of 
the enzyme assay, in that the hydrophobic moiety here contributes to the inhibitor 
binding and the bulky modifications are not in favor. 
 
 
Figure 3.4a Crystal structure of PfENR with triclosan analogs of the 6-position 
substitution: compound 12. 
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Figure 3.4b Compound 14. 
 
Figure 3.4c Compound 23. 
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Figure 3.4d Compound 43. 
 
 
Figure 3.4e Overlap of 6-subsitution analogs binding in the flipped orientation. 
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Figure 3.4f Compound 32. 
 
 
Figure 3.4g Ring A of compound 32 blocks NAD+ binding.  
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The crystal structures of these derivatives are probes for revealing the 
interactions that could contribute to the inhibitor affinity at this NADH access tunnel. In 
compound 23 (the carboxamido group), the amine group interacts with the oxygen from 
the carbonyl group in the backbone of Ala217, and it forms a hydrogen bond at a 
distance of 3.1 Å. Compounds 12 and 43 use the methyl and benzyl group to form van 
der Waals interactions to the side chains of Ala319, Ala322, and Val222, and these two 
compounds are the most potent inhibitors among the 6-position substituted derivatives. 
Compound 14 (formyl group) is a potent inhibitor with a non-bulky modification, which 
is not expected to cause any penalty for binding. The crystal structures explain the two-
rings-flipping phenomenon, because there is no available space at the original 6-position 
direction to accommodate additional modification. All the space at this direction is 
occupied by the side chain of the Tyr267, which prevents the binding of these 6-
substituted analogs and results in a flipped binding conformation. Interestingly, one of 
the weak inhibitors, compound 32, binds in the same orientation as the original one in 
the triclosan structure (Fig 3.4f). However, the electron density for the α7 (residues 
318−325) is missing because this region becomes completely disordered on compound 
32 binding. Due to the narrow space between inhibitor and Tyr267, compound 32 binds 
in a conformation with a flipped ring A. The 1-hydroxyl group on the ring A flips 141°, 
measured from the 1-hydroxyl of triclosan to the 1-hydroxyl of compound 32 with a 
center at the 1-carbon in the ring A, and the flipping ring disrupts the critical hydrogen 
bond between inhibitor and the hydroxyl of the Tyr277 side chain. In this binding 
conformation, the ring A is placed where the nicotinamide moiety of NADH and ring A 
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of triclosan bind (Fig 3.4g). Therefore, NADH is not seen in this structure. The oxygen 
of the sulfonyl group forms a hydrogen bond to a water molecule at a distance of 2.5 Å, 
and this water molecule also forms a hydrogen bond with the oxygen of the carbonyl 
group of Leu315 at a distance of 2.3 Å. The structure of compound 23 suggests that 
designing a substitution at the 6-position might cause either swapping the positions of 
ring A and ring B, or the ring A flipping. Both conformations result in losing the 
hydrogen bond to Tyr277, which explains why the inhibition by the 6-position 
derivatives is not as potent as triclosan. 
 
The inhibitor binding site defined by the triclosan analogs with substitution 
at 2'-, 4'-, 5-, and 6- position 
            The inhibitor-binding site was surrounded by helix α7 (Pro314−Lys325) and α8 
(Tyr366−Tyr375) at the front, and two loop regions (Ala217−Gln223 and 
Tyr267−Met281) at the back, surrounding where NAD binds. The portal of this 
inhibitor/substrate binding site to the solvent-accessible surface is on the side between 
loop (Ala217−Gln223) and α7 (Arg318−Ile323). The shape of the entrance is narrow 
with a size of 12 Å × 6 Å. Most inhibitors bind at the upper part of the portal, which is 
close to Val222 and Ala322. The lower part of the portal near Arg318 and Asn218 is 
where CoA binds. At the center of the binding site is Tyr277. It is evident that the 
formation of the hydrogen bond to Tyr277 is crucial for substrate or inhibitor binding. 
The inner part of the binding pocket is hydrophobic and is surrounded by Tyr267, 
Ile323, Ala320, Phe368, Pro314, and Ala372 right above the nicotinamide moiety of the 
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NAD, which is where the 5-chloro group from the triclosan is placed in the binding site. 
We found that the bulky substituted modification at this binding direction can lead to 
conformational changes to open up to two new hydrophobic interaction sites. The lower 
site is the one that displayed isoniazid-NAD adduct binding. This site is surrounded by 
Tyr267, Pro314, and Ala372. The upper new interaction site is formed on a flipped 
Phe368, which is caused by the larger moiety substituted at the 5-position of ring A on 
triclosan.  
 
New chemical backbone templates discovered by compound library 
screening  
 Although triclosan is a potent inhibitor of PfENR, the majority of triclosan gets 
glucuronated in the human liver. The enzyme UDP-glucuronosyl transferase catalyzes 
this reaction by transferring a glucuronosyl moiety to a substrate that contains hydroxyl 
and amine groups. In this case, the 1-hydroxyl from triclosan becomes a glucuronidated 
phenolic hydroxyl moiety, which will result in a drastic decrease in the affinity to 
PfENR due to the loss of that critical hydrogen bond to the hydroxyl of Tyr277. 
Consequently, glucuronated triclosan is not a potent inhibitor of PfENR, and a new 
compound with a new chemical template is needed for inhibitor optimization. From the 
SAR study of the triclosan analogs, compounds with 5-substitution showed low IC50 in 
the nanomolar range and induced a conformational change at the side chain of Phe368. 
This side chain flipping opens up a new site for optimizing the inhibitor affinity. 
Therefore, compound libraries containing 55,000 structurally diverse compounds were 
  
 
 
103 
tested using a high-throughput screening method. Among the libraries, 880 compounds 
from the Prestwick Chemical Library were FDA-approved drugs. Another 2,000 
compounds from the MicroSource spectrum collection were marketed drugs and natural 
products. The Tuberculosis Antimicrobial Acquisition and Coordinating Facility 
(TAACF) Diversity set contained 1,200 compounds. A commercial compound library 
from ChemDiv for TB testing also was screened. The results of the high-throughput 
screen were filtered by criteria including an IC50 below 1 uM, divergence from the FAS-
I inhibitors, and compound solubility. A few chemical templates, which had the potential 
for the design of higher potency inhibitors and good correlation between in vitro and in 
vivo studies, were selected. The enzymatic screen of PfENR against their chemical 
libraries led to the identification of three series of platforms (piperidines, indoles, and 
tetrahydroisoquinolines) (Table 3.2). Each one of them was picked to target specific 
regions in the active site of PfENR, to pursue the SAR study within each group, and to 
validate the key residues for improving inhibitor-binding affinity. The first series is 
piperidine, which aimed to reach the buried Tyr267 to form a hydrogen bond. Then, the 
indole series was picked to reach the isoniazid-binding pocket by modifying the 
substitution around the indole ring. The tetrahydroisoquinolines were selected based on 
forming a π-π interaction with NAD+. In all three series, the hydrogen bond to the 
hydroxyl of Tyr277 is a conserved interaction. This hydrogen bond also is crucial for the 
inhibitor affinity. To preserve this interaction between inhibitor and protein, an acryl 
amide was selected to be the central unit of all compounds with new backbone template. 
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Table 3.2 Chemical structure and IC50 of the compounds with the new backbone. 
piperidine  PfENR IC50 (µM) 
Pf IC50 
(µM) 
325 
 
0.006 2.1 
Indole  PfENR IC50 Pf IC50 
313 
 
0.54 17.6 
059 
 
1.0 n/a 
160 
 
0.61 n/a 
363 
 
0.92 n/a 
813 
 
0.41 n/a 
865 
 
0.41 n/a 
914 
 
NA n/a 
023 
 
14 n/a 
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Table 3.2 Continued 
THQ  PfENR IC50 Pf IC50 
698 
 
0.005 0.72 
853 
 
0.09 1.66 
855 
 
0.29 3.75 
987 
 
0.092 5.8 
696 
 
0.085 3.12 
745 
 
0.028 n/a 
146 
 
0.064 0.12 
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The complex structure of PfENR and a piperidine compound 
The goal of this piperidine series is to make an interaction with Tyr267 that has 
been shown in the structure of the isoniazid:NAD adduct (PDB:2NQ8). One compound 
325 from the piperidine series has high affinity to PfENR and the IC50 value is 5 nM. 
The crystal structure reveals a central moiety, an acryl amide fused in the piperidine 
ring, and resides at the region that form a hydrogen bond to the hydroxyl group of 
Tyr277 at a distance of 2.4 Å (Fig 3.5). The piperidine ring stacks with the nicotinamide 
moiety from NAD+. The other major hydrophobic interaction is at the portal of the 
active site, which is formed between Val222 and the pyridine ring of compound 325 at a 
distance of 4.3 Å measured from the gamma-carbon of Val222 to the 4-carbon on the 
pyridine ring. The urea moiety linked to the pyridine ring formed two hydrogen bonds to 
the backbone oxygen of Ala219 with a distance of 2.9 Å, and 3.4 Å to the two nitrogens 
on the urea moiety. On the other side of compound 325, the tri-chloro-benzyl-methoxyl 
group is located at the hydrophobic site inside the active site, and has hydrophobic 
interactions with Tyr371, Phe368, and Ile323. The two chloro groups (2-chloro and 4-
chloro) form chloro-arene interactions to the aromatic ring of Tyr267 and Tyr371. The 
distance from the 2-chloro to the aromatic ring of Tyr267 is 3.2 Å, and it is 3.4 Å from 
the aromatic ring of Tyr371. The interactions between the tri-chloro-benzyl group to 
protein residues of Tyr267, Tyr371, Val274, and Phe368 suggest that the hydrophobic 
modification to reach these three residues will increase binding affinity.  
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Figure 3.5 Binding of the piperidine compound 325 in the active site.  
 
The complex structures of PfENR and the compounds with indole platform 
 For the eight compounds (313, 059, 160, 813, 023, 914, 363, and 865) from this 
indole series, the acryl amide moiety, which is the moiety at the center of the molecules, 
is kept to form a hydrogen bond to the hydroxyl from Tyr277. The conserved indole 
group is attached to the nitrogen of the acryl amide moiety. Six compounds (313, 059, 
160, 813, 023, and 914) have a 2-aminopyridine group linked through the -ene group of 
the acryl amide moiety. The other two compounds (363 and 865) have a 3,4-dihydro-
1,8-naphthyridin-2-one group attached at this position on the acryl amide moiety. The 2-
aminopridine and naphthyridinone groups are designed to reach Asn218 and Ala219. 
Hence, the indole group will lie inside the active site and the modification at the position 
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of N-, 2-, 4-, and 8- could reach the hydrophobic pocket, constituted by Tyr267, Ile367, 
Phe368, and Ile323. The IC50 values for the indole series are in the range of 0.4 µM to 
14 µM. Except for the compound 023 with an IC50 of 14 µM, the rest of the indole 
compounds are at 0.4 µM to 1 µM. Compounds 813 and 865 show the lowest IC50 of 0.4 
µM (Table 3.2). 
 The crystals were obtained by co-crystallization. Each compound was incubated 
with protein and screened with a grid of 48 conditions around the hit condition. Data 
collection and structural determination were as optimized previously, and the crystals 
had the same packing with identical space group and unit cell as the crystals of 
PfENR:NADH. The indole compounds all bind in the same orientation and the indole 
ring, as proposed, lies in the hydrophobic pocket and forms a T-shaped aromatic ring 
interaction to Tyr277. Except for the indole ring of compounds 160 and 023, all the 
indole rings are at the same orientation and the N-methyl moiety on the indole rings has 
hydrophobic interactions with Ala372 and Val274. The distance of the N-methyl to the 
γ-carbon on Val274 and β-carbon on Ala372 is 4.4 Å and 3.7 Å, respectively. The 7-
position modifications (7-methoxyl, 7-methyl, and 7-chloro) on the indole ring, shown in 
the structure of compound 059 (Fig 3.6b), 363 (Fig 3.6f), 813 (Fig 3.6d), and 914 (Fig 
3.6h), point at the direction of Phe368 and form hydrophobic interactions with the 
aromatic ring of Phe368. The distance is 3.8 Å, measured from the carbon on the 7-
methoxy of compound 059 to the γ-carbon of Phe368. The 2-methyl modification in 
compound 813 reaches the isoniazid binding site that is approached by the isoniazid-
NADH adduct. Here, the modification on the 2-position could form an interaction with 
  
 
 
109 
the aromatic ring of Tyr267. Due to the inhibitor binding conformation, the modification 
at the 4-position induces the indole ring to flip by 180°. This results in the N-methyl 
moiety of compound 160 pointing at Val222 and Ile323 (Fig 3.6c). The distance from 
the carbon of N-methyl to the γ-carbon of Val222 is 3.4 Å, and Ile323 interacts with the 
indole ring at a distance of 3.1 Å from the δ-carbon to the 1-nitrogen from the indole 
ring. The 4-methoxy moiety lies in the isoniazid-binding site. Compound 023 also shows 
a flipped indole ring (Fig 3.6e). Therefore, the N-benzyl moiety binds to where Ile323 is 
originally located and causes conformational changes at the α7 (residues 319−324), 
which is the reason why residues 322−325 become disordered and have no electron 
density. The other bulky modification is made in compound 313 with a benzyl-methoxy 
moiety at the 7-position on the indole ring. This bulky substitution does not induce 
indole ring flipping (Fig 3.6a). Instead, the 7-benzyl methoxy moiety reaches the 
hydrophobic site to interact with Phe368 and Tyr371. 
 The analysis of the correlation between the IC50 value and the inhibitor structures 
shows that bulky substitution at N-position and 4-position induces indole ring flipping. 
On binding, the bulky moiety on the indole ring (such as that of compound 023) de-
stabilizes the secondary structure of helix-7 and decrease the inhibitor potency. 
However, the bulky moiety modified at the 7-position (such as that in compound 313) is 
able to reach the hydrophobic site of Phe368 and Tyr371, and keep the IC50 value similar 
to compounds 813 and 865, which are the most potent inhibitors of this series. 
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Figure 3.6a Crystal structure of indole compound binding in the active site: indole 
compound 313. 
 
 
Figure 3.6b Indole compound 059. 
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Figure 3.6c Indole compound 160. 
 
 
Figure 3.6d Indole compound 813. 
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Figure 3.6e Indole compound 023. 
 
 
Figure 3.6f Indole compound 363.
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Figure 3.6g Indole compound 865. 
 
 
Figure 3.6h Indole compound 914. 
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Figure 3.6i Indole compounds overlap. 
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The complex structures of PfENR and compounds with 
tetrahydroisoquinoline platform 
 The goal of the tetrahydroisoquinoline (THQ) series is to reach the hydrophobic 
site that has been explored with the indole series, and to further optimize the inhibitor 
potency. In this series, the center template base is still an acryl amide moiety, which is 
now fused to a tetrahydroisoquinoline moiety on the nitrogen of the acryl amide moiety 
(Table 3.2). To explore the hydrophobic site and the entrance portal, compounds with 
THQ moiety are elongated with another two rings. Therefore, the THQ compounds have 
at least three ring systems, including the center moiety of tetrahydroisoquinoline, 
pyridinyl, and benzyl rings. Compounds in this series all have a benzyl-methoxyl moiety 
connected at the 6-position of the tetrahydroisoquinoline moiety. The modifications on 
the benzyl ring, including cyano- substitution (698, 853, 855, 987, 696, and 146) and 
halogen-substitution (698 and 745), are used to define the potential residues at the 
hydrophobic site that make interactions with inhibitors. On the other side of the 
compound, the 3-carbon on the acryl amide (2-propenamide) moiety is linked with a 2-
aminopyridine moiety as a base for further modification. Four compounds (987, 696, 
745, and 146) are designed with further modification on the 2-aminopyridine ring such 
as the attachment of the acetyl (696), 3-methoxypropanamino (987), and pyridinyl (745 
and 146). Amazingly, the compounds in this series have IC50 in the range of 5−288 nM. 
First, compared to all the triclosan analogs and the indole series, this 
tetrahydroisoquinoline series has the lowest IC50 on average. The IC50 of compounds 745 
and 698 is 28 nM and 5 nM, respectively, which is lower than the IC50 of triclosan. 
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 The crystal structures with THQ compounds were obtained through co-
crystallization by the optimized-grid screening method. Crystals were produced in the 
same space group and were indexed to the same unit cell as those of PfENR:NAD. 
Therefore, the crystal structure were solved by using the PfENR structure with triclosan 
bound (PDB:1NHG) using a refinement program (rigid body program in REFMAC from 
CCP4 suite). Out of seven THQ compounds, six crystal structures of PfENR-THQ 
complex were obtained. The binding orientation shows that the 2-aminopyridine moiety 
locates at the entrance portal and the THQ ring forms a T-shaped aromatic interaction 
with Tyr277, which results the benzyl ring binding in the hydrophobic site (Fig 3.7). The 
hydrogen bond between the oxygen from the acryl amide and the hydroxyl from Tyr277 
is still conserved in this series. Compounds 698 (Fig 3.7a), 855 (Fig 3.7c), and 853 (Fig 
3.7b) have identical 2-aminopyridine ring binding at the entrance portal. The nitrogen 
from the 2-amino moiety forms a hydrogen bond to the oxygen of Asn218 at a distance 
of 3.4 Å, and the nitrogen from the pyridine ring forms a hydrogen bond to the nitrogen 
on the backbone of Ala219 at a distance of 2.9 Å. The pyridine ring has van der Waals 
interactions with Ala222, Ala322, and Ile323 at a distance range of 3.6−4.2 Å. One of 
the modifications on this pyridine ring, 5-carboxyl-pyridinyl moiety (745) seems to form 
extra interactions with Ala322 and Gln223, where it forms hydrogen bonds with the 
oxygen on the carboxyl moiety (Fig 3.7f). One is at a distance of 3.2 Å from the oxygen 
on the backbone of Ala322, and the other is at a distance of 3.0 Å between the nitrogen 
on the side chain of Gln223 to the oxygen of carboxyl moiety. 
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Figure 3.7 Crystal structures of the THQ compounds binding in the active site. 
 
 
Figure 3.7a THQ compound 698. 
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Figure 3.7b THQ compound 853. 
 
 
Figure 3.7c THQ compound 855. 
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Figure 3.7d THQ compound 987. 
 
 
Figure 3.7e THQ compound 696. 
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Figure 3.7f THQ compound 745. 
 
The side chains of Phe368, Tyr371, Pro314, Val274, and Ile426 from the 
adjacent protein molecule make van der Waals interactions to the benzyl ring. The 
interactions from the adjacent molecule also are observed in the structure of compound 
313 from the indole series. Compounds 855 (Fig 3.7c), 987 (Fig 3.7d), and 696 (Fig 
3.7e) all contain a cyano moiety attached to the para position of the benzyl ring. This 
cyano moiety points to Asp424 from the adjacent molecule, and the cyano moiety likely 
interacts with the carbonyl on the backbone of Asp424 at a distance of 3.4 Å, measured 
from the nitrogen of the cyano to the oxygen from the carbonyl of Asp424. Residues 
from Asp425−Glu432, as a part of the C-terminal loop, were missing in the previously 
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determined crystal data. When PfENR co-crystallized with 987 and 696, these residues 
form a new helix that had not been seen before, which interacts with the cyano- 
substitution on the benzyl moiety (compound 987 and 696). The modifications on the 
ortho position of this benzyl moiety in compounds 745, 698, and 853 show interactions 
with residues of Phe368 and Tyr267. The chloro substitution from compound 698 
interacts with the hydroxyl of Tyr267 at a distance of 3.4 Å from the chloro to the 
oxygen of the Tyr267 hydroxyl. Yet, the chloro substitution of compound 745 forms a 
chloro-π interaction with Phe368. A cyano substitution on the ortho position from 
compound 853 binds at the same position as the chloro substitution from compound 745, 
and has a CN-π interaction with Phe368. 
 The analysis of the correlation between the IC50 value and the THQ structures 
shows that the ortho substitution on the benzyl ring is crucial to make a compound such 
as 698 with an IC50 value of 5 nM. When comparing compounds 698 and 855, the 
compound 855 without o-chloro substitution as the only structural difference from 698, 
and its IC50 is 288 nM. Even with an o-cyano substitution (853), the affinity for PfENR 
is not as strong as that of 698. This highlights the interaction between the chloro to the 
hydroxyl group of Tyr267. Alternatively, the o-chloro is able to form the Cl-π interaction 
to Phe368, which increases the binding affinity of 745 with an IC50 of 28 nM. The o-
substitution on the benzyl ring forms interactions with aromatic rings such as Tyr267, 
Phe368, and Tyr371, which also is supported by the structure of compound 325 and its 
low IC50 of 5 nM. However, modifications on the 2-aminopyridine ring are not as critical 
as those on the benzyl ring located in the hydrophobic site, because compound 696 and 
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745 with different modifications show similar values of IC50. Despite the low 
contribution to affinity from the modification on this pyridine ring, one advantage for 
drug optimization is found by comparing 146 and 855. Compound 146 with a bulky 
substitution (5-floro-pyridinyl group) has lower IC50 than 855. This suggests that further 
modification on the 2-aminopyridine ring will not dampen the inhibition, but it could be 
used for improving compound solubility, which could lead to better IC50 in vivo. 
 
3.3 Methods 
Expression and purification of PfENR 
  The PfENR-pET28a vector was made previously in the lab and was transformed 
in Rosetta-2 BL21 (DE3) cells (Novagen). The cells were grown in Terrific broth at 
37°C, and when the cell culture reached OD600 of 0.8, isopropyl-1-thio-D-
galactopyranoside (IPTG) was added to a final concentration of 1mM for induction. 
Then, the culture was further incubated for 5 hours at 37°C to overexpress the protein. 
Cell pellets were spun down at 4,000 rpm for 30 minutes and resuspended in buffer A 
(20 mM Tris pH 8.0, 500 mM NaCl, and 50 mM imidazole). The suspended cells were 
disrupted using a French press, followed by centrifuging at 15,000 rpm for 1 hour to 
remove cell debris. The clear supernatant was filtered by 0.22 µ m syringe filter and 
passed through a nickel column (Pharmacia). 
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Inhibition study 
 The PfENR inhibition enzyme assays were done in a 96-well format by 
monitoring oxidation of NADH at 340 nm and reading by plate reader (POLARstar 
Optima). The pre-mix containing 50 nM PfENR, 400 µ M NADH, and 40 µ M NAD+ in 
buffer of 20 mM Tris pH 7.5 and 150mM NaCl was transferred in aliquots to a 
COSTAR 96-well plate. Inhibitors were added to the well, and the incubation was at 
room temperature for 30 minutes. The substrate, 300 μM crotonoyl-CoA, was added by 
injector from the plate reader (POLARstar Optima) to initiate the reaction. The IC50 was 
calculated from a dose-response plot of enzyme fractional activity as a function of 
inhibitor concentration. 
 
Crystallization, data collection and structure refinement 
 Pure protein was used for setting up the hanging-drop and vapor-diffusion 
method, and was crystallized with NADH and inhibitors. One method to obtain protein-
inhibitor complex structure is the soaking method, which produces crystals of the binary 
complex containing PfENR and NADH. The final concentration of protein is 20 mg/mL 
in buffer of 20 mM Tris pH 7.5 and 150 mM NaCl. Prior to setting up the crystallization 
plate, 4 mM NADH was added to the protein, and the well solution was made with 2.5 
M (NH4)2SO4 and 0.1 M sodium acetate pH 5.6. The cover slides were used to mix the 
drops with 2 μL of protein incubated with NADH and 2 μL of well solution. The cover 
slides on each well were sealed, and the drops on the slides were equilibrated against the 
well solution at 18°C with the crystallization plate placed in a vibration-free 
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environment. Once crystals were formed, 1μL of inhibitor dissolved in acetonitrile (1−5 
mM) was directly added to the drops containing crystals for the soaking process. This 
might take 1−3 weeks to allow inhibitors to have enough occupancy in the active site. 
The other method is co-crystallization, in which 20 mg/mL protein was mix with 0.5−1 
mM inhibitor on ice for one hour before setting up the crystallization plate. The plates 
had 48 conditions on a grid, with a gradient change in concentration of (NH4)2SO4 along 
the columns (from 1.9−3.0 M) and a gradient change of sodium acetate along the rows 
(from 0.085−0.115 M). The plates were set by a robotic system (Art Robbins) with the 
sitting-drop vapor-diffusion method, and equilibrated at 18°C. Crystals from these two 
methods were mounted in the cryoprotectant paratone for data collection. During data 
collection, the crystals were collected under cryostream at 120 K, and were rotated in 
step from 0° to 120−180° with an oscillation angle of 1°. The crystals from soaking and 
co-crystallization were isomorphous to those of the binary complex, and were 
crystallized in the space group of P43212 with unit cells of a = b = 134.0 Å, c = 84.0 Å. 
Each asymmetrical unit contains a dimer of PfENR. 
 Due to the protein-inhibitor crystals being isomorphous, the initial phase was 
obtained from the previously solved PfENR-NAD+ structure by running rigid-body 
refinement in the REFMAC program (CCP4). Each data set was refined by CCP4 or 
PHENIX and viewed by COOT. The protein coordinates of the PfENR-NADH complex 
(PDB:1VRW) were used to calculate the Fo−Fc and 2Fo−Fc electron density maps. 
Viewing with COOT, data with an average resolution of 2.5−3.0 Å had inhibitor fitted 
based on the Fo−Fc map, and were subsequently refined with PHENIX. 
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4. FUNCTIONAL IDENTIFICATION AND STRUCTURAL STUDY OF TAIL FIBER 
PROTEINS FROM MYCOBACTERIOPHAGE BXZ1 
 
 
4.1 Introduction 
 Bacteriophages are known as phage and belong to a group of viruses that can 
only infect bacteria[115]. Viruses are tiny particles (in the nanometer range) that carry 
genetic material in their core, and a protective protein coat surrounds the viral 
genome[116, 117]. These particles are the most abundant biological entities in the 
biosphere, which self-replicate through a wide spectrum of foreign organisms (animals, 
plants, insects, and bacteria)[118, 119]. They live in diverse environmental conditions 
and exist in a variety of forms that are defined by the host’s preference, morphology, 
genome type, and lifestyle[118]. A virus that can infect bacteria is called a 
bacteriophage[119]. Based on the phage morphology and nucleic acid properties, 95% of 
bacteriophages are classified in the Caudovirales order[120, 121].  In this order, they are 
characterized by a double-stranded DNA (dsDNA) genome and a tail organelle. The 
phages in Caudovirales share similar structural organization with a polyhedral head 
(capsid) that contains linear dsDNA[117, 121]. The capsid is attached to a tail, and the 
apparatus on the end of the tail is constructed into a special system that is responsible for 
recognizing the host and penetrating the bacterial cell wall[117]. 
 Phages have a host range to infect certain bacteria specifically. This infection is 
efficient and has two types: lysogenic and lytic infection. The lytic infection can be 
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defined by plaque formation[119, 122]. A single phage injects the genome into bacteria 
in order to engage the cellular mechanism inside the host to become suitable for the 
phage to propagate. This process of lytic infection is then followed by bacterial rupture, 
which allows the progeny phages to release[118, 123]. Among the bacteriophages, tailed 
phages are found to be predominant. All tailed phages from the order Caudovirales are 
subdivided into three families based on the tail morphology: Myoviridae (long 
contractile tail), Siphoviridae (long noncontractile tail), and Podoviridae (short 
noncontractile tail)[121]. The construction of a phage tail requires multiple proteins from 
a tail assembly pathway. This pathway is thought to add to the complexity and metabolic 
cost of building the tail structures. However, the tailed phages have a long history of co-
evolution with bacteria. The prevalence of tailed phages implies that the tails must 
provide phages with a tremendous evolutionary advantage[117]. 
 The functions of the phage tail are designated for host cell recognition, 
attachment to the targeted bacteria, and penetration of the cell envelope[124]. Hence, 
this extra organelle in bacteriophage, which has not been observed in any other viruses, 
is an important mediator that facilitates the ability to fulfill the infection at an early 
stage. The phage tail is built into a cylindrical shape and is constructed by proteins 
polymerized in a helical conformation. At the distal part of the tail, it encompasses the 
fixation structures and the penetration device that contains the baseplate, spike, and tail 
fiber. The tail fiber is constituted at the most distal part of the tail, which extends from 
the base plate[125, 126]. The function of the tail fiber is in host recognition by making 
the first contact with the specific bacteria[73]. Despite the conserved tail organelle 
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within all the bacteriophages in Caudovirales, the tail morphology and the structure of 
the tail fiber reveal a major discrepancy among the three families of the tailed 
bacteriophages. The difference in the tail morphology lies in the tail length, and it has 
been used for phage classification. Electron microscopic images of the phages reveal that 
the tail length of Siphoviridae and Myoviridae is much longer than that in Podoviridae, 
and the length might be related to host selection and infection capacity of a phage[127, 
128]. The tail fibers from Siphoviridae and Podoviridae are constructed by a shorter 
peptide chain, and there is only one type of the tail fiber reported for each of these two 
phage families. By contrast, Myoviridae has two types of tail fibers. One type of tail 
fiber is the same as that observed in Siphoviridae and Podoviridae, and it is known as the 
minor tail fiber[129]. The other is known as the major tail fiber; it contains a unique 
structure, which features six major tail fibers that extend from the base plate[125]. The 
structure of the major tail fiber in Myoviridae displays a longer length than its own 
minor tail fiber and the tail fiber of the other phage families. The major tail fiber has an 
assembly of a long fiber with a kink in the middle, and the end of this major tail fiber is 
constructed of major tail fiber proteins (major TFPs)[130]. Clearly, this suggests the 
importance of the major TFPs in the early process of phage infection. 
 The major TFP located at the tip of the tail fiber makes the very first contact with 
a receptor on the surface of the bacteria. This protein plays an important role in 
providing specific recognition and tight binding to allow phage docking on the bacteria. 
The tail fiber initiates crucial binding to the bacteria in the process of the phage 
infection, and it is likely that this binding results in host specificity[124]. Myoviridae 
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utilize this major TFP to recognize bacteria while floating and randomly encountering 
organisms in the environment. Once the binding of the major TFP to the bacteria is 
established, it allows the phage to settle on the surface, and the kinks in the major tail 
fiber allow the minor TFP to make secondary contact onto the bacterial surface. 
Consequently, the tail spikes hold on to the surface and induce the conformational 
changes in the base plate[125]. The tail is contracted in order to penetrate the membrane 
and inject the phage genome into the bacteria[126]. Because the binding between the 
major TFPs and the bacteria is the required first step of phage infection, elucidation of 
the molecular structures of the major TFPs has been crucial for understanding bacterial 
recognition by bacteriophages. Any knowledge gained about the mechanism of 
recognition by the tail fiber proteins could be applied toward diagnosis and therapy of 
the diseases caused by bacteria. 
 Mycobacteriophages are known as phages that cause infections specifically in 
mycobacteria. It has been discovered that two different mycobacteriophages (I3 and 
bxz1) could be used as a tool for gene transduction in several species of 
mycobacteria[127, 131]. Phage I3 and bxz1 are lysogenic phages, which integrate phage 
nucleic acids into the bacterial genome; phage proliferation depends on bacterial 
reproduction [122]. They have shown to be capable of transducing auxotrophic and 
drug-resistance markers in Mycobacterium smegmatis (M. smeg). These transducing 
phages in mycobacteriophage are both found in Myoviridae, which contain the major tail 
fibers in the tail structure. Bxz1, which was first isolated from soil samples, has shown 
higher transduction efficiency than I3[131]. Particularly in mycobacteriophages, the tight 
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binding of the major TFP to the bacterial surface is likely to be one of the factors that 
result in a higher frequency of genetic transduction in mycobacteria. In our study, we 
have identified the gene encoding TFP in bxz1 by comparing the genetic sequences of 
TFPs from other bacteriophages such as T4 and TM4. Based on our hypothesis of the 
identified TFP gene, the binding of an engineered major TFP to the bacterial surface will 
demonstrate the bacterial targeting mechanism of the mycobacteriophage. Additionally, 
the crystal structure of the TFP from bxz1, reported here, is the first TFP structure of 
mycobacteriophages. The structure reveals a fold, which is observed in viral fiber 
protein, and exhibits a novel structure of the major TFPs from all bacteriophages. 
 
4.2 Results and discussion 
Identification of the tail fiber protein of mycobacteriophage  
Due to the ability of efficient gene transduction and a specific host range to M. 
smeg, mycobacteriophage bxz1 was selected for identification of tail fiber protein (TFP). 
Mycobacteriophage Bxz1 is in the Myoviridae family, where only 1% of the 
mycobacteria are classified.[128, 132] This phage has a specific host range and exhibits 
specificity to M. smeg and M. vaccae, but not to Mtb[131]. The specificity between the 
bxz1 and M. smeg was used to guide the elucidation of the mechanism of phage 
recognition. Furthermore, M. smeg is a common model used in the lab for Mtb-related 
studies because of its short doubling time. The advantage of using the M. smeg-bxz1 
model is that M. smeg is not pathogenic to humans, but is able to cause infection in mice. 
Therefore, the application can be expanded to test the therapeutic and diagnostic design 
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in a mouse model. 
Although the genomic sequence of bxz1 has been assembled, the assignment of 
gene function has not yet been completed. To identify the gene that functions as TFP, the 
gene cluster of the tail assembly and the tape-measure protein were first explored. The 
TFP gene is commonly found with tape-measure protein in the operon of the tail that is 
observed in the gene organization of mycobacteriophage TM4 (Fig 4.1a) and 
lactococcus phage TP901-1. This tape-measure protein is a basic component to the tail 
assembly, and it is also a tool used to determine the length of the phage tail. For 
example, gp17 is annotated as a tape-measure protein in Siphoviridae TM4. In the 
proximate region, the gene gp14 that is found to be a putative TFP in TM4 is located 
within this tail assembly operon. In the genome of the lactococcus phage TP-901, the 
gene orf45 is a tape-measure protein, which is in the tail assembly at the adjacent region 
to its tail fiber protein orf49. When the genome of bxz1 was newly sequenced, Pedulla et 
al. reported that gp95 in bxz1 is a homolog to gp17 in TM4. Proximal to gp95, the gene 
gp112 is reported to be a TFP. This shows that bxz1 also follows the pattern of tail 
assembly gene clusters containing the genes encoded as tape-measure protein and TFP 
(Fig 4.1b). Based on the nucleotide length of gp112 and the sequence alignment to that 
in other Myoviridae, this gene should be identified as the minor TFP in bxz1. However, 
the major TFP could not be found in the proximity of this tail assembly. 
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Figure 4.1 Gene organization of tail assembly in (a) TM4 and (b) bxz1. (c) The 
proximal region of the putative major tail fiber protein (TFP) in bxz1.[128] 
 
There are no reports or clear indications of the major TFP in bxz1. The only 
information that could lead to finding the major TFP in the genome of bxz1 is that gp112 
was reported to be a homolog to the gp232 within its own genome, even though gp232 is 
not located in the tail assembly (Fig 4.1c). When looking into the gene organization of 
the major TFP (gp37) from enterobacteriophage T4, the TFP is not located in the tail 
assembly region where the tape-measure protein is typically found. Therefore, T4 and 
(a) TM4 
(b) bxz1 
(c) bxz1 
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bxz1 could have similarities in the gene organization of the major TFP, because both of 
them are in the same subclass of Myoviridae. The sequence alignment shows a sequence 
identity of 34% in the range of the residues 228−298 from gp112 (301 residues in total) 
and residues 1081−1149 from gp232 (1151 residues in total) (Fig 4.2a). These regions 
displaying aligned sequence are where the tips of the major and minor TFP individually 
form. The identified major TFP (gp37) and minor TFP (gp112) in T4 also have a similar 
pattern in their sequence alignment. Like the sequence similarity in gp112 and gp232, 
the residues 751−870 of gp37 (1026 residues in total) and the residues 273−405 of gp12 
(527 residues in total) have a sequence identity of 28%, and yet these regions showing 
sequence similarity are not directly at the C-terminus (Fig 4.2b). Therefore, the 
similarity in the protein sequence at the C-terminus, which has been observed for 
translations of gp112 and gp232, might not be conserved in all species from Myoviridae. 
However, it suggests that these major and minor TFPs of bxz1 might interact with 
similar receptors from M. smeg. 
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Figure 4.2 Sequence alignment of the major TFP and the minor TFP from two 
strains of Myoviridae. (a) gp232 and gp112 from mycobacteriophage bxz1; (b) gp37 and 
gp12 from enterobacteriophage T4. 
Figure 4.2a  
Figure 4.2b  
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The protein sequence of TFP, especially the C-terminal residues, provides the 
specificity in phage binding to bacteria. Therefore, the protein sequence of TFP for each 
phage is unique, which makes the identification difficult. The alignment of two major 
TFPs (gp223 and gp37) does not show similarity throughout the whole protein sequence. 
The variation of the protein sequence among the TFPs is expected because this 
difference in TFPs contributes to the specific recognition to different types of bacteria. 
Despite the fact that bxz1 is evolutionarily related to T4, the phage T4 does not infect 
mycobacteria. Targeting on different hosts could be a result of a distinctive protein 
sequence, where the C-terminal residues correspond to the recognition and specificity of 
the receptors from bacteria. Therefore, the diverse protein sequences and structures 
within TFPs, which are inherent to the protein, makes the identification a challenge. 
 
Demonstration of truncated form of tail fiber protein binding to M. smeg 
 The goal of the study is to demonstrate that gp232 functions as a major TFP in 
bxz1 that binds to the surface of M. smeg. This demonstration of the binding will be 
inspected by two detection methods, by engineering gp232 with two different tags (the 
fused-fluorescent tag and the nano-gold tag) for visualization. In general, Myoviridae 
have major TFPs at the distal portion of the tail fibers. Our hypothesis is that the C-
terminal domain is sufficient to contribute the binding and specificity. Therefore, gp232 
binding to M. smeg is demonstrated with a truncated gp232 containing the C-terminal 
domain, which is a putative binding domain, that is designed based on the secondary 
structure prediction. The truncated gp232 was cloned from genomic DNA of 
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mycobacteriophage bxz1 obtained from the Hartful lab, which contains 237 amino acids 
from the C-terminal region. For fluorescent detection, the truncated gp232 was fused 
with a green fluorescent protein (GFP) tag at the N-terminus that resulted in a 
polypeptide chain of 52 kDa. 
 The fluorescent detection involves attaching a fluorophore at the N-terminal of 
the protein to assist in capturing the association between the truncated gp232 and M. 
smeg under a fluorescent microscope. This constructed protein (GFP-trunc-gp232) 
should show affinity and specificity to M. smeg. Consequently, the GFP signal should 
localize at the cell wall of M. smeg. The truncated protein was expressed in E. coli and 
purified on a Ni-column followed by gel filtration column. Once pure protein was 
obtained, incubating the protein with the bacteria clearly exhibited that the M. smeg 
carried the green fluorescence protein. Examining the protein’s (GFP-trunc-gp232) 
reaction with bacteria such as E. coli indicated that the protein specifically binds to the 
molecules on the surface of M. smeg, but it does not bind to the molecules on the surface 
of E. coli. Noticeably, this experiment exhibited that the binding of gp232 was specific 
in its selection of bacteria (Fig 4.3). 
  
 
 
136 
 
Figure 4.3 Truncated gp232 with an N-terminal GFP tag binds to M. smegmatis as 
observed by fluorescent microscope. 
 
Figure 4.3  
Fluorescent image Brightfield image Brightfield + green filter 
M. smeg 
E. coli 
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The second detection method was to use the gold nano-particles (nano-gold) as a 
signal for the binding of the truncated protein gp232, which can be examined and 
imaged by the electron microscope. The nano-gold particles are commercially available, 
and a particle size of 5 nm was selected because the nanometer scale matched the size of 
the mycobacteriophage (10-15 nm) in relation to the size of M. smeg (~2−8 µm). They 
are spherical nano-gold nanoparticles, which are coated with Ni-NTA (nickel-
nitrilotriacetic acid). The His-tag of the truncated gp232 would bind to the Ni from the 
NTA that is conjugated on the surface of the nano-gold particles on incubation. In 
addition, the binding between gp232 and M. smeg will form during incubation, when the 
binding interface of gp232 makes contact with the surface of M. smeg. To allow the 
nano-gold particles to catch the bound gp232, the first incubation was made with gp232 
and M. smeg, so that the protein can localize on the surface of M. smeg. Then, the 
incubation was spun down to separate the excess free gp232 that was not fixed with M. 
smeg.  After removing the supernatant containing unbound gp232, the nano-gold 
particles were added to the pellet to explicitly detect the bound gp232 on the surface of 
M. smeg. The nano-gold localized at the cell surface was observed by electron 
microscopy (TEM) (Fig 4.4). The result supports our proposed function for gp232 as a 
major tail fiber protein that binds to the mycobacterial surface to allow the phage to 
carry out the infection. 
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Figure 4.4 Truncated gp232 labeled with Ni-NTA-nanogold binds to the bacterial 
surface of M. Smeg as viewed by electron microscopy (JEOL1200). 
Figure 4.4  
• Ni-NTA-Nanogold is 
attached to the truncated tail 
fiber protein by 
polyhistidine(His)-tag 
chelating with Ni.  
• Using electron 
microscope(JEOL1200) to 
detect Ni-NTA-Nanogold on 
the surface of the cell wall.  
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The binding of gp232 and the components located in the cell wall of M. smeg 
The gp232 protein binding on the surface of M. smeg indicates that the receptor 
localizes in the waxy cell wall. If the binding is strong, the truncated gp232 should get 
pulled down to the cell debris, which contains the cell wall components after cell lysis. 
To demonstrate the specific binding to the cell wall components from M. smeg, the 
protein was incubated in separate vials with different cell debris, including that from E. 
coli, Mtb, and M. smeg. Purified gp232 was added to the cell suspension directly before 
lysis. The results exhibited that the majority of the gp232 (~90%) was pulled down with 
the cell debris of M. smeg (Fig 4.5). This suggests that the binding between the receptor 
and gp232 is tight enough so that gp232 gets sedimented with the cell wall components, 
instead of the gp232-receptor complex remaining in the solution. This result implies that 
the receptor possibly has a moiety that contributes to the strong association to the cell 
wall. As controls, when the same procedure was applied to E. coli and Mtb lysates, the 
protein stayed in the supernatant and was not pulled-down by the cell wall components. 
This result confirmed the target specificity, in which gp232 recognizes a particular 
molecule from M. smeg. 
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Figure 4.5 Truncated gp232 binds to the cell debris of M. smeg. Comparing the 
amount of gp232 in lane 1, lane 2, and lane 5, the cell debris of M. smeg pulled down the 
most truncated gp232. 
 
Figure 4.5 
M 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
T
B 
M. 
smeg 
E. 
coli 
 
     
  
 
 
141 
Overall structure of the truncated gp232  
 The truncated gp232 with 237 amino acids (residues 914−1151) and a His tag 
was purified and the protein was crystallized. For phasing, crystals also were produced 
with Se-Met incorporated in the peptide chain due to the lack of homolog structure. The 
best quality crystals for both were obtained using PEG2000 in buffer bicine pH 9.0 with 
additives (either mannose, NAG, or LDAO). The protein crystallized in the P212121 
space group with a dimer of trimers per asymmetrical unit. The unit cell dimensions 
were a = 90.56 Å, b = 92.85 Å, c = 192.73 Å, α = β = γ = 90.0°. The crystals were 
sensitive to the condition change in solution when transferring to cryoprotectant (1 M 
mannose and 25% PEG2000). Data were collected using the synchrotron source (APS 
and ALS) to 2.0 Å. The structure was solved by the MAD phasing method using the 
anomalous signal of Se that diffracted to 2.8 Å. The final model consisted of residues 
from 917−1151 and had a crystallographic R-factor of 0.24 and R-free of 0.30. Nine 
residues from the N-terminal were not visible in the electron density. Seven of these 
residues included the initial methionine and six polyhistidines. The structure was built 
with 234 amino acids from residues 917−1151 and revealed a novel structure of the 
phage tail fiber protein that had no sequence similarity to any known structure. 
 It is known that TFPs form a homotrimer, and these three monomers intertwine 
into an entity as a functional molecule, which also is observed in the structure of the 
truncated gp232 (Fig 4.6). The crystal structure shows that the overall dimensions of a 
homotrimer are 110 × 48 × 48 Å, where three polypeptide chains display identical 
structures (RMSD values of 2.4 Å for C-α atoms). These three subunits of the 
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homotrimer are twisted and intertwined in a prolonged spiral shape along the longest 
axis of its overall structure, and the trimer formation results as a 3-fold axis at the center 
of this trimer. These three polypeptide chains fold into a functional molecule, which 
shows three domains (head domain, shaft domain, and foot domain). The head domain 
(residues 917−1039) and the foot domain (residues 1081−1151) are globular and 
connected by the neck domain (residues 1040−1080) (Fig 4.6). Due to the polypeptide 
chain packing conformation at the neck domain, the twisting is observed in each 
polypeptide chain from the first N-terminal domain to the C-terminal domain rotated 
about 240° along the 3-fold axis. Within the homotrimer, the main force contributing to 
trimer formation is hydrophobic interactions, which are formed at the central 3-fold axis 
of the trimer throughout the whole functional unit. One of the signatures is that the 
hydrophobic residues, such as phenylalanine, from each monomer form a triad geometry 
at the central axis. 
  
 
 
143 
 
 
 
Figure 4.6 Overall structure of the truncated gp232. 
Figure 4.6 
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 The connection head domain 
 The head domain of gp232 protein, composed of 123 amino acids, is a 
connection domain to the rest of TFP (residues 1−914) from the N-terminus, and it is the 
largest domain in the structure of the trunc-gp232 structure (Fig 4.7). The overall 
secondary structure in the head domain is mainly made of coils, and it has 73% residues 
in the form of coils. The trimer has a parallel helix bundle (residues 921−928) that is the 
only helix throughout the whole structure, and it is connected to the rest of the N-
terminal residues. Next to the helix, in the head domain, there is a beta globular 
sandwich domain, which is composed of two beta-sheets (beta 2−4 and beta 5−7). The 
inner beta sheet is anti-parallel to a beta-meander motif composed of beta 5 (residues 
1002−1005), beta 6 (residues 1014−1017), and beta 7 (residues 1032−1037). This beta 
sheet (beta 5−7) from each monomer is close to the interface of the trimer in the center. 
There are two long omega-loop motifs connecting beta 5 to beta 6 and beta 6 to beta 7. 
At the interface, this inner beta sheet utilizes hydrophobic residues, including Leu1036, 
Ile(1015 and 1035), Val(1003, 1004, and 1005), and Ala1002 to maintain the trimeric 
state through the formation of hydrophobic interactions. The outer beta sheet is 
composed of beta 2 (residues 938−940), beta 3 (residues 963−966), and beta 4 (residues 
976−979). The residue Phe933 on the first loop connecting the helix to the outer beta 
sheet (beta 2−4) holds one crucial interaction at the trimer interface. This inter-chain π-π 
interaction is repeatedly observed at the interface throughout the homotrimer in this 
structure. Three outer sheets from each monomer form individually into a mixed 
crossover beta sheet of a psi-loop motif. The overall outlook of this N-terminal head 
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domain is like a propeller with non-crystallographic 3-fold symmetry along the longest 
axis. The axis is parallel to the helix bundle and the outer sheets look like blades of a 
propeller. 
 
 
 
Figure 4.7 Overall outlook of the connection head domain in the truncated gp232. (a) 
Viewing the connection head domain from the side; (b) viewing the connection head 
domain along the 3-fold axis from the top. 
 
 The shaft domain 
 This narrow tube-like domain in the structure of this truncated gp232, which 
contains 42 amino acids in each monomer (residues 133−174), connects the head and the 
foot domains (Fig 4.8). It is constituted by three highly intertwined subunits, and the 
trimer twists to an angle of 240°. Each chain has two strand-loop-strand hairpin motifs. 
Figure 4.7  
(a) (b) 
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Here, the hairpin motifs from each monomer form a triple beta-spiral fold with the other 
two monomers. This domain architecture has not been reported in any other tail fiber 
protein from bacteriophages. However, this beta-spiral fold was found in a few of the 
fiber proteins in mammalian reovirus and adenovirus.  
 The long loop (28 Å) connecting the first beta-hairpin motif to the N-terminal 
connection head domain is the narrowest part of the whole structure (only 10 Å × 10 Å 
in width), and contributes hydrophobic and hydrophilic interactions to the neighboring 
chain that sustain the trimeric conformation. The hydrophilic interactions are seen at the 
interface of the two chains. The oxygen of Asp1056 forms a hydrogen bond (2.8 Å) with 
the hydroxyl of Thr1045 from the adjacent monomer. Another hydrogen bond at this 
interface at a distance of 3.1 Å is between the oxygen of Asp1056 and the oxygen of 
Ser1047. The hydrophobic interactions are made by four sets of hydrophobic residues, 
which individually form triad geometry, including Val1041, Phe1044, Val1050, and 
Phe1057. Out of three hydrophobic Phe triad interactions observed in this structure, 
there are two located in the first layer of the triple beta-spiral (residues 1045−1059). In 
the second layer of the triple beta-spiral (residues 1060−1076), the force that holds the 
trimer together is from three hydrophobic triad interactions (Val1067, Leu1074, and 
Leu1076), and the hydrophobic interactions with neighboring chains. For example, the 
interaction is found between the γ-carbon of Val1061 and the δ-carbon Leu1074 of the 
other chain, and the distance is 3.9 Å. The other hydrophobic interaction is between 
Val1062 to Val1070 at a distance of 3.5 Å between the γ-carbons of Val1062 and 
Val1070. 
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Figure 4.8 Shaft domain of the truncated gp232. (a) Viewing the shaft domain 
from the side; (b) viewing the shaft domain along the 3-fold axis from the top. 
  
The receptor-recognition foot domain 
 The C-terminal receptor-recognition foot domain is the tip of the gp232 tail fiber 
protein, composed of three beta-sandwich motifs. Each beta-sandwich motif has 73 
amino acids (residues 1082−1151) and folds into two crossover anti-parallel beta-sheets 
(Fig 4.9). This motif in the gp232 is different from the greek-key motif found in the foot 
domain of the other TFPs from Siphoviridae. Three beta sandwich motifs are folded and 
packed into this foot domain with 3-fold symmetry, which is a common feature in most 
TFPs. These three globular motifs expand 6 Å outward in diameter from the shaft 
domain, which is the narrowest region of the overall structure, creating a large cavity at 
Figure 4.8 
(
(
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the center of this foot domain. The surface area used to make contact on the bacterial 
receptors is about 800 Ǻ2, which is much larger than that of gp37 of T4, but it is similar 
in size with that of the other known TFPs from Siphoviridae and Podoviridae. 
 The total number of interactions at the interface between the monomers to 
maintain the trimeric form in the foot domain is found to be fewer than the other two 
domains. There are two sets of hydrophobic triad interactions contributed by two 
residues from each chain (Ala1082 and Val1151). Only one inter-chain hydrophilic 
contact is found at the interface of the two beta-sandwich motifs, which is the hydrogen 
bond formed between the oxygen of Thr1104 and the ζ-nitrogen of Lys1084 from the 
neighboring chain at the distance is 3.1 Å. There are fewer interactions between the 
dimer found in the foot domain. Therefore, the interactions between these three beta-
sandwich motifs from each chain are not as tight as those that are formed in the N-
terminal head and the shaft domains. The interactions that hold this foot domain into a 
trimer appeared only in the upper half of this domain, which is closer to the shaft 
domain. This suggests that the lower part of the foot domain could be flexible. The lower 
part of the foot domain, which is the major site for recognizing the receptor from the 
surface of bacteria, has a cavity that is constructed by three chains at the center. The 
centered cavity and the loose packing at the lower part of the foot domain suggests that 
TFP could be flexible at the recognition site. Consequently, this cavity could have the 
ability to change conformation, or expand to accommodate the receptor that could 
facilitate the receptor binding. 
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Figure 4.9 Foot domain of the truncated gp232. (a) Viewing the foot domain from the 
side; (b) viewing the foot domain along the 3-fold axis from the top; (c) viewing the foot 
domain along the 3-fold axis from the bottom. 
 
 
Figure 4.9  
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Overall structural comparison to bacteriophage tail fiber proteins from 
Myoviridae (T4), Siphoviridae (Lactococcus phages), and Podoviridae (T7) 
 Due to the lack of the studies on TFPs in mycobacteriophages, the binding 
mechanism remains unclear. Hence, all of the tail fiber proteins in mycobacteriophages 
were identified putatively based on sequence alignment. However, the sequence 
similarity is not sufficient among all the bacteriophage TFPs for unambiguous gene 
identification. Without sequence similarity to those known TFPs, the TFP identification 
is difficult. This is a challenge that was faced during the identification of the major TFP 
in bxz1. Here, the major TFP of mycobacteriophage bxz1 is identified successfully and 
its structure is the first reported from mycobacteriophage. Currently, there is at least one 
solved TFP structure for each subclass of dsDNA bacteriophage. Nevertheless, the 
protein sequence alignment showed that the gp232 from bxz1 has no detectable 
homology to any of the tail fiber proteins with known structures. Despite the diversity in 
protein sequences, distinctive structures of TFPs are still evolutionarily related to the 
function of TFP. Comparing the protein structures available in the database indicates that 
all TFPs have the intertwined homotrimer conformation equipped with a foot domain at 
the C-terminus, which is likely used for making contact to bacterial receptors. The 
structure of tail fiber protein gp232 maintains those features, but it also shows a very 
unique fold in comparison to the known tail fiber structures.  
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The structural comparison of gp232 to TFPs from T4 
 T4 and bxz1 are both categorized under the family Myoviridae. The common 
feature of having two cell-attachment organelles, a minor tail fiber and a major tail fiber, 
were found in both T4 and bxz1. Despite a common origin between bxz1 and T4, the 
structures of the major and minor TFPs in T4 have been reported and the overall 
structures are completely different from gp232 (Fig 4.10). Nevertheless, there is an N-
terminal domain of the minor TFP in T4 that is similar to the N-terminal connection 
head domain in gp232. However, the rest of the protein structure at the C-terminus is 
formed mainly by coils and does not have any distinguishable domains. The other TFP 
in T4, gp37, exhibits a very long sword-like structure that is completely different from 
the structure of gp232. The driving force used to hold three peptide chains into a trimer 
is abundantly contributed from the hydrophobic triad interactions in the gp232. By 
contrast, it is the coordination bonds to the 7 iron ions that hold the trimer in gp37 
together. Each iron ion forms 6 coordination bonds to the histidines at the center axis of 
the protein, where the hydrophobic triads are located in gp232. There is no domain 
formed at the C-terminus of two TFPs in T4, and the last 80 residues on the C-terminus 
are not as crucial as those in gp232. The last 80 residues in gp232 form a beta-sandwich 
motif, where three of the residues build a foot domain and present a receptor recognition 
site that is larger than the major TFP in T4. The significant structural difference that is 
observed in the TFPs of the T4 and the bxz1 is an indicator of the difference in receptor 
recognition. It further indicates that these TFPs have specificity on different receptors 
from the surface of the bacterial wall. 
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Figure 4.10 Structures of tail fiber proteins from bacteriophages and the viral fiber 
protein. (a) gp232 from mycobacteriophage bxz1; (b) gp37 (PDB:2XGF) from 
enterobacteriophage T4; (c) orf49 (PDB:2F0C) from lactococcal phage TP901-1; (d) 
RBP (PDB: 2BSD) from lactococcal phage P2; (e) gp17 (PDB:4A0T) from 
bacteriophage T7; (f) fiber protein (PDB:1QIU) from adenovirus; (g) fiber protein 
(PDB:3S6Z) from reovirus. 
  
 
Figure 4.10  
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The structural comparison of gp232 and TFPs from lactococcal phage in 
Siphoviridae 
Siphoviridae has a long non-contractile tail and only the minor tail fibers are 
attached directly to the base plate. There are only three structures of the minor TFPs that 
have been solved from the lactococcal phages of the strains TP901-1, P2, and bIL170.  
All of them share high structural similarity, except for the TFP of P2 because it contains 
an extra inserted domain (Fig 4.10). The overall structures of these minor TFPs are still 
formed into a trimer, but are different from the structure of gp232. The two structures 
from TP901-1 and bIL170 only have a helical bundle at the N-terminus and a triple-
stranded beta-helical stalk as the shaft domain. At the end domain at the C-terminus, 
these minor TFPs have three beta-barrel motifs that form a foot domain. However, the 
folding of this domain is similar to the foot domain of gp232. Each chain of the TFP in 
P2 has an extra domain inserted between the helical bundle and the stalk. The three extra 
domains combined with the helical bundle become a similar assembly as that seen in the 
N-terminal head domain of gp232. Despite the difference in the shaft domain, the 
similarity in the domain architecture between gp232 and these minor TFPs from 
Siphoviridae suggests that evolutionary selection might affect the folding of the TFPs. 
That is why the major TFP in the bxz1 (one of the few Myoviridae that infect 
mycobacteria) has a foot domain similar to the TFPs of Siphoviridae, so that it can adapt 
the efficient phage infection mechanism of Siphoviridae to mycobacteria. 
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The minor TFP of Podoviridae T7 shows a foot domain similar to the foot 
domain of gp232 
 There is only one solved protein structure of TFP in Podoviridae T7, which is 
one family of the bacteriophage with a substantially shorter tail organelle. The phages in 
this family lack the long tail seen in Siphoviridae and Myoviridae, which make them the 
smallest bacteriophages. It is likely that the short tail of Podoviridae is not suitable for 
infecting bacteria with thick cell walls, which explains why no mycobacteriophage is 
found in this phage family. Due to the different host range, the TFP of Podoviridae T7 
has the least probability of having any structural similarity with the TFPs of bxz1. The 
middle domain of the TFP (gp17) in T7 is a beta-structured pyramid domain. This 
domain has been seen in the proteins that make the assembly of the cell-penetrating 
device in Myoviridae (phage P2 and phi92), but it is very different from the shaft domain 
of gp232 (Fig 4.10). However, the structure of this gp17 in T7 shows that it has a foot 
domain with a size and fold that are unexpectedly close to what is seen in the foot 
domain of the gp232. Currently, gp17 is the only known TFP to have a foot domain 
similar to that in gp232. This indicates that the overall fold of the foot domain does not 
define the specificity for recognition, but the exact residue composition or the 
electrostatic potential on that recognition surface defines the host specificity. 
 
The potential planar recognition site at the foot domain of gp232  
 The foot domain, which is built from only the C-terminal residues of the 
monomers, results in a tetrahedron conformation with four triangular faces. Three of the 
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triangular faces, connecting the shaft domain, are the interfaces of any two monomers 
from the homotrimer. The last triangular face is the only face of this foot domain 
containing all three monomers of the trimer. It is located at the bottom, which implies a 
potential phage-bacteria recognition site. This planar recognition site of gp232 is 
perpendicular to the three-fold symmetry axis of the homotrimer (Fig 4.11a). It may be 
speculated that this site is where mycobacteriophage bxz1 makes the first contact with 
the mycobacterial surface. At the center of the recognition site, there is an entrance to a 
cavity that is located at the center of this foot domain. It is known that tail fiber plays an 
essential role at the initial stage of phage infection by making contact with the bacterial 
surface. The tip of the tail fiber that is composed of the C-terminal residues of TFP 
provides the attachment and the host specificity. This has been demonstrated in tuning 
the infection of phage P2 by swapping the C-terminal residues with the other TFPs. 
Therefore, the specificity of bxz1 targeting on M. smeg would likely come from the 
recognition site and the cavity in the foot domain of the major TFP. 
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Figure 4.11 Potential receptor-recognition surface of the bacteriophage TFPs and the vial 
fiber proteins. (a) gp232 from mycobacteriophage bxz1; (b) gp37 (PDB:2XGF) from 
enterobacteriophage T4; (c) orf49 (PDB:2F0C) from lactococcal phage TP901-1; (d) 
RBP (PDB:2BSD) from lactococcal phage P2; (e) gp17 (PDB: 4A0T) from 
bacteriophage T7; (f) fiber protein (PDB:1QIU) from adenovirus; (g) fiber protein 
(PDB:3S6Z) from reovirus; (h) the bottom view of the cavity with three different surface 
potentials, which is centered at the receptor-recognition site [red, negatively charged 
residues (Asp and Glu), blue; positively charged residues (Arg and Lys); yellow, 
hydrophobic residues (Ala, Val, Leu, and Ile)]; (i) side view. 
 
  The structural insights of the foot domain, including the recognition site and the 
cavity, could suggest the phage-bacteria recognition mechanism. The structures of the 
Figure4.11 
(a) (b) (d) (c) (e) (f) (g) 
(h) (i) 
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foot domain in the TFPs are likely to be diverse to accommodate different bacterial 
receptors on the surface. Each TFP might have a different structure at this recognition-
binding site to adapt its distinctive and selective interaction with the receptors on the 
bacterial surface. The recognition binding site of gp232, containing 12 Ser (residues 
1116,1133,1138, and 1142), 6 Asp (residues 1113 and 1118), and 6 Glu (residues 1135 
and 1137) in the trimer, is a potential binding site with a dense population of negatively 
charged and hydrophilic residues. These residues are lined up at the edge of the 
triangular binding face, displaying a negatively charged patch of two Asp residues and 
two Glu residues on each side. This patch could make the initial contact by interacting 
with the positively charged atoms on the surface of the bacteria, which may lead to 
further receptor recognition binding to the other parts of the foot domain. The additional 
interactions could be contributed by the cavity formed at the center of the foot domain. It 
has an entrance at the center of the binding site with three hydrophobic Leu residues 
guarding the entrance. The property of the cavity is important because it might assist in 
determining the specificity and tight binding to a receptor. The cavity is in a mushroom-
like shape that has a hydrophobic stem and a hydrophilic cap region (Fig 4.12). The stem 
of this mushroom-like cavity serves as a portal and is formed by hydrophobic residues 
1119−1122 (AVLV), Phe111, and Trp1124. One of the residues, Leu1121, is on the 
stem where it connects to the recognition site. On the other side of the stem is the 
deepest part of the cavity, which is the cap of the mushroom. This cap is hydrophilic and 
composed of 3 His1108 and 3 Ser1110. It is possible that, on binding, the structural 
conformation changes to open the narrowest part of hydrophobic stem at Leu1121, and 
  
 
 
158 
the hydrophobic residues of the stem clamp on the hydrophobic part of the bacterial 
receptor. Moreover, the region inside the cavity between the stem and cap contains three 
small pockets. The residues (R1112, R1146, W1124, T1148, and S1110) of each 
monomer each construct a small compartment with positive potential on the surface. The 
structure of this foot domain shows that, from the recognition site to the cavity inside, 
the potential on the surface is from negative charge to hydrophobic at the stem region 
and to positive charge at the cap region. Therefore, the negatively charged residues 
(Asp1118, Asp1113, Glu1135, and Glu1137) at the recognition site are used to grab onto 
the cell surface. On contact with the bacterial surface, the cavity could form interactions 
with a specific receptor. 
 
 
Figure 4.12 A mushroom-like cavity at the center of potential receptor-recognition 
surface. The surface is colored by hydrophobicity (orange: hydrophobic, blue: 
hydrophilic). 
Figure 4.12 
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Structural comparison of the potential receptor-recognition site among all 
the bacteriophage TFPs  
 The overall structure of the truncated gp232 shows that it is unique among the 
known structures of other TFPs in bacteriophage. Apart from the structural diversity 
among all TFPs, the residues at the recognition site also are the products of co-evolution 
between phages and bacteria. Therefore, the residues for making interactions at the 
recognition site are specific toward the distinct cell wall components they interact with. 
A comparison of the recognition sites of all known TFPs shows that the interactions 
between the bacterial receptor and the recognition site can be classified into three types. 
These interactions are made either by positively charged, hydrophobic, or negatively 
charged residues from the TFPs (Fig 4.11a-g). The first type of interaction is through 
positively charged residues and has been shown in the minor TFP (gp12) from phage T4. 
This minor TFP assists the base plate at the end of the phage tail to dock on the bacterial 
cell wall. The residues, Arg and Lys, at the tip of the receptor-binding site of gp12 are 
responsible for the interactions with the bacterial surface. Another TFP from the 
lactococcus phage P2 and the viral fiber protein also have positive residues, Arg and 
Lys, at the recognition site, which make the initial contact. The second type is primarily 
made by hydrophobic residues, which might be Trp, Phe, Leu, Val, or Ala at the binding 
site. The TFP of the lactococcus phage TP901-1 presents a large hydrophobic area, in 
which the receptor-binding site contains Trp, Val, and Ala. A negatively charged residue 
such as Tyr at the recognition site is seen in the structure of gp37 from T4 phage. 
Among all the known structures of TFPs, gp17 from the T7 phage contains a similar 
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architecture in the foot domain, with a cavity that resembles the foot domain of gp232. 
However, there are a few differences. Unlike the Asp and Glu at the recognition site of 
gp232, the first layer of the recognition site in gp17 contains six positively charged Arg 
residues. Three of the six Arg residues point outward from the protein and are potentially 
responsible for making the first contact on the bacterial surface. This recognition site, 
similar to that in gp232, has a planar face with an entrance to a cavity at the center. 
Unlike the narrow portal observed in gp232, the cavity entrance of gp17 is completely 
blocked by a hydrophobic residue (Ala518). The residues found at the entrance in gp17 
are hydrophobic, which resembles the hydrophobic portal in gp232. At the entrance of 
gp17, the residues Ala518 and Asp520 have been reported to hold the binding 
specificity[133]. This implies that the Leu1121 in gp232, which partially blocks the 
portal, may play a role in binding specificity. The cavity of gp17 is smaller, with an 
absence of a positively charged pocket. Thus, the potential binding cavity of gp17 has 
only hydrophobic residues (Phe and Ile) formed inside and positively charged residues at 
the recognition site. Therefore, gp232 is the only TFP that has a cavity right next to the 
entrance that is not completely blocked by hydrophobic residues.  
 
The structural comparison to viral fiber proteins 
 The overall structure of truncated gp232 is novel, and the shaft domain has a 
unique fold that has not been seen in any of the tail fiber proteins from bacteriophages. 
However, the shaft domain resembles the triple beta-spiral motif reported in the fiber 
protein of avian reovirus and adenovirus. Similar to that in gp232, the structures of the 
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viral fiber protein contain a similar and long triple beta-spiral motif in its shaft domain. 
The domain architecture of these viral fiber proteins is the same as that of gp232. They 
also contain three domains known as the tail, the shaft, and the knob domain from the N-
terminus to the C-terminus, which may account for the head, the shaft, and the foot 
domain in gp232, respectively. These viral fiber proteins assist the viruses in choosing 
the hosts in order to induce the infection after fiber proteins attach to the host cell 
receptors. For example, adenovirus seratype 37 (Ad37) uses the viral fiber protein for 
initiating viral infection in humans and leads to severe epidemic keratoconjunctivtis 
(EKC), a contagious ocular disease[134]. This fiber protein has been shown to bind two 
receptors on the cellular surface of the host, including GD1, a glycan, and the virus 
receptor from the host immune system. The structure of the other fiber protein from 
reovirus, named σ1, contains two sets of beta-spiral motifs in the shaft domain, 
connected by a helices bundle, and the foot domain shares a similar fold as that in the 
fiber protein of Ad37. The length of the shaft domain in these viral fiber proteins is 
longer than that in gp232. The shaft domain of gp232 has two beta-spiral repeats and its 
length is 24 Å, whereas the shaft domain of AD37 has four beta-spiral repeats with a 
length of 46 Å (PDB:1QIU). The length of the two sets of beta-spiral motifs in σ1 is 42 
Å with four repeats and 57 Å with another three repeats (PDB:3S6Z). 
Less is known about the interaction of bacteriophage TFP with receptor on the 
bacterial cell surface. Interestingly, it has been shown that the cell-surface glycans bind 
between the second and third repeat of the beta-spiral motif from σ1, instead of the 
receptor-recognition site at the foot domain. The protein structure of σ1 in complex with 
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di-sialic acid (PDB:3S6Z) reveals a carbohydrate-binding site. Due to the structural 
similarity shared between the shaft domains of the σ1 and gp232, the beta-spiral motif in 
the gp232 might serve as a tool to recognize the carbohydrate moieties on the cell 
surface of mycobacteria. Compared to that in the σ1 structure, the potential 
carbohydrate-binding site of gp232 is likely to be at the region composed of the beta-
spiral repeat 1 (residues 1043−1059) and Ser1071 from the beta-spiral motif repeat 2. 
There are two carbohydrate-binding sites in the foot domain reported in the viral 
fiber proteins from adenovirus and reovirus. The adenoviral fiber protein shows GD1a-
glycan binding at the interface of trimer in the foot domain, which is related to the 
receptor-recognition site of gp232. However, the residue composition in the foot domain 
and the recognition site of the AD37 fiber protein (PDB:3N0I) is very different from the 
planer recognition site in gp232. Residues of Lys, Tyr, Ser, and Thr form the 
carbohydrate-binding site of AD37 fiber protein, where the electrostatic surface potential 
is different from that of the Asp-Glu at recognition site of gp232. At the interface of the 
two monomers in the foot domain of gp232, there is a shallow groove constructed by 
Tyr1085, Lys1084, Thr1104, and Lys1114, which has similar residue composition with 
that in AD37, and could serve as a binding site. The location of this shallow groove in 
gp232 can relate to a carbohydrate-binding site of σ1 composed of residues Asn, Gln, 
and Thr, where GM2 and GM3 (glycans on the cellular surface) bind (PDB:4GU3 and 
4GU4). Based on the structures of the two viral fiber proteins bound to receptors, 
structural comparison indicates two new potential sites, in addition to the planar 
recognition site, for binding the glycolipids on the mycobacterial surface.  
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4.3 Methods 
Cloning, expression and purification of the truncated gp232 and the 
truncated gp232 with GFP-tag 
 The gene gp232 was identified as a TFP in mycobacteriophage bxz1, and was 
amplified in a truncated form with the forward primer with an NdeI restriction site and 
the reverse primer with a HindIII restriction site. The template was the gDNA of 
mycobacteriophage bxz1 that was obtained from the Hartful lab. The PCR product was 
purified and digested with the restriction enzymes. This double-stranded DNA was 
ligated into the pET30b vector (Novagen) with kanamycin as antibiotic selection. The 
plasmid containing truncated gp232 (pET30b-trunc-gp232) was transformed into E coli 
BL21 cell line (Novagen), and the transformants were plated on Luria-Bertani (LB) agar 
medium in the presence of kanamycin (50 µg/mL). The other construct of the truncated 
gp232 containing a green fluorescent protein (GFP) tag at the N-terminus also was 
cloned into the pET30 vector. The gene gfp was cloned from the plasmid of pAcGFP1 
from Clontech with the forward primer with NdeI restriction site and the reverse primer 
with BamHI restriction site. This GFP-tag was engineered into the pET30b vector to 
make the pET30b-gfp vector. The truncated form of the gene gp232 (tgp232) was cloned 
again, containing different restriction sites. The PCR product of tgp232 was digested 
with the restriction enzymes and ligated into the pET30b-gfp vector to make the 
pET30b-gfp-tgp232 construct. The product plasmid was transformed into E. coli BL21 
and selected with kanamycin on LB-agar plates. A single colony of both constructs 
(pET30b-trunc-gp232 and pET30b-gfp-tgp232) was picked and used to inoculate the 
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starter culture (20 mL) containing kanamycin (50 µg/mL). The cultures were grown to 
an OD600 of 0.6 at 37°C. Each 20 mL of the inoculant was added to 2 L LB media. After 
incubating in a shaker about 4−5 hours (OD600 ~ 0.6 to 0.8), IPTG was added to the 
cultures at a final concentration of 1 mM to induce protein overexpression, and the 
cultures were further incubated in the shaker for 16 hours at 18°C.    
 The cells were harvested and spun down by centrifuging at 3000×g for 40 
minutes. The pelleted cells were resuspended in the lysis buffer, containing 50 mM Tris 
pH 7.5, 500 mM NaCl, and 2 mM β-mercaptoethanol. DNase at a final concentration of 
10 µg/mL and protease inhibitor cocktail (Novagen) were added before lysing with a 
high-sheer fluid processor. The cell resuspension was passed through a chamber with a 
diameter of ~150 microns under high pressure (18000 psi). The cell debris was separated 
from the crude cell lysate by centrifuging at 10,000×g for 60 minutes at 4°C, and the 
supernatant contained the soluble protein that was designed and engineered in the E. coli 
plasmid. The clarified lysate was passed through a 0.22-µm syringe filter before the 
subsequent chromatographic purification steps. 
Both protein constructs (tunc-gp232 and GFP-tgp232) were obtained at ~ 95% 
purity by affinity column and gel filtration column. Due to the similar pI value of both 
proteins, they were treated with the same purification procedure. The first step was to 
utilize the affinity of the designed N-terminal His-tag to the immobilizing nickel-affinity 
column, which pulled out our target proteins from the lysate. The protein was bound to 
the nickel-affinity column. After washing the column with 5 column-volumes of the 
buffer A, the protein was eluted out with a gradient elution of buffer B (20 mM Tris pH 
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7.5, 500 mM NaCl, 2 mM β-mercaptoethanol, and 500 mM imidazole). Based on the 
absorbance readout at the wavelength of 280 nm recording along with the elution 
gradient, the bound protein was found to elute out at ~100−150 mM imidazole. Those 
fractions were pooled together and concentrated to 2 mL using a Centricon concentrator 
(cutoff 10 K). The protein sample was loaded onto a gel filtration column (Superdex 200 
from GE/Pharmacia) and purified to homogeneity in the buffer with lower salt 
concentration (20 mM Tris pH7.5, 150 mM NaCl, and 2 mM β-mercaptoethanol). Both 
protein constructs of the truncated gp232 were eluted in a major peak that identified the 
molecular weight of both samples in that fraction. The results showed both proteins 
formed into a trimer in solution (~75 kDa for trunc-gp232 and 150 kDa for GFP-
tgp232). Those fractions containing homogeneous protein were collected and 
concentrated to about 6 mg/ml. 
   
Se-Met protein production 
 The plasmid with inserted gene of the truncated gp232 was transformed in the E. 
coli BL21 cell line. A 5-mL cell culture was inoculated with a single colony and grown 
at 37°C for 8 hours. This was added into the starter culture of 250 mL M9 media. The 
starter culture was incubated in the shaker at 37°C for 16 hours. For the large-scale prep, 
each liter of the minimal M9 media was inoculated with 20 mL of the starter culture, and 
the cells were grown at 37°C. When the OD600 reached 0.3, the cell culture (1 L) was 
supplemented with amino acids mix containing 50 mg of isoleucine, leucine, and valine, 
and 100 mg of lysine, phenylalanine, and threonine. After 30 minutes of shaking, the Se-
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methionine (60 mg) was added into the culture. Once the cell density reached OD600 of 
0.6, IPTG was added to induce protein expression, and the cell cultures were incubated 
in the shaker at 16°C for a further 18 hours. The cells were harvested by centrifugation. 
The procedures of lysis and purification were the same as that in the protocol for 
purifying the native protein. The protein was eluted at 100−200 mM imidazole in the 
gradient elution. The fractions containing the pure proteins were pooled and dialyzed 
against the buffer (20 mM Tris pH7.5, 150 mM NaCl, and 2 mM BME). The protein was 
concentrated to 6 mg/mL for crystallization trials. 
  
Culture of M. smeg (mc2 155), M. tuberculosis (mc2 7000), and E. coli  
 The cell culture of M. smeg (mc2 155) was inoculated in media with 1 µL of the 
glycerol stock stored at −80°C. Middlebrook 7H9 broth media with supplements of 0.2% 
dextrose, 0.085% (w/v) NaCl, and 0.05% (v/v) Tween 80 was used. The cells of M. 
tuberculosis also were inoculated in the Middlebrook 7H9 media with an extra 
supplement of 50 µg/mL pantothenate. The cell culture of E. coli (strain BL21) was 
inoculated in LB broth. Both cell cultures were harvested for the binding demonstration 
with gp232 after incubating at 37°C in a rotary shaker to reach an OD600 of 0.6. 
 
Imaging with GFP-tag protein  
 To identify the function of gp232 as a tail fiber protein in the mycobacteriophage 
bxz1, the truncated gp232 was fused with a GFP-tag at the N-terminus and used to 
demonstrate the binding to the bacteria under a fluorescent microscope. The cultures of 
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M. smeg and E. coli, both grown to 0.6 of OD600, were transferred to two different slides. 
The protein (GPF-tgp232) also was added on each slide. The bacteria (M. smeg and E. 
coli) were incubated with protein on the slide for 60 minutes. The cover slide was used 
to cover and fix the bacteria on the focal plane. Two samples were examined under the 
microscope (Nikon, Eclipse TS100-F) equipped with a dichronic mirror in the green 
filter block.  
 
Electron microscopy  
 The truncated gp232 was attached with nano-gold (NG) particles to observe the 
binding between gp232 and the surface of the bacteria using an electron microscope. The 
NG-particles (5 nm, Nanoprobes Company) were incubated with protein on ice, and a 
Ni-NTA (nickel-nitrilotriacetic acid) moiety coated on the surface of the spherical nano-
gold particles formed coordination bonds to the His-tag of the protein. This complex 
(NG-trunc-gp232) was applied to a carbon mesh with M. smeg and images were taken by 
the electron microscope (JEOL1200). 
 
Affinity to the bacteria 
 To compare the affinity for M. smeg, M. tuberculosis, and E. coli, each was 
harvested from a 5-mL cell culture. The cells were spun down and suspended in 1.5 mL 
of buffer (20 mM Tris pH 7.5 and 300 mM NaCl). DNase and protease inhibitor 
cocktails were added, followed by adding protein (trunc-gp232, 6 µM). In the presence 
of the protein, the cells were lysed with a mini-bead beater (Biospec products). The 
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lysates were centrifuged at 10,000×g for 30 minutes to obtain cell debris and clarified 
lysate. The cell debris of each was washed with buffer (20 mM Tris pH 7.5 and 500 mM 
NaCl), and then spun down. The wash step was repeated twice. Samples were taken 
from each step for SDS-page analysis. 
 
Protein crystallization 
 The truncated gp232 of the native form and the truncated gp232 with the Se-
methionine modification were purified to homogeneity. Both proteins (6 mg/mL) were 
screened under 768 crystallization conditions using the sitting-drop vapor-diffusion 
method. Each condition was set up with the volume ratio of 1 to 1 (protein to well 
solution) by a liquid handling robot (mosquito, TTP) in 96-well sitting-drop plates (Art 
Robbins Instruments). The crystallization plates were placed in an environment that 
maintained a constant temperature and limited vibration. Protein crystals appeared in the 
hit conditions after 48 hours, and the quality of the crystals was optimized under several 
hit conditions in the 24-well sitting-drop plate. The best crystals were obtained in a 
crystallization condition containing 100 mM bicine pH 9.0, 20% PEG200, and 4 mM 
beta-OG.  
 
Data collection and structural determination 
 The crystals of the truncated gp232 containing the Se-Met modification were sent 
to the Hung lab and collected in the synchrotron facility of the advanced light source 
(ALS) at the Lawrence Berkeley National Lab. The crystals were mounted in a loop 
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under the cryogenic condition that added ethylene glycol at the final concentration of 
30% (v/v), and flash frozen in the liquid nitrogen. The crystals diffracted to a resolution 
of 2.5 Å and 2.8 Å, and 180° of data were collected using 1°-oscillation range at three 
different wavelengths for the peak, inflection, and remote data.  
 Three datasets collected at the different wavelengths were indexed using 
HKL2000, which showed that the protein crystallized in the space group P212121 with 
the unit cell dimension (peak data) of a = 91.290 Å, b = 93.148 Å, c = 193.652 Å, α = β 
= γ = 90°. All three data were separately integrated and scaled in HKL2000. The 
anomalous signal from the Se in the peak and inflection data was used for phasing. The 
crystal structure was solved by the multi-wavelength anomalous dispersion (MAD) 
method. The scaled data from the three datasets were analyzed by AutoSharp to 
calculate the phase. The initial phase information, the X-ray intensity data, and the 
protein sequence were used as input in AutoSol (PHENIX) that generated an initial 
structural model of our target protein, the truncated gp232. The initial model was viewed 
in COOT, and was fixed to fit in this initial electron density. The final structure was 
obtained after few cycle of refinement (CCP4 and PHENIX). 
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5. CONCLUSION 
 
  This study of lipid-binding proteins focuses on two deadly pathogenic diseases, 
tuberculosis and malaria, which have caused infections that threaten more than one-third 
of the human population. Although both diseases currently have drugs that can cure the 
infection, the emergence of drug-resistant strains reveals the urgent need to find new 
treatments. To eliminate the pathogens, the insight gained from the structures of lipid-
binding proteins can facilitate our search to find inhibitors for the drug target proteins, 
understand the pathogen physiology, and design novel targeted drug delivery. To 
achieve these three goals, the structural studies of lipid-binding proteins were performed 
to identify the protein functions that can be used to understand pathogen physiology and 
for designing therapeutics, and to explore the inhibitor-binding site of a drug-target 
protein. The crystal structure of each lipid-binding protein (LprG, LprA, PfENR, and 
gp232) provided knowledge that can be applied to the goal for each protein, which is set 
to approach pathogen eradication from a specific angle.  
LprG and LprA, two proteins from Mtb, have been reported to be capable of 
inducing the host immune response by activating TLR2. LprG is essential for Mtb to 
survive during infection. The structural determination of LprG and LprA has connected 
the knowledge of genomics and pathogen physiology. The ligand identification study 
showed that LprG binds precursors of LAM and LM, such as tri-acylated glycolipid 
(Ac1PIM2). LprG also can bind LAM and LM. This indicates that the function of LprG 
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is a glycolipid carrier. Previous studies that showed that LprG is on the same operon 
with Rv1410c, a sugar efflux pump, and that the function of Rv1410c requires LprG. 
The result that LprG is a glycolipid-binding protein suggests that LprG has a potential to 
mediate sugar transport. Therefore, the function of LprG is likely associated with 
glycolipid biosynthesis and maintenance of the integrity of the cell wall. The mutant 
LprG (V91W), which was made based on the structural guidance, verifies that LprG 
binding to tri-acylated glycolipids induces the TLR2 reaction. The crystal structure of 
LprA revealed a binding with a di-acyl lipid. The ligand identification showed that LprA 
binds diverse forms of phospholipids (PG, PE, PI, and PIP). This suggests that LprA is a 
phospholipid-binding protein. In combination with the genomic data, these results 
suggest that LprA is on the same operon with Rv1272c and Rv1273c, which are 
homologous to the phospholipids/ lipopolysaccharides transporter (MsbA) in E. coli. 
The result of LprA binding to phospholipids suggests that LprA, like LprG, might 
associate with membrane proteins (Rv1272c and Rv1273c) in assisting phospholipid 
transport. Here, the structural studies of LprG and LprA give the first important evidence 
for identifying the protein function. This provides an example of using protein structure 
as a guide in linking the protein function to pathogen physiology. Ideally, the collected 
information is very useful in understanding the mechanism of pathogen survival that 
would lead to the eradication of the pathogen. 
The enoyl reductase in the type II fatty acid biosynthesis (FAS II) pathway is a 
validated drug target protein in treating pathogenic diseases like malaria because humans 
have only the type I fatty acid biosynthesis (FAS I). In malaria, the FAS II pathway is 
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essential when a parasite (Plasmodium falciparum) enters hepatocytes and multiplies 
rapidly.  The functional mechanism of a known anti-microbial agent, Triclosan, has been 
demonstrated; by inhibiting enoyl reductase (PfENR) and blocking the FAS II 
biosynthesis pathway. The IC50 value of 70 nM indicates that it is a potent inhibitor of 
PfENR in vitro. However, an enzyme in the human liver could glucuronate triclosan and 
disrupts the hydrogen bonding to Tyr277, which weakens the affinity and decreases the 
efficacy. 
The first step is to generate the structure-activity relationships (SAR) by 
screening hundreds of triclosan analogs that would help in finding the key interaction 
between protein and inhibitor. The second step is to apply structural insight of those key 
interactions along the triclosan scaffold onto new sets of chemical scaffolds, which will 
have high affinity and sustain the potency in liver. The SAR study of triclosan-like 
analogs suggests that modification at the 5-position on ring A can maintain the same 
potency as triclosan in the enzyme assay. The modification at the 5-position reveals a 
novel hydrophobic binding site that is observed on Phe368 flipping. This site could be 
used to increase affinity without reducing inhibition, because the 5-fluoro-phenyl analog 
showed a 2-fold stronger inhibition to triclosan. The structural knowledge that we gained 
in the SAR study from analyzing triclosan-like analogs assisted us to obtain the most 
potent inhibitors (698 and 325) against PfENR, with a core scaffold of 
tetrahydroquinoline and piperidine. In finding potent inhibitors, the structural study of 
PfENR helped us to generate prominent inhibitors by fine-tuning the modifications on 
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the core scaffold. This provides the possibility to improve the pharmacokinetic issue that 
triclosan has encountered. 
Mycobacteriophages use tail fiber proteins (TFPs) to make contact on the 
bacterial cell wall, and the binding between phage and bacteria is tight and specific. The 
protein identification and the structural study of TFPs from mycobacteriophage bxz1 
were performed to understand this binding mechanism, which can be applied in a 
targeted drug delivery system. The protein sequence analysis indicated that TFP in 
mycobacteriophage bxz1 is gp232, and the crystal structure is the first solved among all 
mycobacteriophages. The role of gp232 as a TFP in bxz1 has been characterized by 
observing the specific and tight binding between gp232 and M. smegmatis. Here, the 
protein structure helped us to identify the TFP in bxz1, and guided us in designing the 
protein conjugation. On conjugating gp232, the binding specificity and affinity to 
mycobacteria could allow the targeted drug delivery to reduce drug toxicity and to 
enhance drug efficacy by increasing the local concentration at the infection site.  
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APPENDIX A 
THE CRYSTAL STRUCTURE OF LPRG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted with permission from “Mycobacterium tuberculosis lipoprotein LprG 
(Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2 ” by Drage, M. 
G., Tsai, H. C., Pecora, N. D., Moody, D. B., Boom, W. H., Sacchettini, J. C. and 
Harding, C. V. et al. 2010. Nature Structural and Molecular Biology, 17(9): p. 1088-95., 
Copyright 2010 by Nature America, Inc. 
  
 
 
188 
 
  
  
 
 
189 
  
  
 
 
190 
  
  
 
 
191 
  
  
 
 
192 
  
  
 
 
193 
  
  
 
 
194 
  
  
 
 
195 
  
  
 
 
196 
 
 
  
 
 
197 
 
 
 
APPENDIX B 
THE STRUCTURAL STUDY OF TRICLOSAN DERIVATIVES WITH 
MODIFICATION AT THE 2’-POSITION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted with permission from “Synthesis and biological activity of diaryl ether 
inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan 
derivatives” by Freundlich JS, Yu M, Lucumi E, Kuo M, Tsai HC, Valderramos JC, 
Karagyozov L, Jacobs WR Jr, Schiehser GA, Fidock DA, Jacobus DP, Sacchettini JC, 
2006. Bioorganic & Medicinal Chemistry Letters, 16(8), 2163-2169, Copyright 2006 by 
Elsevier Ltd. 
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APPENDIX C 
THE STRUCTURAL STUDY OF TRICLOSAN DERIVATIVES WITH 
MODIFICATION AT THE 5-POSITION 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted with permission from “X-ray structural analysis of Plasmodium falciparum 
enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan 
antimalarial efficacy.” by Freundlich JS, Wang F, Tsai HC, Kuo M, Shieh HM, 
Anderson JW, Nkrumah LJ, Valderramos JC, Yu M, Kumar TR, Valderramos SG, 
Jacobs WR Jr, Schiehser GA, Jacobus DP, Fidock DA, Sacchettini JC, 2007. Journal of 
Biological Chemistry, 282(35), 25436-44, Copyright 2007 by The American Society for 
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